

**THE UNIVERSITY OF ALABAMA AT BIRMINGHAM
SCHOOL OF MEDICINE
CURRICULUM VITAE
AUGUST 2018**

PERSONAL INFORMATION

Name Jeffrey R. Curtis, MD MS MPH

Home Address 505 Founder's Park Circle
Hoover AL 35226

Phone (205) 979-2288, Cell: (205) 937-0585

Rank/Title Jones Harbert – Gene V. Ball Endowed Professor of Medicine
in Rheumatology and Immunology

Department Division of Clinical Immunology and Rheumatology,
UAB Department of Medicine
Department of Epidemiology
UAB School of Public Health (secondary)

Business Address University of Alabama at Birmingham
Division of Clinical Immunology and Rheumatology
510 20th Street South, FOT 802
Birmingham, AL 35294-7201

Phone (205) 975-2176

Email jrcurtis@uabmc.edu

EDUCATION

Institution	Degree	Year
University of California at San Diego	B.S. Biology	1992
Oregon Health Sciences University	M.D.	1999
Oregon Health Sciences University	M.P.H.	1999
Harvard University	Program in Clinical Effectiveness	2006
Harvard School of Public Health	M.S. Epidemiology	2009
Stanford University	Graduate Certificate, Clinical Informatics	2016

LICENSURE & CERTIFICATION

State	Date	Perm./Temp.	Number	Renewal Date
Alabama	4/02	Perm.	24606	12/31/16
Oregon		Perm.	23057	Inactive

PROFESSIONAL CERTIFICATION

	<u>Date</u>
USMLE (parts 1-3)	2000
American Board of Internal Medicine – Internal Medicine	2002
Certified Clinical Densitometrist (ISCD)	2004
American Board of Internal Medicine – Rheumatology	2005, 2016
American Board of Preventive Medicine – Clinical Informatics	2016

POSTDOCTORAL TRAINING

Year	Position	Institution
1999-2002	Resident, Internal Medicine	Oregon Health Sciences University Portland, OR
2002-2005	Fellow in Rheumatology	University of Alabama at Birmingham Birmingham, AL

ACADEMIC APPOINTMENTS

Year	Position	Institution
2007- Present	Director	UAB Arthritis Clinical Intervention Program (ACIP), Birmingham, AL
2005- Present	Co-Director	UAB Center for Education and Research on Therapeutics of Musculoskeletal Disorders (CERTs), Birmingham, AL
2005- Present	Associate Scientist	UAB Center for Metabolic Bone Disease (CMBD), Birmingham, AL
2005- 2008	Assistant Professor of Medicine	UAB Division of Clinical Immunology & Rheumatology, Birmingham, AL
2009- 2014	Associate Professor of Medicine Tenured	UAB Division of Clinical Immunology & Rheumatology, Birmingham, AL
2011- Present	Co-Director	UAB Pharmacoepidemiology and Pharmacoeconomics (PEER) Unit
2014- Present	Associate Scientist	UAB Minority Health & Health Disparities Research Center
2014- Present	Professor of Medicine Tenured	UAB Division of Clinical Immunology & Rheumatology, Birmingham AL

AWARDS & HONORS

Year	Honor
1988	High school valedictorian
1988-1992	University of California Regents Scholar
1988-1992	National Merit Scholar
1988-1992	UCSD Provosts' Honor Roll
1988-1992	UCSD Warren College Scholar
1991-1992	Golden Key National Honor Society & Scholarship Recipient
1991-1992	Outstanding College Students of America
1992	B.S. Biology conferred summa cum laude
1996-1997	Whittle Scholarship Award for academic achievement
1996-1998	Otterdale Scholarship Award for academic achievement
1999	Medical degree (M.D.) conferred cum laude
2003	American College of Rheumatology Research and Education Foundation Clinical Investigator Fellowship Award
2003, 2005	National Institute of Health Clinical Investigator Loan Repayment Award
2003	American College of Rheumatology Fellowship Training Award (UAB)
2004	Pfizer Scholar in Pain Management
2004	American College of Rheumatology Senior Fellow Award
2005	UAB Department of Medicine Frommeyer Award in Investigative Medicine
2005	International Conference on Pharmacoepidemiology & Therapeutic Risk Management Travel Award
2006	Arthritis Foundation Arthritis Investigator Award
2006-2007	U.S. Bone and Joint Decade Young Investigator
2007	ACR-EULAR International Academic Exchange Program
2007	PhRMA Foundation Health Outcomes Research Award
2008	International Society of Clinical Densitometry Young Investigator Award
2008	American Society for Bone and Mineral Research Young Investigator Award
2010	UAB Department of Medicine Research Excellence Award
2010	Max Cooper Award for Excellence in Research
2010	Best Doctors in America

2011	UAB Department of Medicine Research Excellence Award, First Place
2011	ISPE Biologics Special Interest Group, Best Poster Award
2011	Best Doctors in America
2011	American College of Rheumatology within Our Reach Award
2012	UAB Innovation Board Award – Improving Quality of Care in RA
2012	Best Doctors in America
2012	UAB Department of Medicine Research Excellence Award, First Place (Assoc Prof.)
2012	ACR Henry Kunkel Young Investigator Award
2013	William J. Koopman Endowed Professorship in Rheumatology and Immunology
2013	UAB Department of Medicine Research Excellence Award, First Place (Assoc Prof.)
2014	UAB Health Services Foundation, Top Decile in Provider-Patient Communication
2014	UAB Department of Medicine Research Excellence Award, First Place (Assoc Prof.)
2015	Best Doctors in America, General Rheumatology & Rheumatoid Arthritis
2015	UAB Department of Medicine Research Excellence Award, First Place (Full Prof.)
2016	American Society for Clinical Investigation (ASCI)
2016	Best Doctors in America
2016	UAB Department of Medicine Research Excellence Award, Second Place (Full Prof.)
2017	Best Doctors in America
2017	Marguerite Jones Harbert-Gene Ball Endowed Professor
2018	Best Doctors in America

PROFESSIONAL SOCIETIES AND MEMBERSHIPS

2002- Present	American College of Rheumatology (ACR)
2002- Present	International Society of Clinical Densitometry (ISCD)
2002- Present	International Society of Pharmacoepidemiology (ISPE)
2002- Present	American Society for Bone and Mineral Research (ASBMR)
2014- Present	American Medical Informatics Association (AMIA)

COMMITTEES

2005-2007	International Society for Clinical Densitometry (ISCD) State Advocate
2006-2008	ACR Core Expert Panel: Recommendations for the Use of Non-biologic and Biologic Therapies in Rheumatoid Arthritis
2007-2008	President, Alabama Society of Rheumatic Diseases (ASRD)
2007-2014	Consortium of Rheumatology Researchers of North America (CORRONA) publications committee
2007-2009	ACR Research and Education Foundation (REF) study section reviewer
2008-2014	CORRONA pharmacoepidemiology advisory board
2008-2010	ACR Glucocorticoid Induced Osteoporosis Recommendations Core Expert Panel
2009-2010	ASBMR Subtrochanteric Fractures Task Force
2009-2010	ACR Working Group: Recommendations for use of Biologics in Juvenile Inflammatory Arthritis (JIA)
2009-2010	ACR/EULAR RA Flare Definition Workgroup
2010-2011	WHO FRAX International Task Force
2009-2013	Birmingham VA REAP Steering Committee
2010-	ACR Registry and Health Information Technology Committee
2010-2012	ACR Core Expert Panel: Update on Recommendations for the Use of Non-biologic and Biologic Therapies in Rheumatoid Arthritis
2011-	Cochrane Musculoskeletal Review Group Advisory Board
2010-2013	JIA Consolidated Safety Registry (JIA-Core) advisory group
2010	American College of Rheumatology Clinical Trial Priorities and Design Conference
2013-2014	FDA Mini-Sentinel Clinical Trials Workgroup
2013-2015	ACR Content Expert Panel: 2015 RA Recommendations on Use of Biologic and Non-

2013- Biologic DMARDs in RA
 2014-2015 ACR Drug Safety Review Hotline Co-Editor
 2014- PCORnet Data Standards and Security and Network Infrastructure Task Force (DSSNI)
 2014- FDA Mini-Sentinel Planning Board
 2015- CORONA Research Foundation, Scientific Research Committee, chair
 2015- Global Healthy Living Foundation Executive Committee
 2014-2015 ACR Research and Education Foundation (REF) study section reviewer
 2015- Center for Disease Control (CDC) ACIP Herpes Zoster Workgroup
 2015 Arthritis Foundation Registry Workshop Planning Committee
 2015- ACR GIO Guidelines Expert Panel
 2015- Mini-Sentinel/PCORnet Data Linkage Working Group
 2015- FDA Arthritis Advisory Committee (AAC)
 2015- UAB Enterprise Data Warehouse (EDW) Committee
 2016- CARRA External Advisory Council
 2016- Biologics and Biosimilar Collective Intelligence Consortium (BBCIC) autoimmunity workgroup
 2016-18 International Consortium Healthcare Outcome Measures (ICHOM) Arthritis Workgroup
 2016 NOF/ISCD Medicare Data Working Group
 2016- OMERACT RA Registry Special Interest Group
 2017-2018 ACR 2018 Clinical Research Conference chair – Applications of Mobile Health
 2017- ACR Registry & Publications Subcommittee
 2018- OptumLabs-SU2C Cancer Technical Expert Panel (TEP)
 2018- Biologics and Biosimilar Collective Intelligence Consortium (BBCIC) ICD10 conversion workgroup
 2018 ARHP Online Rheumatology Education Portfolio Reviewer
 2017- UAB Clinical Data Innovation Committee, Chair

Data, Safety and Monitoring Boards (DSMB)

2007-2008 Roche Ibandronate [ML19334] (published as PMID: 19145396)
 2008-2013 Roche Tocilizumab Global Pharmacoepidemiology & Safety Monitoring Board
 2009-2010 UCB [RA0010]
 2010-2013 Centocor Golimumab [GO-SAVE] (chair)
 2011-2013 BMS [IM133-001, 133-004]
 2012-2015 Lilly [RA Janus Kinase development program]

UNIVERSITY ACTIVITIES

2005-2008 UAB Clinical initiative: Improving Osteoporosis Care for Fracture Patients
 2007- UAB Rheumatoid Arthritis (RADAR) specialty clinic, co-director
 2007-2010 UAB Quality Improvement project: Increasing DXA Use among Older Women
 2011-2012 UAB AMC21 Informatics Strategic Plan Steering Committee
 2011- Rheumatoid Arthritis Disease Activity (READY) Electronic Measurement Tool for Patient Reported Outcomes

MENTORSHIP ROLES & CURRENT MENTEE SUPPORT

2008- Dr. Amy Warriner [AHRQ Comparative Effectiveness K12]– co-primary
 2008- Dr. Tim Beukelman [NIH CCTS K12] - secondary
 2009-2012 Beth Kitchin (Nutrition, PhD) - secondary
 2010- Dr. Iris Navarro [NIH Rheumatology T32] - primary
 2010- Dr. Jie (Sophie) Zhang [AHRQ Comparative Effectiveness T32]– co-primary
 2010- Dr. Nicole Wright [postdoc comparative effectiveness] – co-primary
 2010- Dr. Huifeng Yun [pharmacoepidemiology, PCORI K12] – co-primary

- 2014- Dr. Michael George [rheumatology, MPH candidate at U Penn] - secondary
- 2015- Sarah Siegel [pharmacoepidemiology, pre-doctoral student at OHSU] – secondary
- 2016- Fenglong Xie [pharmacoepidemiology, pre-doctoral student at UAB] – co-primary
- 2016- Dr. Melissa Mannion [pediatric rheum outcomes research at UAB] – secondary
- 2016- Dr. Siddarth Singh [GI outcomes research at UCSD] – secondary
- 2017- Dr. Bryant England [Health outcomes, comorbidities in arthritis, UNMC] – secondary
- 2017- Dr. Justin Owensby [Health outcomes, evidence implementation, UAB] – primary
- 2017- Dr. Beth Wallace [Health outcomes, U Michigan] – secondary
- 2018- Dr. Namrata Singh [Pharmacoepidemiology, U Iowa] - secondary

EDITORIAL & REVIEWER ACTIVITIES

Standing Review Committees

- 2010-2 *American College of Rheumatology (ACR) Research and Education Foundation (REF), Disease Targeted Research Initiative (DTRI),*
- 2015 *ACR Rheumatology Research Foundation (RRF)*
- 2016 *NIH Health Services Organization and Delivery (HSOD) study section peer reviewer*

Ad-hoc grant reviewer

- 2010 *NIH Neuromuscular, Aging, and Musculoskeletal Epidemiology (NAME)*
- 2010 *Veteran’s Administration Health Services Research*
- 2016 *NIH Health Services Organization and Delivery Study Section (HSOD)*

Editorial boards

- 2012-2015 *Arthritis & Rheumatism Associate Editor*
- 2012-2014 *Arthritis Care & Research Editorial Board*
- 2012-2016 *Pharmacoepidemiology & Drug Safety Editorial Board*

Ad-hoc journal reviewer

Arthritis & Rheumatism, Arthritis Care & Research, Pharmacoepidemiology and Drug Safety, Osteoporosis International, Mayo Clinic Proceedings, Journal of Clinical Rheumatology, Journal of Rheumatology, Medical Care, Clinical Therapeutics, Journal of General Internal Medicine, Journal of Bone and Mineral Research, Seminars Arthritis Rheumatism, Annals of Rheumatic Disease

Ad hoc annual scientific meeting reviewer

ACR Annual Meeting Abstract Reviewer (co-chair, Epi & Health Services Research section, 2012-3) 2012-; ASBMR Annual Meeting Abstract Reviewer; ICPE Annual Meeting Abstract Reviewer 2012-; ASBMR (co-chair, Osteoporosis Health Care Delivery section, 2014)

TEACHING EXPERIENCE AND MAJOR LECTURES

National Consumers League; Washington D.C.

- 2002 “Toxicity related to Over the Counter Nonsteroidal Anti-inflammatory (NSAID) Use” (National Press Club)

UAB Internal Medicine; Montgomery AL

- 2004 “An Approach to Musculoskeletal Disease and Rheumatologic Lab Testing”
- 2006 “What’s New in Osteoporosis 2006: An Update”

UAB Department of Orthopedics; Birmingham, AL

- 2004 “Rheumatoid Arthritis from a Non-Surgeon’s Perspective”
- 2005 “Improving Quality of Care for Patients with Osteoporosis”

UAB Surgical Physician Assistant Training Program; Birmingham, AL

2003 "Systemic Vasculitis"

2004 "Systemic Vasculitis" and "Approach to Rheumatic Disease: Osteoarthritis and Rheumatoid Arthritis"

2005 "Screening and Treatment of Postmenopausal and Glucocorticoid Induced Osteoporosis"

2006 "Rheumatoid Arthritis and Osteoarthritis: the basics"

2007 "Approach to Rheumatic Disease and Rheumatology Lab Testing"

2008 "Approach to Rheumatic Disease and Rheumatology Lab Testing"

UAB Department of Medicine; Birmingham, AL

2004 Introduction to Clinical Medicine medical student small group preceptor

2005-7 "Knee Pain: What You (K)Need to Know" (monthly talks)

Carraway Medical Center Internal Medicine; Birmingham, AL

2004 "Approach to Rheumatic Disease, Musculoskeletal Exam, and Joint Injections"

2005 "Glucocorticoid Induced Bone Disease"

2007 "Improving Quality of Care for Osteoporosis Patients"

Birmingham Bone Club; Birmingham, AL

2005 The Impact of Nutrition on the Risk for Fracture

2006 Bisphosphonate Associated Osteonecrosis of the Jaw

American College of Obstetrics and Gynecology (ACOG); Destin, FL

2006 "Osteoporosis in 2006: Bones of Contention"

Cooper Green Hospital Department of Obstetrics and Gynecology; Birmingham, AL

2006 "Who Do We Treat, and With What?"

University of Miami Department of Obstetrics and Gynecology; Miami, FL

2006 "Osteoporosis 2006: Who to Treat, With What, and For How Long?"

Cooper Green Hospital Department of Internal Medicine; Birmingham, AL

2006 "Evolving Paradigms in Fracture Risk Assessment"

West Texas Rheumatology Association; Odessa, TX

2007 "Osteoporosis 2007: New Considerations for an Old Problem"

Vanderbilt University Division of Rheumatology; Nashville, TN

2007 "Challenges and Opportunities to Improve Quality of Osteoporosis Care"

2007 "Osteoporosis in Non-Caucasians: Are Bones Color-Blind?"

Tennessee State Rheumatology Society; Nashville, TN

2007 "Osteoporosis 2007: Bones of Contention"

American Medical Director's Association: Hollywood, FL (national meeting)

2007 "Managing Osteoporosis in the Real World Long Term Care Setting"

Food and Drug Administration: Government/Path day; Rockville, MD

2007 "Safety of TNF- α Antagonists"

Arthritis Foundation Annual Research Conference; Stone Mountain, GA

2007 "Access to and Safety of Biologic Agents in Rheumatoid Arthritis"

UAB Division of Clinical Immunology & Rheumatology fellows' conference

2006 "Vitamin D: Skeletal & Extra-skeletal effects"

2007 "Vitamin D: Is it Good for More than Just the Bones?"

2008 "Keys to Success in Conducting Clinical Trials"

Atlanta Obstetrical and Gynecological Society

2007 "Preventing Fractures: Practical Considerations in Diagnosis, Treatment and Long Term Follow-up"

Oregon Health Sciences University, Department of Medicine

2008 "Quality of Care for Osteoporosis Patients"

2008 "Administrative Data in Osteoporosis Research: Who Needs It?"

Rheumatology on the Beach, Sandestin, FL

2008 "Are Bacterial Infections Increased in Patients Receiving TNF Inhibitors?"

Society for Georgia Rheumatologists, Savannah GA

2008 "Prevention and Management of Infections in Rheumatoid Arthritis Patients"

American College of Rheumatology (ACR), San Francisco CA (evening symposium)

2009 "Challenges and Opportunities in Treating the Patient with Rheumatoid Arthritis in Today's Environment"

American College of Allergy, Asthma and Immunology (ACAAI), Seattle WA

2008 "Systemic Glucocorticoid Use in Adults: A Rheumatologists' Perspective"

American Society Health System Pharmacists (ASHP), Orlando FL

2008 "Use of Biologic and Non-Biologic DMARDS in the Treatment of Rheumatoid Arthritis"

University of Alabama at Birmingham Division of Endocrinology, Birmingham AL

2008 "Quality of Care in Osteoporosis: What Does it Mean? How Do We Improve it? "

Hamilton Medical Center, Dalton GA

2010 "Emerging Therapies in Rheumatoid Arthritis: From Clinical Trials to the Clinic"

University of Alabama at Birmingham Department of Epidemiology, Birmingham AL

2009 "Propensity Scores: Introduction and Application"

Morehouse School of Medicine Department of Medicine, Atlanta GA

2009 "Emerging Therapies for the Treatment of Rheumatoid Arthritis"

Medical Center of Central Georgia Department of Medicine, Macon GA

2009 "Evaluation and Management of Rheumatoid Arthritis"

University of Alabama at Birmingham Nurse Practitioner Program, Birmingham AL

2009 "Joint Injections: Using Sharp Objects to Make People Happy"

Meharry Medical College, Nashville TN

2009 "Biologics for the Treatment of Rheumatoid Arthritis"

Vanderbilt University Division of Rheumatology, Nashville TN
2009 “Biologics in 2009: More Unique Choices, or More of the Same?”

Princeton Medical Center Department of Internal Medicine, Birmingham AL
2009 “What’s New for Rheumatoid Arthritis in 2009?”

Trinity Medical Center Department of Internal Medicine, Birmingham AL
2009 “Emerging Therapies for RA”

ACR Annual Scientific Meeting, Philadelphia PA
2009 “The Keys to Opening the Door to Diagnosis and Treatment of Early RA”

American Transplant Congress, San Diego CA
2010 “Lessons Learned from Assessing the Safety of Biologics in Autoimmune Diseases”

American College of Rheumatology Clinical Research Conference, Atlanta GA
2011 “Adherence to Musculoskeletal Therapy and Methods To Improve It”

Agency for Healthcare Research and Quality Bone Health Conference, Washington DC
2010 “Improving Osteoporosis Care Through Multi-modal Interventions”

Princeton Baptist Medical Center, Birmingham AL
2012 “Update in Osteoporosis, 2011”

Trinity Medical Center, Birmingham AL
2011 “Managing Osteoporosis: When to Start, and When to Stop”

NIH 4th Annual Conference on the Science of Dissemination and Implementation: Policy and Practice, Bethesda MD
2011 “Improving Care of Osteoporosis: Multimodal Interventions to Improve Testing And Treatment”

UAB Medical Grand Rounds, Birmingham AL
2011 “Perspectives on the Safety of Biologic Agents for Autoimmune Diseases”

Consortium of Rheumatology Educators (CORE), Tampa FL
2011 “RA Therapy in 2011: What are Today’s Best Practices?”

St. Joseph’s Hospital, Hamilton Ontario
2011 Highlights from the ACR 2011 Draft Recommendations for RA Management

McGill University, Montreal Quebec
2011 “Long Term Safety of Osteoporosis Medications”

Notre-Dame Hospital, Montreal Quebec
2011 “What’s New in Rheumatoid Arthritis in 2011? Focus on the Safety of Biologics”

Consortium of Rheumatology Educators (CORE), Atlanta FL
2011 “Current Management of Rheumatoid Arthritis in 2011”

New York University, New York City NY
2011 “Biomarkers, Safety, Technology, and Comorbidities: Integrating to Balance Risks and

Benefits of Rheumatic Disease Treatments”

University of Nebraska Medical Center, Omaha NE; Annual RAIN Meeting
2013 “Innovative Trial Design in Rheumatoid Arthritis: A Way Forward”

University of Alabama at Birmingham, Birmingham AL
2012 “Safety of Biologic Therapies in Inflammatory Arthritis”

USC Division of Rheumatology, Los Angeles CA
2012 “Biomarkers in the Age of Clinical Assessment in RA”

Florida Society of Rheumatology, Orlando FL
2012 “Evidence-Based Management of Rheumatoid Arthritis in 2012”
2012 “Safety is in the Eye of the Beholder”

Cedars-Sinai Medical Center, Los Angeles CA
2012 “Balancing Effectiveness and Safety in RA Therapeutics”

UAB Vascular Biology and Hypertension Symposium; Birmingham AL
2012 Vascular Inflammation as a Consequence of Rheumatic Disease

ACR Annual Scientific Meeting; Washington D.C.
2012 To Measure or Not to Measure in RA: Does it Affect Quality of Care?

University of Florida College of Pharmacy, Gainesville FL
2013 Using Linked Data Sources for Comparative Effectiveness Research

Cleveland Clinic, Rheumatology & Immunology
2013 Risks associated with RA Medications
2013 Use of Observational Data to Facilitate Comparative Effectiveness Research
In Autoimmune Diseases

National Osteoporosis Foundation, Annual Scientific Meeting
2013 Responding to Patient Questions in the Exam Room
2013 Improving Quality of Care in Osteoporosis: A Clinician’s View

University of Massachusetts, Division of Rheumatology
2013 Comparative Safety of RA Medications in 2013

EULAR Annual Meeting, Madrid Spain
2013 New Methodology for Clinical Trials in Rheumatology

ACR Annual Meeting, San Diego CA
2013 Vaccination in Immunocompromised Patients: What does the evidence tell us?
2013 Effectively Incorporating Patient Reported Outcomes into Patient Consultations
2013 “Fine Tuning” Skills for Using Disease Activity Measurement Tools in RA

ACR Annual Reproductive Summit, Washington D.C.
2014 Strengths and Limitations of Registry and Other Data for Studying Pregnancy

National Association of Managed Care Physicians, Orlando FL
2014 Personalized Medicine for Patients with Rheumatoid Arthritis

Medical Learning Group, New York City NY
2014 Cardiovascular Disease and Related Comorbidities in Rheumatoid Arthritis

Kentucky/Indiana Rheumatology State Society, Lexington KY
2014 Rheumatoid Arthritis: New and Emerging Treatments

Puerto Rico Society of Rheumatologists, San Juan PR
2014 Optimal use of Non-Biologic DMARDs in Rheumatoid Arthritis

ASBMR Meet the Professor, Houston TX
2014 Use of Large Databases for Osteoporosis Research

Big Data in Pharma, Boston MA
2014 Linking Data to Support Comparative Effectiveness and Safety Research

ACR Annual Scientific Meeting 2014
2014 Meet the Professor: Vaccination for Patients on Biologic Therapies
2014 New Methods to Support Real-World Effectiveness Studies
2014 Patient Centered Research around PROs: a Frank Discussion

Dermatology Aesthetic and Clinical Conference, Orlando FL
2015 Bringing the Patient and Treatment Team Together in the Discussion of the Recognition and Management of Psoriatic Arthritis

NYU Seminar in Advanced Rheumatology, New York NY
2015 Risks of Rheumatoid Arthritis Treatments in 2015: Focus on Cancer and Infections

Washington University, St. Louis MO
2015 The Safety Profile of Biologic Medications in Rheumatoid Arthritis

Georgia Society for Rheumatology, Augusta GA
2015 Perceptions of Risk for Biologic Medications: Black and Blue, or White and Gold?
2015 The Art and Science of Measurement in Rheumatoid Arthritis

Arthritis Foundation Registry Conference, Atlanta GA
2015 Using Registries and Linked Data Sources to Support Comparative Effectiveness Research

Erlanger Medical Center, Chattanooga TN
2015 Rheumatoid Arthritis: Diagnosis, Treatment, and Comorbidities in 2015

New York University Langone Medical Center, New York City NY
2015 Visiting Professorship

NYUMC Advanced Course in Rheumatology, New York City NY
2016 Infections in Patients with Rheumatic Diseases

University of Memphis, Memphis TN
2016 Comorbidities in RA: Malignancies
2016 Comorbidities in RA: Risk for Infections

Clinical Congress of Rheumatology, Destin FL
2016 Biologic Safety: Black and Blue, or White and Gold?

UAB Primary Care Update in Rheumatology, Hoover AL
2016 Treatment of RA and Spondyloarthritis

Mt. Sinai Hospital (University of Toronto), Toronto CA
2016 Safety of Biologics in 2016: an Update
2016 Big Data in Rheumatology

Hospital for Special Surgery, New York, NY
2016 Understanding and Communicating Risks of Biologics

St. Vincent's Hospital, Melbourne Australia
2016 Managing and Preventing Comorbidities in RA Patients

Stanford University, Palo Alto CA
2016 Using Health IT and Big Data to Study Biologic Safety

National Institutes of Health, NIAMS branch, Washington DC
2016 Fantastic Clinical Data and Where to Find it

National Institutes of Health, NIEHS branch, Washington DC
2016 Incorporating Patient-Generated and Biosensor Data into Clinical Research

Georgetown University, Washington D.C.
2017 Health IT, Big Data and You

Washington D.C. VA Medical Center, Washington D.C.
2017 Health IT to support Clinical Care and Research: Examples from Rheumatology

Biologic and Biosimilar Collective Intelligence Consortium (BBCIC), Washington D.C.
2017 Methodologic Considerations in Biologic Switching

Association of Women in Rheumatology, Hilton Head, SC
2017 Trials, Registries, Health Econ, Oh My!

Yale University, New Haven, CT
2017 Big Data, Small Data and Informatics in Rheumatology

Food and Drug Administration, Washington DC
2017 Matching Real World Data and Evidence to Regulatory Use Cases

University Nebraska Medical Center, Omaha NE
2018 Big Data, Small Data, and Big Data in the Small

PCORnet Annual Meeting, Washington DC
2018 Lessons Learned from the Network: Participant Identification & Recruitment

Arkansas Rheumatology Association, Little Rock AR
2018 Vaccination in Rheumatology Patients: An Update

Arizona Rheumatology Association, Sedona AZ
2018 Big Data in Rheumatology: Who Needs It?

Florida Society of Rheumatology, Orlando FL
2018 Which Rheumatology Patients Need to be Vaccinated, and With What?

Association of Women in Rheumatology, Hilton Head SC
2018 Cardiovascular Risk Prediction in RA Patients

Louisiana Rheumatology Society, New Orleans, LA
2018 Vaccination in Rheumatic Disease Patients

BIBLIOGRAPHY

Original Manuscripts (Published or In Press)

1. Patino FG, Olivieri J, Allison JJ, Mikuls TR, Moreland L, Kovac SH, Juarez L, Person S, Curtis JR, Saag KG: Nonsteroidal Antiinflammatory Drug Toxicity Monitoring and Safety Practices. *J Rheumatol* 2003;30(12):2680-8.
2. Curtis JR, Lander PH, Moreland LW: Swallowing Difficulties from "Dish-Phagia". *J Rheumatol* 2004;31(12):2526-7.
3. Merlino LA, Curtis JR, Mikuls TR, Cerhan JR, Criswell LA, Saag KG, Iowa Women's Health S: Vitamin D Intake Is Inversely Associated with Rheumatoid Arthritis: Results from the Iowa Women's Health Study. *Arthritis Rheum* 2004;50(1):72-7.
4. Curtis JR, Olivieri J, Allison JJ, Gaffo A, Juarez L, Kovac SH, Person S, Saag KG: A Group Randomized Trial to Improve Safe Use of Nonsteroidal Anti-Inflammatory Drugs. *Am J Manag Care* 2005;11(9):537-43.
5. Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A, Spettell CM, Weissman NW, Wilke S, Saag KG: Longitudinal Patterns in the Prevention of Osteoporosis in Glucocorticoid-Treated Patients. *Arthritis Rheum* 2005;52(8):2485-94.
6. Mikuls TR, Saag KG, Curtis JR, Bridges SL, Jr., Alarcon GS, Westfall AO, Lim SS, Smith EA, Jonas BL, Moreland LW, Investigators C: Prevalence of Osteoporosis and Osteopenia among African Americans with Early Rheumatoid Arthritis: The Impact of Ethnic-Specific Normative Data. *J Natl Med Assoc* 2005;97(8):1155-60. PMC1364462.
7. Curtis JR, Westfall AO, Allison J, Freeman A, Kovac SH, Saag KG: Agreement and Validity of Pharmacy Data Versus Self-Report for Use of Osteoporosis Medications among Chronic Glucocorticoid Users. *Pharmacoepidemiol Drug Saf* 2006;15(10):710-8.
8. Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG: Channeling and Adherence with Alendronate and Risedronate among Chronic Glucocorticoid Users. *Osteoporos Int* 2006;17(8):1268-74.
9. Curtis JR, Smith B, Weaver M, Landers K, Lopez-Ben R, Raper JL, Saag M, Venkataraman R, Saag KG: Ethnic Variations in the Prevalence of Metabolic Bone Disease among Hiv-Positive Patients with Lipodystrophy. *AIDS Res Hum Retroviruses* 2006;22(2):125-31.

10. Curtis JR, Kim Y, Bryant T, Allison J, Scott D, Saag KG: Osteoporosis in the Home Health Care Setting: A Window of Opportunity? *Arthritis Rheum* 2006;55(6):971-5.
11. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG: Population-Based Assessment of Adverse Events Associated with Long-Term Glucocorticoid Use. *Arthritis Rheum* 2006;55(3):420-6.
12. Mikuls TR, Curtis JR, Allison JJ, Hicks RW, Saag KG: Medication Errors with the Use of Allopurinol and Colchicine: A Retrospective Study of a National, Anonymous Internet-Accessible Error Reporting System. *J Rheumatol* 2006;33(3):562-6.
13. Saag KG, Gehlbach SH, Curtis JR, Youket TE, Worley K, Lange JL: Trends in Prevention of Glucocorticoid-Induced Osteoporosis. *J Rheumatol* 2006;33(8):1651-7.
14. Shatin D, Rawson NS, Curtis JR, Braun MM, Martin CK, Moreland LW, Becker AF, Patkar NM, Allison JJ, Saag KG: Documented Tuberculin Skin Testing among Infliximab Users Following a Multi-Modal Risk Communication Interventions. *Pharmacoepidemiol Drug Saf* 2006;15(1):11-8.
15. Colon-Emeric C, Lyles KW, Levine DA, House P, Schenck A, Gorospe J, Fermazin M, Oliver K, Alison J, Weisman N, Xie A, Curtis JR, Saag K: Prevalence and Predictors of Osteoporosis Treatment in Nursing Home Residents with Known Osteoporosis or Recent Fracture. *Osteoporos Int* 2007;18(4):553-9. PMC1839837.
16. Colon-Emeric CS, Lyles KW, House P, Levine DA, Schenck AP, Allison J, Gorospe J, Fermazin M, Oliver K, Curtis JR, Weissman N, Xie A, Saag KG: Randomized Trial to Improve Fracture Prevention in Nursing Home Residents. *Am J Med* 2007;120(10):886-92. PMC2288656.
17. Curtis JR, Westfall AO, Allison J, Becker A, Melton ME, Freeman A, Kiefe CI, MacArthur M, Ockershausen T, Stewart E, Weissman N, Saag KG: Challenges in Improving the Quality of Osteoporosis Care for Long-Term Glucocorticoid Users: A Prospective Randomized Trial. *Arch Intern Med* 2007;167(6):591-6.
18. Curtis JR, Martin C, Saag KG, Patkar NM, Kramer J, Shatin D, Allison J, Braun MM: Confirmation of Administrative Claims-Identified Opportunistic Infections and Other Serious Potential Adverse Events Associated with Tumor Necrosis Factor Alpha Antagonists and Disease-Modifying Antirheumatic Drugs. *Arthritis Rheum* 2007;57(2):343-6.
19. Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C: Drug-Specific and Time-Dependent Risks of Bacterial Infection among Patients with Rheumatoid Arthritis Who Were Exposed to Tumor Necrosis Factor Alpha Antagonists. *Arthritis Rheum* 2007;56(12):4226-7. PMC2561262.
20. Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM: Heart Failure among Younger Rheumatoid Arthritis and Crohn's Patients Exposed to Tnf-Alpha Antagonists. *Rheumatology (Oxford)* 2007;46(11):1688-93. PMC2442887.
21. Curtis JR: Managing the Osteoporosis Patient in the Real World. *Journal of the American Medical Directors Association Symposium Reporter* 2007;8(S1):9-16.
22. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG: Risk of Serious Bacterial Infections among Rheumatoid Arthritis Patients Exposed to Tumor Necrosis Factor Alpha Antagonists. *Arthritis Rheum* 2007;56(4):1125-33.

23. Fry RB, Ray MN, Cobaugh DJ, Weissman NW, Kiefe CI, Shewchuk RM, Saag KG, Curtis JR, Allison JJ: Racial/Ethnic Disparities in Patient-Reported Nonsteroidal Antiinflammatory Drug (Nsaid) Risk Awareness, Patient-Doctor Nsaid Risk Communication, and Nsaid Risk Behavior. *Arthritis Rheum* 2007;57(8):1539-45.
24. Segal NA, Felson DT, Torner JC, Zhu Y, Curtis JR, Niu J, Nevitt MC, Multicenter Osteoarthritis Study G: Greater Trochanteric Pain Syndrome: Epidemiology and Associated Factors. *Arch Phys Med Rehabil* 2007;88(8):988-92. PMC2907104.
25. Curtis JR, Cheng H, Delzell E, Fram D, Kilgore M, Saag K, Yun H, Dumouchel W: Adaptation of Bayesian Data Mining Algorithms to Longitudinal Claims Data: Coxib Safety as an Example. *Med Care* 2008;46(9):969-75. PMC2694945.
26. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E: Benefit of Adherence with Bisphosphonates Depends on Age and Fracture Type: Results from an Analysis of 101,038 New Bisphosphonate Users. *J Bone Miner Res* 2008;23(9):1435-41. PMC2574615.
27. Curtis JR, Carbone L, Cheng H, Hayes B, Laster A, Matthews R, Saag KG, Sepanski R, Tanner SB, Delzell E: Longitudinal Trends in Use of Bone Mass Measurement among Older Americans, 1999-2005. *J Bone Miner Res* 2008;23(7):1061-7. PMC2497454.
28. Curtis JR, Laster AJ, Becker DJ, Carbone L, Gary LC, Kilgore ML, Matthews R, Morrisey MA, Saag KG, Tanner SB, Delzell E: Regional Variation in the Denial of Reimbursement for Bone Mineral Density Testing among Us Medicare Beneficiaries. *J Clin Densitom* 2008;11(4):568-74. PMC3429135.
29. Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG: Risk of Hip Fracture after Bisphosphonate Discontinuation: Implications for a Drug Holiday. *Osteoporos Int* 2008;19(11):1613-20. PMC2574626.
30. Kovac SH, Saag KG, Curtis JR, Allison J: Association of Health-Related Quality of Life with Dual Use of Prescription and over-the-Counter Nonsteroidal Antiinflammatory Drugs. *Arthritis Rheum* 2008;59(2):227-33.
31. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Jr., Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE, American College of R: American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. *Arthritis Rheum* 2008;59(6):762-84.
32. Segal NA, Harvey W, Felson DT, Yang M, Torner JC, Curtis JR, Nevitt MC, Multicenter Osteoarthritis Study G: Leg-Length Inequality Is Not Associated with Greater Trochanteric Pain Syndrome. *Arthritis Res Ther* 2008;10(3):R62. PMC2483453.
33. Segal NA, Torner JC, Yang M, Curtis JR, Felson DT, Nevitt MC, Multicenter Osteoarthritis Study G: Muscle Mass Is More Strongly Related to Hip Bone Mineral Density Than Is Quadriceps Strength or Lower Activity Level in Adults over Age 50 Year. *J Clin Densitom* 2008;11(4):503-10. PMC2654209.
34. Cheng H, Gary LC, Curtis JR, Saag KG, Kilgore ML, Morrisey MA, Matthews R, Smith W, Yun H, Delzell E: Estimated Prevalence and Patterns of Presumed Osteoporosis among Older Americans Based on Medicare Data. *Osteoporos Int* 2009;20(9):1507-15. PMC3767011.

35. Curtis JR, Arora T, Xi J, Silver A, Allison JJ, Chen L, Saag KG, Schenck A, Westfall AO, Colon-Emeric C: Do Physicians within the Same Practice Setting Manage Osteoporosis Patients Similarly? Implications for Implementation Research. *Osteoporos Int* 2009;20(11):1921-7. PMC2766011.
36. Curtis JR, Laster A, Becker DJ, Carbone L, Gary LC, Kilgore ML, Matthews RS, Morrissey MA, Saag KG, Tanner SB, Delzell E: The Geographic Availability and Associated Utilization of Dual-Energy X-Ray Absorptiometry (Dxa) Testing among Older Persons in the United States. *Osteoporos Int* 2009;20(9):1553-61. PMC2728788.
37. Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG: Identification and Validation of Vertebral Compression Fractures Using Administrative Claims Data. *Med Care* 2009;47(1):69-72. PMC2711626.
38. Curtis JR, Xi J, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E: Improving the Prediction of Medication Compliance: The Example of Bisphosphonates for Osteoporosis. *Med Care* 2009;47(3):334-41. PMC2693955.
39. Curtis JR, Taylor AJ, Matthews RS, Ray MN, Becker DJ, Gary LC, Kilgore ML, Morrissey MA, Saag KG, Warriner A, Delzell E: "Pathologic" Fractures: Should These Be Included in Epidemiologic Studies of Osteoporotic Fractures? *Osteoporos Int* 2009;20(11):1969-72. PMC2766025.
40. Curtis JR, McClure LA, Delzell E, Howard VJ, Orwoll E, Saag KG, Safford M, Howard G: Population-Based Fracture Risk Assessment and Osteoporosis Treatment Disparities by Race and Gender. *J Gen Intern Med* 2009;24(8):956-62. PMC2710475.
41. Curtis JR, Westfall AO, Cheng H, Saag KG, Delzell E: Risedronate and Alendronate Intervention over Three Years (Reality): Minimal Differences in Fracture Risk Reduction. *Osteoporos Int* 2009;20(6):973-8. PMC2711629.
42. Curtis JR, Arora T, Donaldson M, Alarcon GS, Callahan LF, Moreland LW, Bridges SL, Jr., Mikuls TR: Skeletal Health among African Americans with Recent-Onset Rheumatoid Arthritis. *Arthritis Rheum* 2009;61(10):1379-86. PMC2767103.
43. Curtis JR, Patkar NM, Jain A, Greenberg J, Solomon DH: Validity of Physician-Reported Hospitalized Infections in a Us Arthritis Registry. *Rheumatology (Oxford)* 2009;48(10):1269-72. PMC2744334.
44. Kilgore ML, Morrissey MA, Becker DJ, Gary LC, Curtis JR, Saag KG, Yun H, Matthews R, Smith W, Taylor A, Arora T, Delzell E: Health Care Expenditures Associated with Skeletal Fractures among Medicare Beneficiaries, 1999-2005. *J Bone Miner Res* 2009;24(12):2050-5.
45. Mudano AS, Bian J, Cope JU, Curtis JR, Gross TP, Allison JJ, Kim Y, Briggs D, Melton ME, Xi J, Saag KG: Vertebroplasty and Kyphoplasty Are Associated with an Increased Risk of Secondary Vertebral Compression Fractures: A Population-Based Cohort Study. *Osteoporos Int* 2009;20(5):819-26. PMC4089886.
46. Patkar NM, Curtis JR, Teng GG, Allison JJ, Saag M, Martin C, Saag KG: Administrative Codes Combined with Medical Records Based Criteria Accurately Identified Bacterial Infections among Rheumatoid Arthritis Patients. *J Clin Epidemiol* 2009;62(3):321-7, 27 e1-7. PMC2736855.
47. Anderson J, Sayles H, Curtis JR, Wolfe F, Michaud K: Converting Modified Health Assessment

- Questionnaire (Haq), Multidimensional Haq, and Haqii Scores into Original Haq Scores Using Models Developed with a Large Cohort of Rheumatoid Arthritis Patients. *Arthritis Care Res (Hoboken)* 2010;62(10):1481-8.
48. Becker DJ, Yun H, Kilgore ML, Curtis JR, Delzell E, Gary LC, Saag KG, Morrisey MA: Health Services Utilization after Fractures: Evidence from Medicare. *J Gerontol A Biol Sci Med Sci* 2010;65(9):1012-20.
 49. Beukelman T, Saag KG, Curtis JR, Kilgore ML, Pisu M: Cost-Effectiveness of Multifaceted Evidence Implementation Programs for the Prevention of Glucocorticoid-Induced Osteoporosis. *Osteoporos Int* 2010;21(9):1573-84. PMC3815619.
 50. Craig SM, Yu F, Curtis JR, Alarcon GS, Conn DL, Jonas B, Callahan LF, Smith EA, Moreland LW, Bridges SL, Jr., Mikuls TR: Vitamin D Status and Its Associations with Disease Activity and Severity in African Americans with Recent-Onset Rheumatoid Arthritis. *J Rheumatol* 2010;37(2):275-81. PMC3133625.
 51. Curtis JR, Jain A, Askling J, Bridges SL, Jr., Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A: A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. *Semin Arthritis Rheum* 2010;40(1):2-14 e1. PMC2958101.
 52. Curtis JR, Arora T, Narongroeknawin P, Taylor A, Bingham CO, 3rd, Cush J, Saag KG, Safford M, Delzell E: The Delivery of Evidence-Based Preventive Care for Older Americans with Arthritis. *Arthritis Res Ther* 2010;12(4):R144. PMC2945038.
 53. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, Reed G, Strand V, Kremer JM: Elevated Liver Enzyme Tests among Patients with Rheumatoid Arthritis or Psoriatic Arthritis Treated with Methotrexate and/or Leflunomide. *Ann Rheum Dis* 2010;69(1):43-7. PMC2794929.
 54. Curtis JR, Arora T, Matthews RS, Taylor A, Becker DJ, Colon-Emeric C, Kilgore ML, Morrisey MA, Saag KG, Safford MM, Warriner A, Delzell E: Is Withholding Osteoporosis Medication after Fracture Sometimes Rational? A Comparison of the Risk for Second Fracture Versus Death. *J Am Med Dir Assoc* 2010;11(8):584-91. PMC2950120.
 55. Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH: Physician Preference Motivates the Use of Anti-Tumor Necrosis Factor Therapy Independent of Clinical Disease Activity. *Arthritis Care Res (Hoboken)* 2010;62(1):101-7. PMC2913388.
 56. Donaldson MG, Cawthon PM, Lui LY, Schousboe JT, Ensrud KE, Taylor BC, Cauley JA, Hillier TA, Dam TT, Curtis JR, Black DM, Bauer DC, Orwoll ES, Cummings SR, Osteoporotic Fractures in Men Study G: Estimates of the Proportion of Older White Men Who Would Be Recommended for Pharmacologic Treatment by the New Us National Osteoporosis Foundation Guidelines. *J Bone Miner Res* 2010;25(7):1506-11. PMC3153995.
 57. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkman E, Saag KG: American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. *Arthritis Care Res (Hoboken)* 2010;62(11):1515-26.
 58. Hayes BL, Curtis JR, Laster A, Saag K, Tanner SB, Liu C, Womack C, Johnson KC, Khaliq F, Carbone LD: Osteoporosis Care in the United States after Declines in Reimbursements for

Dxa. *J Clin Densitom* 2010;13(4):352-60. PMC4420198.

59. Javaid MK, Lynch JA, Tolstykh I, Guermazi A, Roemer F, Aliabadi P, McCulloch C, Curtis JR, Felson D, Lane NE, Torner J, Nevitt M: Pre-Radiographic Mri Findings Are Associated with Onset of Knee Symptoms: The Most Study. *Osteoarthritis Cartilage* 2010;18(3):323-8. PMC2990960.
60. Narongroeknawin P, Danila MI, Humphreys LG, Jr., Barasch A, Curtis JR: Bisphosphonate-Associated Osteonecrosis of the Jaw, with Healing after Teriparatide: A Review of the Literature and a Case Report. *Spec Care Dentist* 2010;30(2):77-82. PMC4097110.
61. Neogi T, Nevitt MC, Yang M, Curtis JR, Torner J, Felson DT: Consistency of Knee Pain: Correlates and Association with Function. *Osteoarthritis Cartilage* 2010;18(10):1250-5. PMC2943545.
62. Nevitt MC, Zhang Y, Javaid MK, Neogi T, Curtis JR, Niu J, McCulloch CE, Segal NA, Felson DT: High Systemic Bone Mineral Density Increases the Risk of Incident Knee Oa and Joint Space Narrowing, but Not Radiographic Progression of Existing Knee Oa: The Most Study. *Ann Rheum Dis* 2010;69(1):163-8. PMC2935624.
63. Rassen JA, Solomon DH, Curtis JR, Herrinton L, Schneeweiss S: Privacy-Maintaining Propensity Score-Based Pooling of Multiple Databases Applied to a Study of Biologics. *Med Care* 2010;48(6 Suppl):S83-9. PMC2933455.
64. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, American Society for B, Mineral R: Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2010;25(11):2267-94.
65. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE, Investigators C: Risk of Elevated Liver Enzymes Associated with Tnf Inhibitor Utilisation in Patients with Rheumatoid Arthritis. *Ann Rheum Dis* 2010;69(9):1612-7.
66. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Setoguchi S, Greenberg JD: Explaining the Cardiovascular Risk Associated with Rheumatoid Arthritis: Traditional Risk Factors Versus Markers of Rheumatoid Arthritis Severity. *Ann Rheum Dis* 2010;69(11):1920-5. PMC2963658.
67. Yun H, Kilgore ML, Curtis JR, Delzell E, Gary LC, Saag KG, Morrissey MA, Becker D, Matthews R, Smith W, Locher JL: Identifying Types of Nursing Facility Stays Using Medicare Claims Data: An Algorithm and Validation. *Health Services and Outcomes Research Methodology* 2010;10(1-2):100-10.
68. Yun H, Delzell E, Ensrud KE, Kilgore ML, Becker D, Morrissey MA, Curtis JR: Predicting Hip and Major Osteoporotic Fractures Using Administrative Data. *Arch Intern Med* 2010;170(21):1940-2. PMC4046269.
69. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE, Investigators C: High Disease Activity Is Associated with an Increased Risk of Infection in Patients with Rheumatoid Arthritis. *Ann Rheum Dis* 2011;70(5):785-91.

70. Baddley JW, Winthrop KL, Patkar NM, Delzell E, Beukelman T, Xie F, Chen L, Curtis JR: Geographic Distribution of Endemic Fungal Infections among Older Persons, United States. *Emerg Infect Dis* 2011;17(9):1664-9. PMC3322071.
71. Blank RD, Members FPDC: Official Positions for Frax(R) Clinical Regarding Prior Fractures from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on Frax(R). *J Clin Densitom* 2011;14(3):205-11.
72. Blume SW, Curtis JR: Medical Costs of Osteoporosis in the Elderly Medicare Population. *Osteoporos Int* 2011;22(6):1835-44. PMC3767374.
73. Broy SB, Tanner SB, Members FRDC: Official Positions for Frax(R) Clinical Regarding Rheumatoid Arthritis from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on Frax(R). *J Clin Densitom* 2011;14(3):184-9.
74. Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, Caplan L, Kerr GS, Richards JS, Johnson DS, Sauer BC: Merging Veterans Affairs Rheumatoid Arthritis Registry and Pharmacy Data to Assess Methotrexate Adherence and Disease Activity in Clinical Practice. *Arthritis Care Res (Hoboken)* 2011;63(12):1680-90. PMC5497696.
75. Cauley JA, El-Hajj Fuleihan G, Luckey MM, Members FPDC: Frax(R) International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. *J Clin Densitom* 2011;14(3):237-9.
76. Cauley JA, El-Hajj Fuleihan G, Arabi A, Fujiwara S, Ragi-Eis S, Calderon A, Chionh SB, Chen Z, Curtis JR, Danielson ME, Hanley DA, Kroger H, Kung AW, Lesnyak O, Nieves J, Pluskiewicz W, El Rassi R, Silverman S, Schott AM, Rizzoli R, Luckey M, Members FPC: Official Positions for Frax(R) Clinical Regarding International Differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on Frax(R). *J Clin Densitom* 2011;14(3):240-62.
77. Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, Spettell C, McMahan RM, Fernandes J, Winthrop K, Delzell E: The Comparative Risk of Serious Infections among Rheumatoid Arthritis Patients Starting or Switching Biological Agents. *Ann Rheum Dis* 2011;70(8):1401-6. PMC3128235.
78. Curtis JR, Baddley JW, Yang S, Patkar N, Chen L, Delzell E, Mikuls TR, Saag KG, Singh J, Safford M, Cannon GW: Derivation and Preliminary Validation of an Administrative Claims-Based Algorithm for the Effectiveness of Medications for Rheumatoid Arthritis. *Arthritis Res Ther* 2011;13(5):R155. PMC3308085.
79. Curtis JR, Chen L, Luijckens K, Navarro-Millan I, Goel N, Gervitz L, Weinblatt M: Dose Escalation of Certolizumab Pegol from 200 Mg to 400 Mg Every Other Week Provides No Additional Efficacy in Rheumatoid Arthritis: An Analysis of Individual Patient-Level Data. *Arthritis Rheum* 2011;63(8):2203-8.
80. Curtis JR, Xie F, Chen L, Spettell C, McMahan RM, Fernandes J, Delzell E: The Incidence of Gastrointestinal Perforations among Rheumatoid Arthritis Patients. *Arthritis Rheum* 2011;63(2):346-51. PMC3031757.
81. Curtis JR, Hobar C, Hansbrough K: Injection-Site Burning and Stinging in Patients with Rheumatoid Arthritis Using Injectable Biologics. *Curr Med Res Opin* 2011;27(1):71-8.

PMC3694323.

82. Curtis JR, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, Judd S, Safford M, Solomon DH, Lacroix AZ: Placebo Adherence, Clinical Outcomes, and Mortality in the Women's Health Initiative Randomized Hormone Therapy Trials. *Med Care* 2011;49(5):427-35. PMC4217207.
83. Curtis JR, Delzell E, Chen L, Black D, Ensrud K, Judd S, Safford MM, Schwartz AV, Bauer DC: The Relationship between Bisphosphonate Adherence and Fracture: Is It the Behavior or the Medication? Results from the Placebo Arm of the Fracture Intervention Trial. *J Bone Miner Res* 2011;26(4):683-8. PMC3179329.
84. Curtis JR, Chen SY, Werther W, John A, Johnson DA: Validation of Icd-9-Cm Codes to Identify Gastrointestinal Perforation Events in Administrative Claims Data among Hospitalized Rheumatoid Arthritis Patients. *Pharmacoepidemiol Drug Saf* 2011;20(11):1150-8. PMC3227025.
85. Dimai HP, Chandran M, Members FRDC: Official Positions for Frax(R) Clinical Regarding Smoking from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on Frax(R). *J Clin Densitom* 2011;14(3):190-3.
86. Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Muller-Ladner U, Gaylis NB, Williams S, Reynard M, Tyrrell H: Retreatment with Rituximab Based on a Treatment-to-Target Approach Provides Better Disease Control Than Treatment as Needed in Patients with Rheumatoid Arthritis: A Retrospective Pooled Analysis. *Rheumatology (Oxford)* 2011;50(12):2223-32. PMC3222846.
87. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Nasir A, Setoguchi S, Solomon DH, Investigators C: Tumour Necrosis Factor Antagonist Use and Associated Risk Reduction of Cardiovascular Events among Patients with Rheumatoid Arthritis. *Ann Rheum Dis* 2011;70(4):576-82.
88. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR: Initiation of Tumor Necrosis Factor-Alpha Antagonists and the Risk of Hospitalization for Infection in Patients with Autoimmune Diseases. *JAMA* 2011;306(21):2331-9. PMC3428224.
89. Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Cooper C, Dawson-Hughes B, El-Hajj Fuleihan G, Leslie WD, Lewiecki EM, Luckey MM, McCloskey EV, Papapoulos SE, Poiana C, Rizzoli R, Members FPDC: Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on Frax((R)). Executive Summary of the 2010 Position Development Conference on Interpretation and Use of Frax(R) in Clinical Practice. *J Clin Densitom* 2011;14(3):171-80.
90. Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, Solomon DH, Griffin MR, Ouellet-Hellstrom R, Beukelman T, Grijalva CG, Haynes K, Kuriya B, Lii J, Mitchel E, Patkar N, Rassen J, Winthrop KL, Nourjah P, Saag KG: Study Design for a Comprehensive Assessment of Biologic Safety Using Multiple Healthcare Data Systems. *Pharmacoepidemiol Drug Saf* 2011;20(11):1199-209. PMC3312584.
91. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M,

- Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV, Task Force of the FI: Interpretation and Use of Frax in Clinical Practice. *Osteoporos Int* 2011;22(9):2395-411.
92. Kawai VK, Grijalva CG, Arbogast PG, Curtis JR, Solomon DH, Delzell E, Chen L, Ouellet-Hellstrom R, Herrinton L, Liu L, Mitchel EF, Jr., Stein CM, Griffin MR: Changes in Cotherapies after Initiation of Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2011;63(10):1415-24. PMC3227007.
93. Keystone EC, Curtis JR, Fleischmann RM, Furst DE, Khanna D, Smolen JS, Mease PJ, Schiff MH, Coteur G, Davies O, Combe B: Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-Hoc Analysis of a Randomized Controlled Trial. *J Rheumatol* 2011;38(6):990-6.
94. Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, Eisen SA: Tnf-Alpha Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans with Rheumatoid Arthritis. *Medicine (Baltimore)* 2011;90(2):139-45. PMC3076552.
95. Leib ES, Saag KG, Adachi JD, Geusens PP, Binkley N, McCloskey EV, Hans DB, Members FPDC: Official Positions for Frax((R)) Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by Frax((R)) of the 10 Year Risk of Fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on Frax((R)). *J Clin Densitom* 2011;14(3):212-9.
96. Lewiecki EM, Compston JE, Miller PD, Adachi JD, Adams JE, Leslie WD, Kanis JA, Members FPDC: Frax((R)) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. *J Clin Densitom* 2011;14(3):223-5.
97. Lewiecki EM, Compston JE, Miller PD, Adachi JD, Adams JE, Leslie WD, Kanis JA, Moayyeri A, Adler RA, Hans DB, Kendler DL, Diez-Perez A, Krieg MA, Masri BK, Lorenc RR, Bauer DC, Blake GM, Josse RG, Clark P, Khan AA, Members FPDC: Official Positions for Frax(R) Bone Mineral Density and Frax(R) Simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on Frax(R). *J Clin Densitom* 2011;14(3):226-36.
98. Masud T, Binkley N, Boonen S, Hannan MT, Members FPDC: Official Positions for Frax(R) Clinical Regarding Falls and Frailty: Can Falls and Frailty Be Used in Frax(R)? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on Frax(R). *J Clin Densitom* 2011;14(3):194-204.
99. McCloskey EV, Binkley N, Members FPDC: Frax((R)) Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. *J Clin Densitom* 2011;14(3):181-3.
100. McCloskey EV, Vasikaran S, Cooper C, Members FPDC: Official Positions for Frax(R) Clinical Regarding Biochemical Markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on Frax(R). *J Clin Densitom* 2011;14(3):220-2.
101. Song X, Shi N, Badamgarav E, Kallich J, Varker H, Lenhart G, Curtis JR: Cost Burden of

Second Fracture in the Us Health System. *Bone* 2011;48(4):828-36.

102. Taylor AJ, Gary LC, Arora T, Becker DJ, Curtis JR, Kilgore ML, Morrissey MA, Saag KG, Matthews R, Yun H, Smith W, Delzell E: Clinical and Demographic Factors Associated with Fractures among Older Americans. *Osteoporos Int* 2011;22(4):1263-74. PMC3767033.
103. Warriner AH, Patkar NM, Curtis JR, Delzell E, Gary L, Kilgore M, Saag K: Which Fractures Are Most Attributable to Osteoporosis? *J Clin Epidemiol* 2011;64(1):46-53. PMC5030717.
104. Wise BL, Felson DT, Clancy M, Niu J, Neogi T, Lane NE, Hietpas J, Curtis JR, Bradley LA, Torner JC, Zhang Y: Consistency of Knee Pain and Risk of Knee Replacement: The Multicenter Osteoarthritis Study. *J Rheumatol* 2011;38(7):1390-5. PMC3222910.
105. Zhang J, Shan Y, Reed G, Kremer J, Greenberg JD, Baumgartner S, Curtis JR: Thresholds in Disease Activity for Switching Biologics in Rheumatoid Arthritis Patients: Experience from a Large U.S. Cohort. *Arthritis Care Res (Hoboken)* 2011;63(12):1672-9. PMC3227763.
106. Zhang J, Delzell E, Xie F, Baddley JW, Spettell C, McMahan RM, Fernandes J, Chen L, Winthrop K, Curtis JR: The Use, Safety, and Effectiveness of Herpes Zoster Vaccination in Individuals with Inflammatory and Autoimmune Diseases: A Longitudinal Observational Study. *Arthritis Res Ther* 2011;13(5):R174. PMC3308109.
107. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Lewis JD, Ouellet-Hellstrom R, Patkar NM, Saag KG, Winthrop KL, Curtis JR, Collaboration S: Rates of Hospitalized Bacterial Infection Associated with Juvenile Idiopathic Arthritis and Its Treatment. *Arthritis Rheum* 2012;64(8):2773-80. PMC3409300.
108. Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD, Safety Assessment of Biological Therapeutics C: Rates of Malignancy Associated with Juvenile Idiopathic Arthritis and Its Treatment. *Arthritis Rheum* 2012;64(4):1263-71. PMC3315602.
109. Bharat A, Xie F, Baddley JW, Beukelman T, Chen L, Calabrese L, Delzell E, Grijalva CG, Patkar NM, Saag K, Winthrop KL, Curtis JR: Incidence and Risk Factors for Progressive Multifocal Leukoencephalopathy among Patients with Selected Rheumatic Diseases. *Arthritis Care Res (Hoboken)* 2012;64(4):612-5. PMC3310319.
110. Curtis JR, Yun H, Matthews R, Saag KG, Delzell E: Adherence with Intravenous Zoledronate and Intravenous Ibandronate in the United States Medicare Population. *Arthritis Care Res (Hoboken)* 2012;64(7):1054-60. PMC3355221.
111. Curtis JR, Ewing SK, Bauer DC, Cauley JA, Cawthon PM, Barrett-Connor E, Haney EM, Ishani A, Cremers S, Orwoll E: Association of Intact Parathyroid Hormone Levels with Subsequent Hip Bmd Loss: The Osteoporotic Fractures in Men (Mros) Study. *J Clin Endocrinol Metab* 2012;97(6):1937-44. PMC3387420.
112. Curtis JR, Yun H, Lange JL, Matthews R, Sharma P, Saag KG, Delzell E: Does Medication Adherence Itself Confer Fracture Protection? An Investigation of the Healthy Adherer Effect in Observational Data. *Arthritis Care Res (Hoboken)* 2012;64(12):1855-63. PMC3504186.
113. Curtis JR, John A, Baser O: Dyslipidemia and Changes in Lipid Profiles Associated with Rheumatoid Arthritis and Initiation of Anti-Tumor Necrosis Factor Therapy. *Arthritis Care Res (Hoboken)* 2012;64(9):1282-91. PMC3404153.

114. Curtis JR, Lanas A, John A, Johnson DA, Schulman KL: Factors Associated with Gastrointestinal Perforation in a Cohort of Patients with Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2012;64(12):1819-28. PMC3508293.
115. Curtis JR, Luijgens K, Kavanaugh A: Predicting Future Response to Certolizumab Pegol in Rheumatoid Arthritis Patients: Features at 12 Weeks Associated with Low Disease Activity at 1 Year. *Arthritis Care Res (Hoboken)* 2012;64(5):658-67. PMC3330194.
116. Curtis JR, Yang S, Chen L, Park GS, Bitman B, Wang B, Navarro-Millan I, Kavanaugh A: Predicting Low Disease Activity and Remission Using Early Treatment Response to Antitumour Necrosis Factor Therapy in Patients with Rheumatoid Arthritis: Exploratory Analyses from the Tempo Trial. *Ann Rheum Dis* 2012;71(2):206-12. PMC3698970.
117. Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E: Use of a Disease Risk Score to Compare Serious Infections Associated with Anti-Tumor Necrosis Factor Therapy among High- Versus Lower-Risk Rheumatoid Arthritis Patients. *Arthritis Care Res (Hoboken)* 2012;64(10):1480-9. PMC3687540.
118. Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME: Validation of a Novel Multibiomarker Test to Assess Rheumatoid Arthritis Disease Activity. *Arthritis Care Res (Hoboken)* 2012;64(12):1794-803. PMC3508159.
119. Fisher MC, Furer V, Hochberg MC, Greenberg JD, Kremer JM, Curtis JR, Reed G, Harrold L, Solomon DH: Malignancy Validation in a United States Registry of Rheumatoid Arthritis Patients. *BMC Musculoskelet Disord* 2012;13:85. PMC3403943.
120. Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Kremer J, Greenberg JD: Prescribing Practices in a Us Cohort of Rheumatoid Arthritis Patients before and after Publication of the American College of Rheumatology Treatment Recommendations. *Arthritis Rheum* 2012;64(3):630-8. PMC3253907.
121. Herrinton LJ, Liu L, Chen L, Harrold LR, Raebel MA, Curtis JR, Griffin MR, Solomon DH, Saag KG, Lewis JD: Association between Anti-Tnf-Alpha Therapy and All-Cause Mortality. *Pharmacoepidemiol Drug Saf* 2012;21(12):1311-20. PMC3565563.
122. Kilgore ML, Smith W, Curtis JR, Morrissey MA, Becker DJ, Saag KG, Delzell E: Evaluating Comorbidity Scores Based on Health Service Expenditures. *Medicare Medicaid Res Rev* 2012;2(3). PMC4006378.
123. Maska LB, Sayles HR, O'Dell JR, Curtis JR, Bridges SL, Jr., Moreland LW, Cofield SS, Mikuls TR: Serum Cotinine as a Biomarker of Tobacco Exposure and the Association with Treatment Response in Early Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2012;64(12):1804-10. PMC3467327.
124. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL, Jr., Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS, Investigators T: A Randomized Comparative Effectiveness Study of Oral Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis Rheum* 2012;64(9):2824-35. PMC4036119.
125. Narongroeknawin P, Patkar NM, Shakoory B, Jain A, Curtis JR, Delzell E, Lander PH, Lopez-

- Ben RR, Pitt MJ, Safford MM, Volgas DA, Saag KG: Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Atypical Femoral Fractures Using Administrative Claims Data. *J Clin Densitom* 2012;15(1):92-102. PMC4112756.
126. Outman RC, Curtis JR, Locher JL, Allison JJ, Saag KG, Kilgore ML: Improving Osteoporosis Care in High-Risk Home Health Patients through a High-Intensity Intervention. *Contemp Clin Trials* 2012;33(1):206-12. PMC4045407.
127. Saag KG, Mohr PE, Esmail L, Mudano AS, Wright N, Beukelman T, Curtis JR, Cutter G, Delzell E, Gary LC, Harrington TM, Karkare S, Kilgore ML, Lewis CE, Moloney R, Oliveira A, Singh JA, Warriner A, Zhang J, Berger M, Cummings SR, Pace W, Solomon DH, Wallace R, Tunis SR: Improving the Efficiency and Effectiveness of Pragmatic Clinical Trials in Older Adults in the United States. *Contemp Clin Trials* 2012;33(6):1211-6. PMC3675785.
128. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Jr., Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG: 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2012;64(5):625-39. PMC4081542.
129. Toh S, Li L, Harrold LR, Bayliss EA, Curtis JR, Liu L, Chen L, Grijalva CG, Herrinton LJ: Comparative Safety of Infliximab and Etanercept on the Risk of Serious Infections: Does the Association Vary by Patient Characteristics? *Pharmacoepidemiol Drug Saf* 2012;21(5):524-34. PMC3330193.
130. van der Heijde D, Keystone EC, Curtis JR, Landewe RB, Schiff MH, Khanna D, Kvien TK, Ionescu L, Gervitz LM, Davies OR, Luijckens K, Furst DE: Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-Hoc Analysis of the Rapid 1 Trial. *J Rheumatol* 2012;39(7):1326-33.
131. Viswanathan HN, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Wade SW: Direct Healthcare Costs of Osteoporosis-Related Fractures in Managed Care Patients Receiving Pharmacological Osteoporosis Therapy. *Appl Health Econ Health Policy* 2012;10(3):163-73.
132. Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN: Medication Adherence and Fracture Risk among Patients on Bisphosphonate Therapy in a Large United States Health Plan. *Bone* 2012;50(4):870-5.
133. Warriner AH, Outman RC, Kitchin E, Chen L, Morgan S, Saag KG, Curtis JR: A Randomized Trial of a Mailed Intervention and Self-Scheduling to Improve Osteoporosis Screening in Postmenopausal Women. *J Bone Miner Res* 2012;27(12):2603-10. PMC3502704.
134. Wright NC, Chen L, Niu J, Neogi T, Javiad K, Nevitt MA, Lewis CE, Curtis JR: Defining Physiologically "Normal" Vitamin D in African Americans. *Osteoporos Int* 2012;23(9):2283-91. PMC3677509.
135. Wright NC, Saag KG, Curtis JR, Smith WK, Kilgore ML, Morrissey MA, Yun H, Zhang J, Delzell ES: Recent Trends in Hip Fracture Rates by Race/Ethnicity among Older Us Adults. *J Bone Miner Res* 2012;27(11):2325-32.

136. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A: Efficacy of Tocilizumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and a Previous Inadequate Response to Disease-Modifying Antirheumatic Drugs: The Rose Study. *Ann Rheum Dis* 2012;71(2):198-205.
137. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR: Association between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection among Older Patients with Selected Immune-Mediated Diseases. *JAMA* 2012;308(1):43-9. PMC3683869.
138. Zhang J, Delzell E, Zhao H, Laster AJ, Saag KG, Kilgore ML, Morrissey MA, Wright NC, Yun H, Curtis JR: Central Dxa Utilization Shifts from Office-Based to Hospital-Based Settings among Medicare Beneficiaries in the Wake of Reimbursement Changes. *J Bone Miner Res* 2012;27(4):858-64.
139. Zhang J, Delzell E, Curtis JR: Postherpetic Neuralgia after Herpes Zoster Vaccination—Reply. *Jama* 2012;308(14):1427.
140. Asgari MM, Wu JJ, Gelfand JM, Salman C, Curtis JR, Harrold LR, Herrinton LJ: Validity of Diagnostic Codes and Prevalence of Psoriasis and Psoriatic Arthritis in a Managed Care Population, 1996-2009. *Pharmacoepidemiol Drug Saf* 2013;22(8):842-9. PMC3720770.
141. Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, Mannion ML, Patkar NM, Saag KG, Winthrop KL, Curtis JR, Collaboration S: Brief Report: Incidence of Selected Opportunistic Infections among Children with Juvenile Idiopathic Arthritis. *Arthritis Rheum* 2013;65(5):1384-9. PMC3636167.
142. Bowling CB, Muntner P, Bradbury BD, Kilpatrick RD, Isitt JJ, Warriner AH, Curtis JR, Judd S, Brown CJ, Allman RM, Warnock DG, McClellan W: Low Hemoglobin Levels and Recurrent Falls in U.S. Men and Women: Prospective Findings from the Reasons for Geographic and Racial Differences in Stroke (Regards) Cohort. *Am J Med Sci* 2013;345(6):446-54. PMC3640699.
143. Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, Turner M, Sutton C, Smith DR, Haney DJ, Chernoff D, Hesterberg LK, Carulli JP, Taylor PC, Shadick NA, Weinblatt ME, Curtis JR: Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. *PLoS One* 2013;8(4):e60635. PMC3621826.
144. Curtis JR, McVie T, Mikuls TR, Reynolds RJ, Navarro-Millan I, O'Dell J, Moreland LW, Bridges SL, Jr., Ranganath VK, Cofield SS: Clinical Response within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early Ra: Results from the Tear Trial. *J Rheumatol* 2013;40(5):572-8. PMC3694569.
145. Curtis JR, Chastek B, Becker L, Harrison DJ, Collier D, Yun H, Joseph GJ: Further Evaluation of a Claims-Based Algorithm to Determine the Effectiveness of Biologics for Rheumatoid Arthritis Using Commercial Claims Data. *Arthritis Res Ther* 2013;15(2):404. PMC3672715.
146. Curtis JR, Xie F, Chen R, Chen L, Kilgore ML, Lewis JD, Yun H, Zhang J, Wright NC, Delzell E: Identifying Newly Approved Medications in Medicare Claims Data: A Case Study Using Tocilizumab. *Pharmacoepidemiol Drug Saf* 2013;22(11):1214-21. PMC3856178.
147. Curtis JR, Cai Q, Wade SW, Stolshek BS, Adams JL, Balasubramanian A, Viswanathan HN, Kallich JD: Osteoporosis Medication Adherence: Physician Perceptions Vs. Patients' Utilization. *Bone* 2013;55(1):1-6. PMC3777338.

148. Curtis JR, Shan Y, Harrold L, Zhang J, Greenberg JD, Reed GW: Patient Perspectives on Achieving Treat-to-Target Goals: A Critical Examination of Patient-Reported Outcomes. *Arthritis Care Res (Hoboken)* 2013;65(10):1707-12.
149. Curtis JR, Sharma P, Arora T, Bharat A, Barnes I, Morrisey MA, Kilgore M, Saag KG, Wright NC, Yun HG, Delzell E: Physicians' Explanations for Apparent Gaps in the Quality of Rheumatology Care: Results from the Us Medicare Physician Quality Reporting System. *Arthritis Care Res (Hoboken)* 2013;65(2):235-43. PMC3414685.
150. Dewitt EM, Li Y, Curtis JR, Glick HA, Greenberg JD, Anstrom KJ, Kremer JM, Reed G, Schulman KA, Reed SD: Comparative Effectiveness of Nonbiologic Versus Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis. *J Rheumatol* 2013;40(2):127-36.
151. Ettinger B, Ensrud KE, Blackwell T, Curtis JR, Lapidus JA, Orwoll ES, Osteoporotic Fracture in Men Study Research G: Performance of Frax in a Cohort of Community-Dwelling, Ambulatory Older Men: The Osteoporotic Fractures in Men (Mros) Study. *Osteoporos Int* 2013;24(4):1185-93. PMC3767034.
152. Harrold LR, Salman C, Shoor S, Curtis JR, Asgari MM, Gelfand JM, Wu JJ, Herrinton LJ: Incidence and Prevalence of Juvenile Idiopathic Arthritis among Children in a Managed Care Population, 1996-2009. *J Rheumatol* 2013;40(7):1218-25. PMC5657479.
153. Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD, Collaboration S: Tumor Necrosis Factor Alpha Inhibitor Therapy and Cancer Risk in Chronic Immune-Mediated Diseases. *Arthritis Rheum* 2013;65(1):48-58. PMC3778442.
154. Herrinton LJ, Harrold LR, Liu L, Raebel MA, Taharka A, Winthrop KL, Solomon DH, Curtis JR, Lewis JD, Saag KG: Association between Anti-Tnf-Alpha Therapy and Interstitial Lung Disease. *Pharmacoepidemiol Drug Saf* 2013;22(4):394-402. PMC3618622.
155. Kawai VK, Grijalva CG, Arbogast PG, Curtis JR, Solomon DH, Delzell E, Chen L, Ouellet-Hellstrom R, Herrinton L, Liu L, Mitchell EF, Jr., Stein CM, Griffin MR: Initiation of Tumor Necrosis Factor Alpha Antagonists and Risk of Fractures in Patients with Selected Rheumatic and Autoimmune Diseases. *Arthritis Care Res (Hoboken)* 2013;65(7):1085-94. PMC3631448.
156. Kilgore ML, Curtis JR, Delzell E, Becker DJ, Arora T, Saag KG, Morrisey MA: A Close Examination of Healthcare Expenditures Related to Fractures. *J Bone Miner Res* 2013;28(4):816-20.
157. Kilgore ML, Outman R, Locher JL, Allison JJ, Mudano A, Kitchin B, Saag KG, Curtis JR: Multimodal Intervention to Improve Osteoporosis Care in Home Health Settings: Results from a Cluster Randomized Trial. *Osteoporos Int* 2013;24(10):2555-60. PMC4089895.
158. Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundry JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S, Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI: Using Registries to Identify Adverse Events in Rheumatic Diseases. *Pediatrics* 2013;132(5):e1384-94. PMC3813393.
159. Min Z, Curtis JR, Baddley JW: Epidemiologic Research of Invasive Fungal Infections Using Large Healthcare Databases. *Current Fungal Infection Reports* 2013;7(4):320-25.

160. Mudano AS, Gary LC, Oliveira AL, Melton M, Wright NC, Curtis JR, Delzell E, Harrington TM, Kilgore ML, Lewis CE, Singh JA, Warriner AH, Pace WD, Saag KG: Using Tablet Computers Compared to Interactive Voice Response to Improve Subject Recruitment in Osteoporosis Pragmatic Clinical Trials: Feasibility, Satisfaction, and Sample Size. *Patient Prefer Adherence* 2013;7:517-23. PMC3685447.
161. Navarro-Millan I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL, Jr., Chen L, Cofield SS, Dell'Italia LJ, Moreland LW, O'Dell JR, Paulus HE, Curtis JR: Changes in Lipoproteins Associated with Methotrexate or Combination Therapy in Early Rheumatoid Arthritis: Results from the Treatment of Early Rheumatoid Arthritis Trial. *Arthritis Rheum* 2013;65(6):1430-8. PMC3672346.
162. Navarro-Millan I, Chen L, Greenberg JD, Pappas DA, Curtis JR: Predictors and Persistence of New-Onset Clinical Remission in Rheumatoid Arthritis Patients. *Semin Arthritis Rheum* 2013;43(2):137-43. PMC4184191.
163. Navarro-Millan I, Sattui SE, Curtis JR: Systematic Review of Tumor Necrosis Factor Inhibitor Discontinuation Studies in Rheumatoid Arthritis. *Clin Ther* 2013;35(11):1850-61 e1. PMC3917677.
164. O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL, Jr., Ranganath VK, Moreland LW, Investigators TT: Validation of the Methotrexate-First Strategy in Patients with Early, Poor-Prognosis Rheumatoid Arthritis: Results from a Two-Year Randomized, Double-Blind Trial. *Arthritis Rheum* 2013;65(8):1985-94. PMC4768726.
165. Saag KG, Winthrop K, Curtis JR: Tumor Necrosis Factor, Tuberculosis, Testing, and Treatment: Teeing up the Questions. *Arthritis Care Res (Hoboken)* 2013;65(11):1719-21.
166. Schousboe JT, Paudel ML, Taylor BC, Virnig BA, Cauley JA, Curtis JR, Ensrud KE: Magnitude and Consequences of Misclassification of Incident Hip Fractures in Large Cohort Studies: The Study of Osteoporotic Fractures and Medicare Claims Data. *Osteoporos Int* 2013;24(3):801-10. PMC3738433.
167. Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, Graham DJ, Kowal MK, Kuriya B, Liu L, Griffin MR, Lewis JD, Rassen JA: Cardiovascular Risk in Rheumatoid Arthritis: Comparing Tnf-Alpha Blockade with Nonbiologic Dmards. *Am J Med* 2013;126(8):730 e9-30 e17. PMC4674813.
168. Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR: Heart Failure Risk among Patients with Rheumatoid Arthritis Starting a Tnf Antagonist. *Ann Rheum Dis* 2013;72(11):1813-8.
169. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR: Association between the Initiation of Anti-Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster. *JAMA* 2013;309(9):887-95. PMC3773213.
170. Winthrop KL, Chen L, Fraunfelder FW, Ku JH, Varley CD, Suhler E, Hills WL, Gattey D, Baddley JW, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Herrinton LJ, Fraunfelder FT, Saag KG, Lewis JD, Solomon DH, Curtis JR: Initiation of Anti-Tnf Therapy and the Risk of Optic Neuritis: From the Safety Assessment of Biologic Therapy (Saber) Study. *Am J Ophthalmol* 2013;155(1):183-89 e1. PMC4142597.

171. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, Rosenbaum JT, Herrinton LJ: Mycobacterial Diseases and Antitumour Necrosis Factor Therapy in USA. *Ann Rheum Dis* 2013;72(1):37-42.
172. Winthrop KL, Hills WL, Fraunfelder FT, Fraunfelder FW, Curtis JR: Reply: To Pmid 22967869. *Am J Ophthalmol* 2013;156(2):408.
173. Xue F, Ma H, Stehman-Breen C, Haller C, Katz L, Wagman RB, Critchlow CW, Denosumab Global Safety Assessment T: Design and Methods of a Postmarketing Pharmacoepidemiology Study Assessing Long-Term Safety of Prolia(R) (Denosumab) for the Treatment of Postmenopausal Osteoporosis. *Pharmacoepidemiol Drug Saf* 2013;22(10):1107-14. PMC4230463.
174. Yazici Y, Curtis JR, Ince A, Baraf HS, Lepley DM, Devenport JN, Kavanaugh A: Early Effects of Tocilizumab in the Treatment of Moderate to Severe Active Rheumatoid Arthritis: A One-Week Sub-Study of a Randomised Controlled Trial (Rapid Onset and Systemic Efficacy [Rose] Study). *Clin Exp Rheumatol* 2013;31(3):358-64.
175. Yun H, Curtis JR, Saag K, Kilgore M, Muntner P, Smith W, Matthews R, Wright N, Morrissey MA, Delzell E: Generic Alendronate Use among Medicare Beneficiaries: Are Part D Data Complete? *Pharmacoepidemiol Drug Saf* 2013;22(1):55-63. PMC4052770.
176. Zhang J, Xie F, Delzell E, Chen L, Kilgore ML, Yun H, Saag KG, Lewis JD, Curtis JR: Trends in the Use of Biologic Agents among Rheumatoid Arthritis Patients Enrolled in the Us Medicare Program. *Arthritis Care Res (Hoboken)* 2013;65(11):1743-51.
177. Aslibekyan S, Sha J, Redden DT, Moreland LW, O'Dell JR, Curtis JR, Mikuls TR, Reynolds RJ, Danila MI, Bridges SL, Jr.: Gene-Body Mass Index Interactions Are Associated with Methotrexate Toxicity in Rheumatoid Arthritis. *Ann Rheum Dis* 2014;73(4):785-6. PMC3970399.
178. Aslibekyan S, Brown EE, Reynolds RJ, Redden DT, Morgan S, Baggott JE, Sha J, Moreland LW, O'Dell JR, Curtis JR, Mikuls TR, Bridges SL, Jr., Arnett DK: Genetic Variants Associated with Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results from the Treatment of Early Aggressive Rheumatoid Arthritis Trial. *Pharmacogenomics J* 2014;14(1):48-53. PMC3701736.
179. Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR: Non-Viral Opportunistic Infections in New Users of Tumour Necrosis Factor Inhibitor Therapy: Results of the Safety Assessment of Biologic Therapy (Saber) Study. *Ann Rheum Dis* 2014;73(11):1942-8. PMC4273901.
180. Becker DJ, Arora T, Kilgore ML, Curtis JR, Delzell E, Saag KG, Yun H, Morrissey MA: Trends in the Utilization and Outcomes of Medicare Patients Hospitalized for Hip Fracture, 2000-2008. *J Aging Health* 2014;26(3):360-79.
181. Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Harrison DJ, Joseph GJ, Sauer BC: Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in Us Veterans with Rheumatoid Arthritis. *J Rheumatol* 2014;41(10):1935-43.
182. Curtis JR, Schabert VF, Harrison DJ, Yeaw J, Korn JR, Quach C, Yun H, Joseph GJ, Collier DH: Estimating Effectiveness and Cost of Biologics for Rheumatoid Arthritis: Application of a

Validated Algorithm to Commercial Insurance Claims. *Clin Ther* 2014;36(7):996-1004.

183. Curtis JR, Chen L, Bharat A, Delzell E, Greenberg JD, Harrold L, Kremer J, Setoguchi S, Solomon DH, Xie F, Yun H: Linkage of a De-Identified United States Rheumatoid Arthritis Registry with Administrative Data to Facilitate Comparative Effectiveness Research. *Arthritis Care Res (Hoboken)* 2014;66(12):1790-8. PMC4245366.
184. Curtis JR, Kwok CK, Rizzoli AJ, Welz JA: A Multistakeholder Approach to Improving Quality in Rheumatoid Arthritis: Proceedings from the Rheumatoid Arthritis Quality Expert Medical Panel. *Am Health Drug Benefits* 2014;7(8 Suppl 4):S51-61. PMC4639936.
185. Curtis JR: Reply: To Pmid 22504829. *Arthritis Care Res (Hoboken)* 2014;66(8):1271-2.
186. Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, Mikuls TR, Delzell E, Saag KG, Safford MM, DuVall S, Alexander K, Napalkov P, Winthrop KL, Burton MJ, Kamauu A, Baddley JW: Risk of Hospitalized Bacterial Infections Associated with Biologic Treatment among Us Veterans with Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2014;66(7):990-7. PMC5059836.
187. Curtis JR, Schabert VF, Yeaw J, Korn JR, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier D: Use of a Validated Algorithm to Estimate the Annual Cost of Effective Biologic Treatment for Rheumatoid Arthritis. *J Med Econ* 2014;17(8):555-66.
188. Curtis JR, Wright NC, Xie F, Chen L, Zhang J, Saag KG, Bharat A, Kremer J, Cofield S, Winthrop K, Delzell E: Use of Health Plan Combined with Registry Data to Predict Clinical Trial Recruitment. *Clin Trials* 2014;11(1):96-101. PMC4199104.
189. Curtis JR, Zhang J, Xie F, Beukelman T, Chen L, Fernandes J, Ginsberg S, Spettell C, Yun H, Saag KG, Schiff M: Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States. *Arthritis Care Res (Hoboken)* 2014;66(11):1604-11.
190. Keystone EC, Anisfeld A, Ogale S, Devenport JN, Curtis JR: Continued Benefit of Tocilizumab Plus Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis and Inadequate Clinical Responses by Week 8 of Treatment. *J Rheumatol* 2014;41(2):216-26.
191. Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, Safford MM, Kissela BM, Howard G, Jalbert JJ, Brott TG, Setoguchi S: Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: Reasons for Geographic and Racial Differences in Stroke (Regards) Study Linked with Medicare Claims. *Circ Cardiovasc Qual Outcomes* 2014;7(4):611-9. PMC4109622.
192. Mannion ML, Xie F, Curtis JR, Beukelman T: Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors. *J Rheumatol* 2014;41(10):2078-84.
193. Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger C, Chen L, Xie F, Curtis JR, Lewis JD: Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease. *Clin Gastroenterol Hepatol* 2014;12(5):811-17 e3. PMC3883891.
194. Pappas DA, Kremer JM, Reed G, Greenberg JD, Curtis JR: "Design Characteristics of the Corrona Certain Study: A Comparative Effectiveness Study of Biologic Agents for Rheumatoid Arthritis Patients". *BMC Musculoskelet Disord* 2014;15:113. PMC3978136.
195. Ray M, Curtis JR, Baddley JW: A Case Report of Progressive Multifocal Leucoencephalopathy

(Pml) Associated with Adalimumab. *Ann Rheum Dis* 2014;73(7):1429-30.

196. Safford MM, Barasch A, Curtis JR, Outman R, Saag K: Bisphosphonates and Hip and Nontraumatic Subtrochanteric Femoral Fractures in the Veterans Health Administration. *J Clin Rheumatol* 2014;20(7):357-62.
197. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP: Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2014;29(1):1-23.
198. Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, Hochberg MC, Reed G, Tsao P, Greenberg JD: Comparative Cancer Risk Associated with Methotrexate, Other Non-Biologic and Biologic Disease-Modifying Anti-Rheumatic Drugs. *Semin Arthritis Rheum* 2014;43(4):489-97.
199. Tajeu GS, Delzell E, Smith W, Arora T, Curtis JR, Saag KG, Morrissey MA, Yun H, Kilgore ML: Death, Debility, and Destitution Following Hip Fracture. *J Gerontol A Biol Sci Med Sci* 2014;69(3):346-53. PMC3976138.
200. Thacker EL, Muntner P, Zhao H, Safford MM, Curtis JR, Delzell E, Bittner V, Brown TM, Levitan EB: Claims-Based Algorithms for Identifying Medicare Beneficiaries at High Estimated Risk for Coronary Heart Disease Events: A Cross-Sectional Study. *BMC Health Serv Res* 2014;14:195. PMC4101858.
201. Warriner AH, Outman RC, Feldstein AC, Roblin DW, Allison JJ, Curtis JR, Redden DT, Rix MM, Robinson BE, Rosales AG, Safford MM, Saag KG: Effect of Self-Referral on Bone Mineral Density Testing and Osteoporosis Treatment. *Med Care* 2014;52(8):743-50. PMC4101066.
202. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, Nduaka CI, Benda B, Gruben D, Nakamura H, Komuro Y, Zwillich SH, Wang L, Riese RJ: Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-Label, Longterm Extension Studies. *J Rheumatol* 2014;41(5):837-52.
203. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B: The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine. *J Bone Miner Res* 2014;29(11):2520-6. PMC4757905.
204. Wu JJ, Liu L, Asgari MM, Curtis JR, Harrold L, Salman C, Herrinton LJ: Initiation of Tnf Inhibitor Therapy and Change in Physiologic Measures in Psoriasis. *J Eur Acad Dermatol Venereol* 2014;28(10):1380-7. PMC4201939.
205. Yun H, Curtis JR, Guo L, Kilgore M, Muntner P, Saag K, Matthews R, Morrissey M, Wright NC, Becker DJ, Delzell E: Patterns and Predictors of Osteoporosis Medication Discontinuation and Switching among Medicare Beneficiaries. *BMC Musculoskelet Disord* 2014;15:112. PMC4022369.
206. Zhang HF, Gauthier G, Hiscock R, Curtis JR: Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Oral Nonbiologic or Biologic Disease-Modifying Antirheumatic Drugs. *Arthritis Res Ther* 2014;16(4):420. PMC4180135.

207. Zhang J, Chen L, Delzell E, Muntner P, Hillegass WB, Safford MM, Millan IY, Crowson CS, Curtis JR: The Association between Inflammatory Markers, Serum Lipids and the Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis. *Ann Rheum Dis* 2014;73(7):1301-8.
208. Zhang J, Chen L, Delzell E, Muntner P, Hillegass WB, Safford MM, Millan IY, Crowson CS, Curtis JR: Republished: The Association between Inflammatory Markers, Serum Lipids and the Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis. *Postgrad Med J* 2014;90(1070):722-9.
209. Zhang J, Delzell E, Curtis JR, Hooven F, Gehlbach SH, Anderson FA, Jr., Saag KG: Use of Pharmacologic Agents for the Primary Prevention of Osteoporosis among Older Women with Low Bone Mass. *Osteoporos Int* 2014;25(1):317-24.
210. Barnabe C, Sun Y, Boire G, Hitchon CA, Haraoui B, Thorne JC, Tin D, van der Heijde D, Curtis JR, Jamal S, Pope JE, Keystone EC, Bartlett S, Bykerk VP, Investigators C: Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (Catch). *PLoS One* 2015;10(8):e0135327. PMC4547697.
211. Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F, Roy JA, Aarons CB, Osterman MT, Forde KA, Curtis JR, Lewis JD: Mortality Associated with Medical Therapy Versus Elective Colectomy in Ulcerative Colitis: A Cohort Study. *Ann Intern Med* 2015;163(4):262-70. PMC4925099.
212. Burton MJ, Curtis JR, Yang S, Chen L, Singh JA, Mikuls TR, Winthrop KL, Baddley JW: Safety of Biologic and Nonbiologic Disease-Modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis B Virus Infection: A Retrospective Cohort Study. *Arthritis Res Ther* 2015;17:136. PMC4489034.
213. Crandall CJ, Hovey KM, Andrews CA, Cauley JA, Manson JE, Wactawski-Wende J, Wright NC, Li W, Beavers K, Curtis JR, LeBoff MS: Bone Mineral Density as a Predictor of Subsequent Wrist Fractures: Findings from the Women's Health Initiative Study. *J Clin Endocrinol Metab* 2015;100(11):4315-24. PMC4702460.
214. Crandall CJ, Hovey KM, Cauley JA, Andrews CA, Curtis JR, Wactawski-Wende J, Wright NC, Li W, LeBoff MS: Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative Study. *J Bone Miner Res* 2015;30(11):2086-95. PMC4615529.
215. Curtis JR, Chastek B, Becker L, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier DH: Cost and Effectiveness of Biologics for Rheumatoid Arthritis in a Commercially Insured Population. *J Manag Care Spec Pharm* 2015;21(4):318-29.
216. Curtis JR, Yang S, Chen L, Pope JE, Keystone EC, Haraoui B, Boire G, Thorne JC, Tin D, Hitchon CA, Bingham CO, 3rd, Bykerk VP: Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. *Arthritis Care Res (Hoboken)* 2015;67(10):1345-53. PMC4580563.
217. Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL: Incidence and Complications of Interstitial Lung Disease in Users of Tocilizumab, Rituximab, Abatacept and Anti-Tumor Necrosis Factor Alpha Agents, a Retrospective Cohort Study. *Arthritis Res Ther* 2015;17:319. PMC4641344.
218. Curtis JR, Churchill M, Kivitz A, Samad A, Gauer L, Gervitz L, Koetse W, Melin J, Yazici Y: A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol. *Arthritis Rheumatol*

2015;67(12):3104-12. PMC5063165.

219. Curtis JR, Xie F, Yun H, Saag KG, Chen L, Delzell E: Risk of Hospitalized Infection among Rheumatoid Arthritis Patients Concurrently Treated with a Biologic Agent and Denosumab. *Arthritis Rheumatol* 2015;67(6):1456-64.
220. Curtis JR, Perez-Gutthann S, Suissa S, Napalkov P, Singh N, Thompson L, Porter-Brown B, Actemra Pharmacoeconomics B: Tocilizumab in Rheumatoid Arthritis: A Case Study of Safety Evaluations of a Large Postmarketing Data Set from Multiple Data Sources. *Semin Arthritis Rheum* 2015;44(4):381-8.
221. Dias-Barbosa C, Guillemin I, Aassi M, Bernasconi C, Brethous M, Reiss W, Arnould B, Curtis JR: Methotrexate Adherence Questionnaire: A New Tool to Assess Adherence in Patients Treated with Methotrexate. *Value Health* 2015;18(7):A714-5.
222. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD: The Comparative Effectiveness of Abatacept Versus Anti-Tumour Necrosis Factor Switching for Rheumatoid Arthritis Patients Previously Treated with an Anti-Tumour Necrosis Factor. *Ann Rheum Dis* 2015;74(2):430-6. PMC4316858.
223. Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, Etzel CJ, Cox V, Yoshida K, Reed GW, Solomon DH: Discontinuation of Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis in Low-Disease Activity: Persistent Benefits. Data from the Corrona Registry. *Ann Rheum Dis* 2015;74(6):1150-5.
224. Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GD, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH: Proceedings from the American College of Rheumatology Reproductive Health Summit: The Management of Fertility, Pregnancy, and Lactation in Women with Autoimmune and Systemic Inflammatory Diseases. *Arthritis Care Res (Hoboken)* 2015;67(3):313-25.
225. Kent ST, Safford MM, Zhao H, Levitan EB, Curtis JR, Kilpatrick RD, Kilgore ML, Muntner P: Optimal Use of Available Claims to Identify a Medicare Population Free of Coronary Heart Disease. *Am J Epidemiol* 2015;182(9):808-19. PMC4617296.
226. LaFleur J, DuVall SL, Willson T, Ginter T, Patterson O, Cheng Y, Knippenberg K, Haroldsen C, Adler RA, Curtis JR, Agodoa I, Nelson RE: Analysis of Osteoporosis Treatment Patterns with Bisphosphonates and Outcomes among Postmenopausal Veterans. *Bone* 2015;78:174-85.
227. Muntner P, Gutierrez OM, Zhao H, Fox CS, Wright NC, Curtis JR, McClellan W, Wang H, Kilgore M, Warnock DG, Bowling CB: Validation Study of Medicare Claims to Identify Older Us Adults with Ckd Using the Reasons for Geographic and Racial Differences in Stroke (Regards) Study. *Am J Kidney Dis* 2015;65(2):249-58. PMC4721899.
228. Nadkarni A, You M, Resuehr H, Curtis JR: The Risk for Cardiovascular Events Associated with Hyperlipidemia among Patients with and without Rheumatoid Arthritis. *J Arthritis* 2015;4(4). PMC4727537.
229. Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger CM, Chen L, Xie F, Curtis JR, Lewis JD: Effectiveness and Safety of Immunomodulators with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease. *Clin Gastroenterol Hepatol* 2015;13(7):1293-301 e5; quiz e70, e72. PMC4475667.

230. Overman RA, Farley JF, Curtis JR, Zhang J, Gourlay ML, Deal CL: Dxa Utilization between 2006 and 2012 in Commercially Insured Younger Postmenopausal Women. *J Clin Densitom* 2015;18(2):145-9. PMC4420644.
231. Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, Greenberg JD, Curtis JR: Herpes Zoster Reactivation in Patients with Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. *Arthritis Care Res (Hoboken)* 2015;67(12):1671-8.
232. Ranganath VK, Motamedi K, Haavardsholm EA, Maranian P, Elashoff D, McQueen F, Duffy EL, Bathon JM, Curtis JR, Chen W, Moreland L, Louie J, Amjadi S, O'Dell J, Cofield SS, St Clair EW, Bridges SL, Jr., Paulus HE: Comprehensive Appraisal of Magnetic Resonance Imaging Findings in Sustained Rheumatoid Arthritis Remission: A Substudy. *Arthritis Care Res (Hoboken)* 2015;67(7):929-39. PMC4482777.
233. Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, Mikuls TR: Modifiable Factors Associated with Allopurinol Adherence and Outcomes among Patients with Gout in an Integrated Healthcare System. *J Rheumatol* 2015;42(3):504-12. PMC4922495.
234. Silverman S, Curtis J, Saag K, Flahive J, Adachi J, Anderson F, Chapurlat R, Cooper C, Diez-Perez A, Greenspan S, Hooven F, Le Croix A, March L, Netelenbos JC, Nieves J, Pfeilschifter J, Rossini M, Roux C, Siris E, Watts N, Compston J: International Management of Bone Health in Glucocorticoid-Exposed Individuals in the Observational Glow Study. *Osteoporos Int* 2015;26(1):419-20. PMC4873770.
235. Solomon DH, Greenberg J, Curtis JR, Liu M, Farkouh ME, Tsao P, Kremer JM, Etzel CJ: Derivation and Internal Validation of an Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis: A Consortium of Rheumatology Researchers of North America Registry Study. *Arthritis Rheumatol* 2015;67(8):1995-2003.
236. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, Hochberg MC, Tsao P, Greenberg JD: Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events. *Arthritis Rheumatol* 2015;67(6):1449-55. PMC4446181.
237. Unni S, Yao Y, Milne N, Gunning K, Curtis JR, LaFleur J: An Evaluation of Clinical Risk Factors for Estimating Fracture Risk in Postmenopausal Osteoporosis Using an Electronic Medical Record Database. *Osteoporos Int* 2015;26(2):581-7.
238. Warriner AH, Outman RC, Allison JJ, Curtis JR, Markward NJ, Redden DT, Safford MM, Stanek EJ, Steinkellner AR, Saag KG: An Internet-Based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users. *J Rheumatol* 2015;42(8):1478-83.
239. Wright NC, Curtis JR, Arora T, Smith WK, Kilgore ML, Saag KG, Safford MM, Delzell ES: The Validity of Claims-Based Algorithms to Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw. *PLoS One* 2015;10(7):e0131601. PMC4498926.
240. Yun H, Xie F, Delzell E, Chen L, Yang S, Saag KG, Joseph G, Harrison D, Curtis JR: The Comparative Effectiveness of Biologics among Older Adults and Disabled Rheumatoid Arthritis Patients in the Medicare Population. *Br J Clin Pharmacol* 2015;80(6):1447-57. PMC4693474.
241. Yun H, Delzell E, Saag KG, Kilgore ML, Morrissey MA, Muntner P, Matthews R, Guo L, Wright N, Smith W, Colon-Emeric C, O'Connor CM, Lyles KW, Curtis JR: Fractures and Mortality in Relation to Different Osteoporosis Treatments. *Clin Exp Rheumatol* 2015;33(3):302-9.

PMC5733785.

242. Yun H, Badley JW, Curtis JR, Winthrop K: Reply: To Pmid 25201241. *Arthritis Care Res (Hoboken)* 2015;67(7):1041-2.
243. Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Winthrop K, Baddley JW, Curtis JR: Risk of Hospitalised Infection in Rheumatoid Arthritis Patients Receiving Biologics Following a Previous Infection While on Treatment with Anti-Tnf Therapy. *Ann Rheum Dis* 2015;74(6):1065-71. PMC4441344.
244. Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Winthrop K, Baddley JW, Curtis JR: Risks of Herpes Zoster in Patients with Rheumatoid Arthritis According to Biologic Disease-Modifying Therapy. *Arthritis Care Res (Hoboken)* 2015;67(5):731-6. PMC5765980.
245. Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, Chen L, Beukelman T, Saag KG, Curtis JR: Impact of Biologic Agents with and without Concomitant Methotrexate and at Reduced Doses in Older Rheumatoid Arthritis Patients. *Arthritis Care Res (Hoboken)* 2015;67(5):624-32. PMC4412783.
246. Accortt NA, Bonafede MM, Collier DH, Iles J, Curtis JR: Risk of Subsequent Infection among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs. *Arthritis Rheumatol* 2016;68(1):67-76.
247. Alten R, Bingham CO, 3rd, Cohen SB, Curtis JR, Kelly S, Wong D, Genovese MC: Antibody Response to Pneumococcal and Influenza Vaccination in Patients with Rheumatoid Arthritis Receiving Abatacept. *BMC Musculoskelet Disord* 2016;17:231. PMC4880815.
248. Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O'Malley CD, Saag K, Curtis JR: Glucocorticoid Exposure and Fracture Risk in Patients with New-Onset Rheumatoid Arthritis. *Osteoporos Int* 2016;27(11):3239-49.
249. Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, Zhang J, Curtis JR: The Risk of Hospitalized Infection Following Initiation of Biologic Agents Versus Methotrexate in the Treatment of Juvenile Idiopathic Arthritis. *Arthritis Res Ther* 2016;18(1):210. PMC5032246.
250. Bonafede MM, Curtis JR, McMorrow D, Mahajan P, Chen CI: Treatment Effectiveness and Treatment Patterns among Rheumatoid Arthritis Patients after Switching from a Tumor Necrosis Factor Inhibitor to Another Medication. *Clinicoecon Outcomes Res* 2016;8:707-15. PMC5144914.
251. Bowling CB, Bromfield SG, Colantonio LD, Gutierrez OM, Shimbo D, Reynolds K, Wright NC, Curtis JR, Judd SE, Franch H, Warnock DG, McClellan W, Muntner P: Association of Reduced Egfr and Albuminuria with Serious Fall Injuries among Older Adults. *Clin J Am Soc Nephrol* 2016;11(7):1236-43. PMC4934847.
252. Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Joseph GJ, Harrison DJ, Sauer BC: Clinical Outcomes and Biologic Costs of Switching between Tumor Necrosis Factor Inhibitors in Us Veterans with Rheumatoid Arthritis. *Adv Ther* 2016;33(8):1347-59. PMC4969320.
253. Charles-Schoeman C, Wang X, Lee YY, Shahbazian A, Navarro-Millan I, Yang S, Chen L, Cofield SS, Moreland LW, O'Dell J, Bathon JM, Paulus H, Bridges SL, Jr., Curtis JR: Association of Triple Therapy with Improvement in Cholesterol Profiles over Two-Year

Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis Rheumatol* 2016;68(3):577-86. PMC4774543.

254. Coburn BW, Cheetham TC, Rashid N, Chang JM, Levy GD, Kerimian A, Low KJ, Redden DT, Bridges SL, Jr., Saag KG, Curtis JR, Mikuls TR: Rationale and Design of the Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (Ramp-up) Study. *Contemp Clin Trials* 2016;50:106-15. PMC5035615.
255. Colantonio LD, Kent ST, Kilgore ML, Delzell E, Curtis JR, Howard G, Safford MM, Muntner P: Agreement between Medicare Pharmacy Claims, Self-Report, and Medication Inventory for Assessing Lipid-Lowering Medication Use. *Pharmacoepidemiol Drug Saf* 2016;25(7):827-35. PMC5039944.
256. Curtis JR, Bykerk VP, Aassi M, Schiff M: Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review. *J Rheumatol* 2016;43(11):1997-2009.
257. Curtis JR, Bharat A, Chen L, Greenberg JD, Harrold L, Kremer JM, Sommers T, Pappas D: Agreement between Rheumatologist and Patient-Reported Adherence to Methotrexate in a Us Rheumatoid Arthritis Registry. *J Rheumatol* 2016;43(6):1027-9. PMC4891269.
258. Curtis JR, Harrold LR, Asgari MM, Deodhar A, Salman C, Gelfand JM, Wu JJ, Herrinton LJ: Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a Us Health Care Setting. *Perm J* 2016;20(4):4-10. PMC5101083.
259. Curtis JR, Xie F, Mackey D, Gerber N, Bharat A, Beukelman T, Saag KG, Chen L, Nowell B, Ginsberg S: Patient's Experience with Subcutaneous and Oral Methotrexate for the Treatment of Rheumatoid Arthritis. *BMC Musculoskelet Disord* 2016;17(1):405. PMC5037591.
260. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL: Real-World Comparative Risks of Herpes Virus Infections in Tofacitinib and Biologic-Treated Patients with Rheumatoid Arthritis. *Ann Rheum Dis* 2016;75(10):1843-7. PMC5553444.
261. Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, Soma K, Wang L, Riese R: Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancies across the Rheumatoid Arthritis Clinical Development Programme. *Ann Rheum Dis* 2016;75(5):831-41. PMC4853586.
262. Curtis JR, Danila M. D., Chen, Lang, Chan, Benjamin, Ehst, Ben, Xie, Fenglong, Winthrop, Kevin L.m Yun, Huifeng: Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents. *Journal of Psoriasis and Psoriatic Arthritis* 2016;1(3). PMC5800414.
263. Danila MI, Outman RC, Rahn EJ, Mudano AS, Thomas TF, Redden DT, Allison JJ, Anderson FA, Anderson JP, Cram PM, Curtis JR, Fraenkel L, Greenspan SL, LaCroix AZ, Majumdar SR, Miller MJ, Nieves JW, Safford MM, Silverman SL, Siris ES, Solomon DH, Warriner AH, Watts NB, Yood RA, Saag KG: A Multi-Modal Intervention for Activating Patients at Risk for Osteoporosis (Apropos): Rationale, Design, and Uptake of Online Study Intervention Material. *Contemp Clin Trials Commun* 2016;4:14-24. PMC4955389.
264. Deodhar A, Mease PJ, Reveille JD, Curtis JR, Chen S, Malhotra K, Pangan AL: Frequency of Axial Spondyloarthritis Diagnosis among Patients Seen by Us Rheumatologists for Evaluation of Chronic Back Pain. *Arthritis Rheumatol* 2016;68(7):1669-76. PMC5094500.
265. Edmonds SW, Cram P, Lou Y, Jones MP, Roblin DW, Saag KG, Wright NC, Wolinsky FD, Investigators P: Effects of a Dxa Result Letter on Satisfaction, Quality of Life, and

Osteoporosis Knowledge: A Randomized Controlled Trial. *BMC Musculoskelet Disord* 2016;17(1):369. PMC5000520.

266. Ensrud KE, Blackwell TL, Fink HA, Zhang J, Cauley JA, Cawthon PM, Black DM, Bauer DC, Curtis JR, Orwoll ES, Barrett-Connor E, Kado DM, Marshall LM, Shikany JM, Schousboe JT, Osteoporotic Fractures in Men Research G: What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study. *J Bone Miner Res* 2016;31(8):1500-3. PMC5065098.
267. Harnett J, Curtis JR, Gerber R, Gruben D, Koenig A: Corrigendum to "Initial Experience with Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination with Conventional Synthetic Dmards in 2 Us Health Care Claims Databases" *Clin Ther* 38 (2016) 1451-63. *Clin Ther* 2016;38(11):2506-07.
268. Harnett J, Curtis JR, Gerber R, Gruben D, Koenig A: Initial Experience with Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination with Conventional Synthetic Dmards in 2 Us Health Care Claims Databases. *Clin Ther* 2016;38(6):1451-63.
269. Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM: Comparative Effectiveness of Abatacept Versus Tocilizumab in Rheumatoid Arthritis Patients with Prior Tnfi Exposure in the Us Corrona Registry. *Arthritis Res Ther* 2016;18(1):280. PMC5134270.
270. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Kavanaugh A, Saunders KC, Shan Y, Spruill TM, Pappas DA, Greenberg JD: Identifying Factors Associated with Concordance with the American College of Rheumatology Rheumatoid Arthritis Treatment Recommendations. *Arthritis Res Ther* 2016;18:94. PMC4845312.
271. Herrinton LJ, Harrold L, Salman C, Liu L, Goldfien R, Asgari M, Gelfand JM, Wu JJ, Curtis JR: Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009. *Perm J* 2016;20(1):4-12. PMC4732788.
272. Jalal H, O'Dell JR, Bridges SL, Jr., Cofield S, Curtis JR, Mikuls TR, Moreland LW, Michaud K: Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2016;68(12):1751-57.
273. Mamtani R, Clark AS, Scott FI, Brensinger CM, Boursi B, Chen L, Xie F, Yun H, Osterman MT, Curtis JR, Lewis JD: Association between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study. *Arthritis Rheumatol* 2016;68(10):2403-11. PMC5042817.
274. Mannion ML, Xie F, Baddley J, Chen L, Curtis JR, Saag K, Zhang J, Beukelman T: Analysis of Health Care Claims During the Peri-Transfer Stage of Transition from Pediatric to Adult Care among Juvenile Idiopathic Arthritis Patients. *Pediatr Rheumatol Online J* 2016;14(1):49. PMC5012002.
275. Navarro-Millan I, Darrah E, Westfall AO, Mikuls TR, Reynolds RJ, Danila MI, Curtis JR, Investigators C, Rosen A, Bridges SL, Jr.: Association of Anti-Peptidyl Arginine Deiminase Antibodies with Radiographic Severity of Rheumatoid Arthritis in African Americans. *Arthritis Res Ther* 2016;18(1):241. PMC5075170.
276. Navarro-Millan I, Yang S, DuVall SL, Chen L, Baddley J, Cannon GW, Delzell ES, Zhang J, Safford MM, Patkar NM, Mikuls TR, Singh JA, Curtis JR: Association of Hyperlipidaemia,

Inflammation and Serological Status and Coronary Heart Disease among Patients with Rheumatoid Arthritis: Data from the National Veterans Health Administration. *Ann Rheum Dis* 2016;75(2):341-7. PMC4752663.

277. Navarro-Millan I, Herrinton LJ, Chen L, Harrold L, Liu L, Curtis JR: Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. *PLoS One* 2016;11(3):e0149781. PMC4805235.
278. Nowell WB, Merkel PA, Schanberg LE, Curtis JR: Reenergizing Research While Improving Patient Care. *Provider* 2016;42(6):37-8, 41, 43 passim.
279. Ormseth MJ, Yancey PG, Solus JF, Bridges SL, Jr., Curtis JR, Linton MF, Fazio S, Davies SS, Roberts LJ, 2nd, Vickers KC, Kon V, Michael Stein C, Investigators T: Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. *Arthritis Rheumatol* 2016;68(9):2099-105. PMC5001900.
280. Pappas DA, John A, Curtis JR, Reed GW, Karki C, Magner R, Kremer JM, Shewade A, Greenberg JD: Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry. *Rheumatol Ther* 2016;3(1):103-15. PMC4999578.
281. Park JK, Yang JA, Ahn EY, Chang SH, Song YW, Curtis JR, Lee EB: Survival Rates of Cancer Patients with and without Rheumatic Disease: A Retrospective Cohort Analysis. *BMC Cancer* 2016;16:381. PMC4942908.
282. Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, Lewis JD: Risk of Nonmelanoma Skin Cancer Associated with the Use of Immunosuppressant and Biologic Agents in Patients with a History of Autoimmune Disease and Nonmelanoma Skin Cancer. *JAMA Dermatol* 2016;152(2):164-72. PMC5935268.
283. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T, American College of R: 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2016;68(1):1-25.
284. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T: 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol* 2016;68(1):1-26.
285. Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R: Head-to-Head Comparison of Certolizumab Pegol Versus Adalimumab in Rheumatoid Arthritis: 2-Year Efficacy and Safety Results from the Randomised Exxelerate Study. *Lancet* 2016;388(10061):2763-74.
286. Wampler Muskardin T, Vashisht P, Dorschner JM, Jensen MA, Chrabot BS, Kern M, Curtis JR, Danila MI, Cofield SS, Shadick N, Nigrovic PA, St Clair EW, Bingham CO, 3rd, Furie R, Robinson W, Genovese M, Striebich CC, O'Dell JR, Thiele GM, Moreland LW, Levesque M, Bridges SL, Jr., Gregersen PK, Niewold TB: Increased Pretreatment Serum Ifn-Beta/Alpha

Ratio Predicts Non-Response to Tumour Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis. *Ann Rheum Dis* 2016;75(10):1757-62. PMC4860184.

287. Winthrop K, Siegel S, Chen L, Yun H, Chan B, Baddley JW, Ehst BD, Curtis JR: Comparative Infectious Risk of Immunosuppressive Therapies Used in Psoriasis. *J Psoriasis and Psoriatic Arthritis* 2016;2 Winter 2016(1).
288. Xie F, Yun H, Bernatsky S, Curtis JR: Brief Report: Risk of Gastrointestinal Perforation among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. *Arthritis Rheumatol* 2016;68(11):2612-17. PMC5538140.
289. Xie F, Colantonio LD, Curtis JR, Safford MM, Levitan EB, Howard G, Muntner P: Linkage of a Population-Based Cohort with Primary Data Collection to Medicare Claims: The Reasons for Geographic and Racial Differences in Stroke Study. *Am J Epidemiol* 2016;184(7):532-44. PMC5044809.
290. Yen PY, Lara B, Lopetegui M, Bharat A, Ardoin S, Johnson B, Mathur P, Embi PJ, Curtis JR: Usability and Workflow Evaluation of "Rheumatic Disease Activity" (Ready). A Mobile Application for Rheumatology Patients and Providers. *Appl Clin Inform* 2016;7(4):1007-24. PMC5228141.
291. Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR: Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. *Arthritis Rheumatol* 2016;68(1):56-66.
292. Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, Saag KG, Singh J, Curtis JR: Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. *Arthritis Rheumatol* 2016;68(9):2328-37. PMC5396838.
293. Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, Safford MM, Kent ST, Osterman MT, Lewis JD, Saag K, Singh JA, Curtis JR: Comparative Effects of Biologics on Cardiovascular Risk among Older Patients with Rheumatoid Arthritis. *Ann Rheum Dis* 2016;75(10):1813-8.
294. Beukelman T, Curtis JR, Saag KG: Serious Infections in Childhood-Onset Systemic Lupus Erythematosus: Using Administrative Claims Data to Investigate Disease Outcomes. *Arthritis Care Res (Hoboken)* 2017;69(11):1617-19.
295. Burton MJ, Curtis JR, Yang S, Chen L, Singh JA, Mikuls TR, Winthrop KL, Baddley JW: Safety of Biologic and Nonbiologic Disease-Modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection. *J Rheumatol* 2017;44(5):565-70.
296. Calabrese LH, Xie F, Yun H, Winthrop KL, Baddley JW, Calabrese C, Curtis JR: Herpes Zoster and the Risk of Stroke in Patients with Autoimmune Diseases. *Arthritis Rheumatol* 2017;69(2):439-46. PMC5548372.
297. Carlesso LC, Segal NA, Curtis JR, Wise BL, Frey Law L, Nevitt M, Neogi T: Knee Pain and Structural Damage as Risk Factors for Incident Widespread Pain: Data from the Multicenter Osteoarthritis Study. *Arthritis Care Res (Hoboken)* 2017;69(6):826-32. PMC5354981.
298. Charles-Schoeman C, Yin Lee Y, Shahbazian A, Wang X, Elashoff D, Curtis JR, Navarro-Millan I, Yang S, Chen L, Cofield SS, Moreland LW, Paulus H, O'Dell J, Bathon J, Louis Bridges S, Jr., Reddy ST: Improvement of High-Density Lipoprotein Function in Patients with Early Rheumatoid Arthritis Treated with Methotrexate Monotherapy or Combination Therapies

in a Randomized Controlled Trial. *Arthritis Rheumatol* 2017;69(1):46-57. PMC5195879.

299. Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR: Outcomes of Tumor Necrosis Factor Inhibitor Cycling Versus Switching to a Disease-Modifying Anti-Rheumatic Drug with a New Mechanism of Action among Patients with Rheumatoid Arthritis. *J Med Econ* 2017;20(5):464-73.
300. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J: Long-Term Safety of Tofacitinib for the Treatment of Rheumatoid Arthritis up to 8.5 Years: Integrated Analysis of Data from the Global Clinical Trials. *Ann Rheum Dis* 2017;76(7):1253-62. PMC5530353.
301. Curtis JR, Lee EB, Martin G, Mariette X, Terry KK, Chen Y, Geier J, Andrews J, Kaur M, Fan H, Nduaka CI: Analysis of Non-Melanoma Skin Cancer across the Tofacitinib Rheumatoid Arthritis Clinical Programme. *Clin Exp Rheumatol* 2017;35(4):614-22.
302. Curtis JR, Xie F, Smith C, Saag KG, Chen L, Beukelman T, Mannion M, Yun H, Kertesz S: Changing Trends in Opioid Use among Patients with Rheumatoid Arthritis in the United States. *Arthritis Rheumatol* 2017;69(9):1733-40.
303. Curtis JR, Chen L, Greenberg JD, Harrold L, Kilgore ML, Kremer JM, Solomon DH, Yun H: The Clinical Status and Economic Savings Associated with Remission among Patients with Rheumatoid Arthritis: Leveraging Linked Registry and Claims Data for Synergistic Insights. *Pharmacoepidemiol Drug Saf* 2017;26(3):310-19. PMC5332325.
304. Curtis JR, Schulze-Koops H, Takiya L, Mebus CA, Terry KK, Biswas P, Jones TV: Efficacy and Safety of Tofacitinib in Older and Younger Patients with Rheumatoid Arthritis. *Clin Exp Rheumatol* 2017;35(3):390-400.
305. Curtis JR, Wright GC, Strand V, Davis CS, Hitraya E, Sasso EH: Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann Et Al. *Arthritis Rheumatol* 2017;69(4):863-65.
306. Curtis JR, Chen L, Higginbotham P, Nowell WB, Gal-Levy R, Willig J, Safford M, Coe J, O'Hara K, Sa'adon R: Social Media for Arthritis-Related Comparative Effectiveness and Safety Research and the Impact of Direct-to-Consumer Advertising. *Arthritis Res Ther* 2017;19(1):48. PMC5341200.
307. Curtis JR, Herrem C, Ndlovu N, O'Brien C, Yazici Y: A Somatization Comorbidity Phenotype Impacts Response to Therapy in Rheumatoid Arthritis: Post-Hoc Results from the Certolizumab Pegol Phase 4 Predict Trial. *Arthritis Res Ther* 2017;19(1):215. PMC5622491.
308. Curtis JR, Winthrop K, O'Brien C, Ndlovu MN, de Longueville M, Haraoui B: Use of a Baseline Risk Score to Identify the Risk of Serious Infectious Events in Patients with Rheumatoid Arthritis During Certolizumab Pegol Treatment. *Arthritis Res Ther* 2017;19(1):276. PMC5732488.
309. Curtis JR, Zhang R, Krishnaswami S, Anisfeld A, Chen Y, Strengholt S, Chen C, Geier J: Use of a Risk Characterisation Approach to Contextualise the Safety Profile of New Rheumatoid Arthritis Treatments: A Case Study Using Tofacitinib. *Clin Rheumatol* 2017;36(3):683-88. PMC5323490.

310. England BR, Mikuls TR, Xie F, Yang S, Chen L, Curtis JR: Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis. *Arthritis Rheumatol* 2017;69(12):2351-58. PMC5711552.
311. George MD, Baker JF, Hsu JY, Wu Q, Xie F, Chen L, Yun H, Curtis JR: Perioperative Timing of Infliximab and the Risk of Serious Infection after Elective Hip and Knee Arthroplasty. *Arthritis Care Res (Hoboken)* 2017;69(12):1845-54. PMC5529262.
312. Grabner M, Boytsov NN, Huang Q, Zhang X, Yan T, Curtis JR: Costs Associated with Failure to Respond to Treatment among Patients with Rheumatoid Arthritis Initiating Tnfi Therapy: A Retrospective Claims Analysis. *Arthritis Res Ther* 2017;19(1):92. PMC5433023.
313. Henkle E, Aksamit TR, Barker AF, Curtis JR, Daley CL, Anne Daniels ML, DiMango A, Eden E, Fennelly K, Griffith DE, Johnson M, Knowles MR, Leitman A, Leitman P, Malanga E, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Prieto D, Salathe M, Thomashow B, Tino G, Turino G, Wisclenny S, Winthrop KL: Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results from an Ntm Info & Research Patient Survey and the Bronchiectasis and Ntm Research Registry. *Chest* 2017;152(6):1120-27. PMC6026272.
314. Levin MJ, Bresnitz E, Popmihajlov Z, Weinberg A, Liaw KL, Willis E, Curtis JR: Studies with Herpes Zoster Vaccines in Immune Compromised Patients. *Expert Rev Vaccines* 2017;16(12):1217-30.
315. Mazor KM, Richards A, Gallagher M, Arterburn DE, Raebel MA, Nowell WB, Curtis JR, Paolino AR, Toh S: Stakeholders' Views on Data Sharing in Multicenter Studies. *J Comp Eff Res* 2017;6(6):537-47. PMC6022827.
316. Sauer BC, Teng CC, Tang D, Leng J, Curtis JR, Mikuls TR, Harrison DJ, Cannon GW: Persistence with Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in Us Veterans with Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2017;69(3):313-22.
317. Singh JA, Ramachandaran R, Yu S, Curtis JR: Allopurinol Use and the Risk of Acute Cardiovascular Events in Patients with Gout and Diabetes. *BMC Cardiovasc Disord* 2017;17(1):76. PMC5348884.
318. Singh JA, Ramachandaran R, Yu S, Yang S, Xie F, Yun H, Zhang J, Curtis JR: Is Gout a Risk Equivalent to Diabetes for Stroke and Myocardial Infarction? A Retrospective Claims Database Study. *Arthritis Res Ther* 2017;19(1):228. PMC5646136.
319. Wells AF, Curtis JR, Betts KA, Douglas K, Du EX, Ganguli A: Systematic Literature Review and Meta-Analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. *Clin Ther* 2017;39(8):1680-94 e2.
320. Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, Hirose T, Nduaka CI, Wang L, Mendelsohn AM, Fan H, Chen C, Bananis E: Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. *Arthritis Rheumatol* 2017;69(10):1960-68. PMC5656820.
321. Wolinsky FD, Hall SF, Lou Y, Edmonds SW, Saag KG, Roblin DW, Wright NC, Jones MP, Cram P, Investigators P, Curtis JR, Morgan SL, Schlechte JA, Williams JH, Zelman DJ: The Cost of a Patient Activation Intervention for Achieving Successful Outcomes: Results from the Paadrn Randomized Controlled Trial. *Osteoporos Int* 2017;28(10):3061-66. PMC5670012.

322. Wolinsky FD, Lou Y, Edmonds SW, Saag KG, Roblin DW, Wright NC, Jones MP, Cram P, Investigators P: The Effects of a Patient Activation Intervention on Smoking and Excessive Drinking Cessations: Results from the Paadrn Randomized Controlled Trial. *Osteoporos Int* 2017;28(10):3055-60. PMC5670005.
323. Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki EM, Shergy WJ, Curtis JR, Cutter GR, Danila MI, Kilgore ML, Lewis EC, Morgan SL, Redden DT, Warriner AH, Saag KG: Assessing the Feasibility of the Effectiveness of Discontinuing Bisphosphonates Trial: A Pilot Study. *Osteoporos Int* 2017;28(8):2495-503. PMC5734645.
324. Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki EM, Shergy WJ, Curtis JR, Cutter GR, Danila MI, Kilgore ML, Lewis EC, Morgan SL, Redden DT, Warriner AH, Saag KG: Erratum To: Assessing the Feasibility of the Effectiveness of Discontinuing Bisphosphonates Trial: A Pilot Study. *Osteoporos Int* 2017;28(8):2505.
325. Wright NC, Delzell ES, Smith WK, Xue F, Auroa T, Curtis JR: Improving Medical Record Retrieval for Validation Studies in Medicare Data. *Pharmacoepidemiol Drug Saf* 2017;26(4):393-401.
326. Yun H, Xie F, Baddley JW, Winthrop K, Saag KG, Curtis JR: Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. *J Rheumatol* 2017;44(7):1083-87. PMC5724562.
327. Yun H, Xie F, Beyl RN, Chen L, Lewis JD, Saag KG, Curtis JR: Risk of Hypersensitivity to Biologic Agents among Medicare Patients with Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2017;69(10):1526-34. PMC5420339.
328. Zamora NV, Christensen R, Goel N, Klokke L, Lopez-Olivo MA, Kristensen LE, Carmona L, Strand V, Curtis JR, Suarez-Almazor ME: Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An Omeract Special Interest Group Report. *J Rheumatol* 2017;44(12):1894-98.
329. Accortt NA, Lesperance T, Liu M, Rebello S, Trivedi M, Li Y, Curtis JR: Impact of Sustained Remission on the Risk of Serious Infection in Patients with Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2018;70(5):679-84. PMC5947836.
330. Balasubramanian A, Wade SW, Adler RA, Saag K, Pannacciulli N, Curtis JR: Glucocorticoid Exposure and Fracture Risk in a Cohort of Us Patients with Selected Conditions. *J Bone Miner Res* 2018. In Press.
331. Bartlett SJ, Gutierrez AK, Butanis A, Bykerk VP, Curtis JR, Ginsberg S, Leong AL, Lyddiatt A, Nowell WB, Orbai AM, Smith KC, Bingham CO, 3rd: Combining Online and in-Person Methods to Evaluate the Content Validity of Promis Fatigue Short Forms in Rheumatoid Arthritis. *Qual Life Res* 2018. In Press.
332. Beukelman T, Xie F, Chen L, Horton DB, Lewis JD, Mamtani R, Mannion MM, Saag KG, Curtis JR: Risk of Malignancy Associated with Paediatric Use of Tumour Necrosis Factor Inhibitors. *Ann Rheum Dis* 2018;77(7):1012-16.
333. Boers M, Curtis JR, Singh J, Cofield S, Bridges S, o'Dell JR, Leatherman S: A Novel Method of Combined Assessment of Benefit and Harm: Omeract 3x3 Methodology Applied to Two Active Comparator Trials. *Arthritis Care & Research* 2018. Online First.
334. Bohn R, Cooney M, Deodhar A, Curtis JR, Golembesky A: Incidence and Prevalence of Axial

Spondyloarthritis: Methodologic Challenges and Gaps in the Literature. *Clin Exp Rheumatol* 2018;36(2):263-74.

335. Chernoff D, Curtis JR: Determination of the Minimally Important Difference (Mid) in Multi-Biomarker Disease Activity (MbdA) Test Scores: Impact of Diurnal and Daily Biomarker Variation Patterns on MbdA Scores. *Clinical Rheumatology* 2018. In Press.
336. Cohen S, Curtis JR, DeMasi R, Chen Y, Fan H, Soonasra A, Fleischmann R: Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis. *Rheumatol Ther* 2018;5(1):283-91. PMC5935628.
337. Curtis JR, Xie F, Chen L, Saag KG, Yun H, Muntner P: Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study. *Ann Rheum Dis* 2018;77(3):386-92.
338. Curtis JR, Trivedi M, Haraoui B, Emery P, Park GS, Collier DH, Aras GA, Chung J: Defining and Characterizing Sustained Remission in Patients with Rheumatoid Arthritis. *Clin Rheumatol* 2018;37(4):885-93. PMC5880849.
339. Curtis JR, Xie F, Chen L, Greenberg JD, Zhang J: Evaluation of a Methodological Approach to Define an Inception Cohort of Rheumatoid Arthritis Patients Using Administrative Data. *Arthritis Care Res (Hoboken)* 2018. In Press.
340. Curtis JR, Greenberg JD, Harrold LR, Kremer JM, Palmer JL: Influence of Obesity, Age, and Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis. *Semin Arthritis Rheum* 2018;47(4):472-77.
341. Curtis JR, Yang S, Singh JA, Xie F, Chen L, Yun H, Muntner P, Kent ST, Levitan EB, Safford MM, Saag KG, Zhang J: Is Rheumatoid Arthritis a Cardiovascular Risk Equivalent to Diabetes? *Arthritis Care Res (Hoboken)* 2018. Online First.
342. Curtis JR, Chen L, Danila MI, Saag KG, Parham KL, Cush JJ: Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-Target Management Strategies in Rheumatoid Arthritis. *J Rheumatol* 2018;45(1):40-44. PMC5750102.
343. Curtis JR, Xie F, Yang S, Danila MI, Owensby JK, Chen L: Uptake and Clinical Utility of the Multi-Biomarker Disease Activity Testing in the U.S. *J Rheumatol* 2018. In Press.
344. Danila MI, Outman RC, Rahn EJ, Mudano AS, Redden DT, Li P, Allison JJ, Anderson FA, Wyman A, Greenspan SL, LaCroix AZ, Nieves JW, Silverman SL, Siris ES, Watts NB, Miller MJ, Curtis JR, Warriner AH, Wright NC, Saag KG: Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial. *J Bone Miner Res* 2018;33(5):763-72. PMC6016546.
345. Danila MI, Melnick JA, Curtis JR, Menachemi N, Saag KG: Use of Scribes for Documentation Assistance in Rheumatology and Endocrinology Clinics: Impact on Clinic Workflow and Patient and Physician Satisfaction. *J Clin Rheumatol* 2018;24(3):116-21.
346. Dehoratius RJ, Brent LH, Curtis JR, Ellis LA, Tang KL: Satisfaction with Subcutaneous Golimumab and Its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept. *Patient* 2018;11(3):361-69. PMC5948248.
347. England BR, Mikuls TR, Curtis JR: Reply. *Arthritis Rheumatol* 2018;70(2):320.

348. Henkle E, Chan B, Curtis JR, Aksamit T, Griffith D, Daley C, Winthrop K: Bronchiectasis Patient Characteristics and Utilization History in the U.S. Medicare Population with Prescription Drug Plans, 2006-2014. *Chest* 2018. In Press.
349. Herrinton L, Liu L, Curtis JR: Anti-Tnf and Physiologic Measures of Metabolic Disease in Rheumatoid Arthritis. *Journal of Clinical Rheumatology* 2018. In Press.
350. Lewis JD, Scott FI, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Bewtra M, Chen L, Yun H, Xie F, Curtis JR: Increased Mortality Rates with Prolonged Corticosteroid Therapy When Compared with Antitumor Necrosis Factor-Alpha-Directed Therapy for Inflammatory Bowel Disease. *Am J Gastroenterol* 2018;113(3):405-17. PMC5886050.
351. Lewis JD, Scott FI, Curtis JR, Chen L, Johnson FR, Reed SD, Xie F, Gilroy E, Brensinger C, Roy JA, Yun H, Sandler RS, Chen W, Osterman MT: Patient Valued Comparative Effectiveness of Corticosteroids Versus Anti-Tnf Alpha Therapy for Inflammatory Bowel Disease. In.: Patient-Centered Outcomes Research Institute; 2018.
352. Machado MAA, Moura CS, Guerra SF, Curtis JR, Abrahamowicz M, Bernatsky S: Effectiveness and Safety of Tofacitinib in Rheumatoid Arthritis: A Cohort Study. *Arthritis Res Ther* 2018;20(1):60. PMC5865387.
353. Maniadas N, Curtis JR, Toth E, Wang X, Szegvari B, Schiff M, Mountian I, Nassim M: A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences. *Advances in Therapy* 2018. In Press.
354. Michael Lewiecki E, Wright NC, Curtis JR, Siris E, Gagel RF, Saag KG, Singer AJ, Steven PM, Adler RA: Hip Fracture Trends in the United States, 2002 to 2015. *Osteoporos Int* 2018;29(3):717-22.
355. Navarro-Millan I, Gamboa CM, Curtis JR, Safford MM: Lipid Management among Individuals with Inflammatory Arthritis in the National Reasons for Geographic and Racial Differences in Stroke (Regards) Cohort. *J Int Med Res* 2018;46(1):62-69. PMC6011298.
356. Navarro-Millan I, Zinski A, Shurbaji S, Johnson B, Fraenkel L, Willig J, Danila MI, Yun H, Curtis JR, Safford MM: Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient Reported Outcome Data Collection: A Qualitative Study. *Arthritis Care Res (Hoboken)* 2018. In Press.
357. Nowell WB, Curtis JR, Crow-Hercher R: Patient Governance in a Patient Powered Research Network for Adult Rheumatology Conditions. *Med Care* 2018. In Press.
358. Ogdie-Beatty A, Greenberg J, Kremer JM, Curtis JR, Palmer JL, Solomon D, Kavanaugh A: Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tnf Inhibitor. *The Journal of Rheumatology* 2018. In Press.
359. Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD: Prevalence of Cardiovascular Disease and Major Risk Factors in Patients with Rheumatoid Arthritis: A Multinational Cross-Sectional Study. *Clin Rheumatol* 2018. In Press.
360. Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB: Prophylactic Effect of Trimethoprim-

Sulfamethoxazole for Pneumocystis Pneumonia in Patients with Rheumatic Diseases Exposed to Prolonged High-Dose Glucocorticoids. *Ann Rheum Dis* 2018;77(5):644-49. PMC5909751.

361. Park JW, Curtis JR, Lee EB: Response To: 'Can We Prescribe Tmp/Smx Prophylaxis without Any Concerns Equally for All Patients with Rheumatic Disease?' By Suyama and Okada. *Ann Rheum Dis* 2018. Online First.
362. Roblin DW, Cram P, Lou Y, Edmonds SW, Hall SF, Jones MP, Saag KG, Wright NC, Wolinsky FD, Investigators P: Diet and Exercise Changes Following Bone Densitometry in the Patient Activation after Dxa Result Notification (Paadrn) Study. *Arch Osteoporos* 2018;13(1):4.
363. Singh S, Facciorusso A, Singh AG, Castele NV, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ: Obesity and Response to Anti-Tumor Necrosis Factor-Alpha Agents in Patients with Select Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. *PLoS One* 2018;13(5):e0195123. PMC5957395 consulted for Takeda and Illumina. Dr. Sandborn has served as a consultant and received research funding from Janssen, Abbvie, UCB Pharma, Takeda, and Pfizer. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products to share.
364. Vinet E, De Moura C, Pineau CA, Abrahamowicz M, Curtis JR, Bernatsky S: Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumour Necrosis Factor Alpha Inhibitors: Cohort Study. *Arthritis Rheumatol* 2018. In Press.
365. Wallace B, Saag KG, Curtis JR, Waljee AK: Just the Frax: Management of Glucocorticoid-Induced Osteoporosis. *Gastroenterology* 2018;154(3):748-50.
366. Xie F, Colantonio LD, Curtis JR, Kilgore ML, Levitan EB, Monda KL, Safford MM, Taylor B, Woodward M, Muntner P: Development of Algorithms for Identifying Fatal Cardiovascular Disease in Medicare Claims. *Pharmacoepidemiol Drug Saf* 2018;27(7):740-50.
367. Xie F, Chen L, Yun H, Curtis JR: Reply. *Arthritis Rheumatol* 2018;70(5):795-96.

Original Manuscripts (Submitted and Under Review, or In preparation)

1. Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle S, Grauer A, Curtis JR: Risk of Subsequent Fracture after Prior Fracture among Older Women. *Osteoporosis International*. Submitted.
2. Burmester GR, Curtis JR, Yun H, Fitzgerald O, Winthrop KL, Azevedo VF, Rigby WFC, Kanik KS, Wang C, Biaswas P, Jones TV, Palmetto N, Hendrikx T, Menon S, Rojo R: The Safety Profile of Tofacitinib for the Treatment of Psoriatic Arthritis: Integrated Analysis of Two Phase 3 Studies and a Long Term Extension and Comparison with Study with Real-World Data. Submitted.
3. Chang L, Curtis JR, Zhu B, Qian L, Araujo AB, Larmore C, Tanaka Y, Ransome S, Michaud K: Remission and Residual Pain and Stiffness among an Online Community of U.S. Patients with Rheumatoid Arthritis. *J Rheumatol*. Submitted.
4. Curtis JR, Busch HM, Eaton C, Gionfriddo MR, Mixon AM, Schwartz ST, Shireman T, White CW, Watt SJ, Soonasra A, Piperni C, Assaf AR: A Collaborative Approach to Benefit Risk Communication Tailored for Improving Quadruple-Aim Outcomes. *Current Medical Research and Opinion*. Submitted.
5. Curtis JR, Flake II DD, Weinblatt ME, Shadick NA, Østergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas D, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS: Development of an Adjusted Multi-Biomarker Disease Activity (MbdA) Score for Rheumatoid Arthritis (Ra) That Accounts for Age, Gender and Adiposity with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage. Submitted.
6. Curtis JR, Safford M: Explaining the Healthy Adherer Effect in the Whi. In Prep.
7. Curtis JR, Xie F, Yang S, Bernatsky S, Chen L, Yun H, Winthrop K: Herpes Zoster in Tofacitinib: Risk Is Further Increased with Glucocorticoids but Not Methotrexate. *Arthritis Care & Research*. Submitted.
8. Curtis JR, Genovese M, Radawski C, Hauber B, Nowell WB, Hollis K, Gaich C, DeLozier A, Gavigan K, Reynolds M, Cardoso A: Patients' Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the Us. In.
9. Curtis JR, Haraoui P: Use of a Global Risk Score to Identify the Risk of Serious Infectious Events in Patients with Rheumatoid Arthritis at Initiation of Certolizumab Pegol Treatment. In Prep.
10. Desai RJ, Kim SC, Curtis JR, Bosco JLF, Eichelberger B, Barr CE, Lockhart CM, Bradbury BD, Clewell J, Cohen HP, Gagne J: JoboBSW: Methodologic Considerations for Non-Interventional Studies of Switching from Reference Biologic to Biosimilars. *Pharmacoepidemiol Drug Saf*. Submitted.
11. Elewaut D, Braun J, Anderson JK, Arikian D, Chen S, Hojnik M, Curtis JR: Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials across Nine Different Diseases. Submitted.
12. George MD, Baker JF, Winthrop K, Alemao E, Chen L, Connolly S, Simon T, Wu Q, Xie F, Yang S, Curtis JR: Timing of Abatacept before Elective Arthroplasty and Risk of Post-Operative Outcomes. Submitted.

13. Giles JT, Bridges SL, O'Dell JR, Cofield S, Howard G, Curtis JR, Moreland LW: Circulating Adipokines and Radiographic Progression in Early Aggressive Rheumatoid Arthritis. Submitted.
14. Haynes K, Avillach P, Carton TW, Curtis JR, Fahey K, Garcia C, Harkins T, Hwang W, McMahill CN, Meltzer D, Oliveira E, Pawlosk iPA, Prochaska M, Puro J, Selvam N, Platt R: Development of a Learning Health System to Advance Comparative Effectiveness Research and Medical Product Safety Surveillance Capacity through Data Linkage: A Sentinel-Pcornet Collaboration. Submitted.
15. Henkle E, Curtis JR, Chen L, Chan B, Aksamit TR, Daley CL, Griffith DE, Winthrop KL: Comparative Risks of Inhaled Corticosteroids and Macrolides in Medicare Enrollees with Bronchiectasis AJRCCM. Submitted.
16. Incerti D, Curtis JR, Shafrin J, Lakdawalla D, Jansen JJ: A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. Submitted.
17. Jagpal A, O'Beirne R, Morris MS, Johnson B, Willig J, Yun H, Cherrington AL, Fraenke IL, Curtis JR, Safford MM: Making Room for Rheumatoid Arthritis Patients' Symptoms in Treatment Decisions: A Physician Perspective Study. Submitted.
18. Kan HJ, Dyagilev K, Schulam P, Saria S, Kharrazi H, Bodycombe D, Molta C, Curtis JR: Factors Associated with Physicians Prescriptions for Rheumatoid Arthritis Drugs Not Filled by Patients. Submitted.
19. Lemay CA, Mazor KM, Kremer JM, Nowell WB, Bingham CO, Curtis JR, Ruderman EM, Harrold LR: Is This Really the Way We Should Go? Patient Perspectives on Managing Rheumatoid Arthritis. Submitted.
20. Leverenz DL, Eudy AM, Jayasundara M, Haroun T, McDaniel G, Nowell WB, Curtis JR, Crow-Hercher R, White W, Ginsberg S, E. B. Clowse M: Contraception Methods Used by Women with Rheumatoid Arthritis and Psoriatic Arthritis. Submitted.
21. Li X, Fireman BH, Curtis JR, Arterburn DE, Fisher DP, Moyneur E, Gallagher M, Raebel MA, Nowell WB, Lagreid L, Toh S: Privacy-Protecting Analytical Methods Permit Multivariable-Adjusted Analysis Using Only Aggregate-Level Data in Multi-Center Distributed Data Networks: Results from Empirical Analyses. *Journal of Clinical Epidemiology*. Submitted.
22. Lillegraven S, Greenberg JD, Reed GW, Saunders KC, Curtis JR, Harrold L, Hochberg MC, Pappas D, Kremer JM, Solomon DH: Anti-Inflammatory Treatment and the Risk of Diabetes in Rheumatoid Arthritis. Submitted.
23. Machado MAdÁ, Moura CSd, Klein M, Winthrop K, Carleton B, Abrahamowicz M, Feld J, Curtis JR, Bernatsky S: Therapy Completion of Direct-Acting Antivirals for Hepatitis C. Submitted.
24. Mathur P, Thompson J, Danila M, Embi PJ, Curtis JR: Design and Development of Mhealth App Framework for Electronic Collection & Analysis of Patient Reported Outcome Data for Better Patient Care. Submitted.
25. Melton M, Curtis JR, Warriner A, Xue F, Wright N: Identification of Patients with Primary Diagnosis of Hypocalcemia from Claims Data – a Validation Study. Submitted.

26. Mikuls TR, Cheetham TC, Levy GD, Rashid N, Kerimian A, Low KJ, Coburn BW, Redden DT, Saag KG, Foster J, Chen L, Curtis JR: A Pharmacist-Led Intervention to Improve Gout Medication Adherence and Outcomes with Urate Lowering Therapy: A Site Randomized Trial. Submitted.
27. Navarro-Millán I, Yang S, Chen L, Yun H, Jagpal A, Bartels CM, Fraenkel L, Safford MM, Curtis JR: Screening of Hyperlipidemia among Patients with Rheumatoid Arthritis in the United States. Submitted.
28. Nowell WB, Higginbotham P, Curtis JR, Johnson B, O'Beirne R, Willig J, Gerber N, Ginsberg S, Safford M: Patients' Prioritization of Education Topics in Rheumatic Disease. Submitted.
29. Owensby JK, Chen L, O'Beirne R, Ruderman E, Harrold LR, Melnick JA, Safford MM, Curtis JR, Danila MI: Patient- and Physician- Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis. Submitted.
30. Scott FI, Johnson FR, Bewtra M, Brensinger CM, Roy JA, Reed SD, Osterman MT, Mamtani R, Chen L, Yun H, Xie F, Curtis JR, Lewis JD: Improved Quality of Life with Anti-Tnf Therapy Compared to Continued Corticosteroid Utilization in Crohn's Disease. Inflammatory Bowel Diseases Journal. Submitted.
31. Singh JA, Curtis JR, Saag KG: Letter to the Editor Regarding the Krebs Article: Effect of Opioid Vs Nonopioid Medications on Pain-Related Function in Patients with Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The Space Randomized Clinical Trial. Submitted.
32. Singh S, Curtis JR, Ray GT, Wu JJ, Fireman B, Liu L, Goldfien R, Herrinton LJ: Separate and Combined Effects of Anti-Tumor Necrosis Factor-A and Methotrexate on Serious Adverse Cardiovascular Events in Rheumatoid Arthritis. Submitted.
33. Teeple A, Ginsburg S, Howard L, Huff L, Reynolds C, Walls D, Ellis L, Curtis JR: Patients' Experiences and Attitudes About Non-Medical Switching of Biosimilars: Results from an Online Patient Survey. Submitted.
34. Voshaar MAHO, Gupta ZD, Bijlsma JWJ, Boonen A, Chau J, Courvoisier DS, Curtis JR, Ellis B, Ernestam S, Gossec L, Hale C, Hornjeff J, Leung YY, Lidar M, Mease P, Michaud K, Mody GM, Ndosi M, Opava CH, Pinheiro GRC, Salt M, Soriano ER, Taylor WJ, Voshaar MJH, Weel AEAM, Wit Md, Wulffraat N, Laar MAFJvd, Vonkeman HE: Outcomes That Matter to People Living with Inflammatory Arthritis; a Global Standard Set, Developed by the International Consortium for Health Outcome Measurement (Ichom) Working Group for Inflammatory Arthritis. Arthritis Care & Research. Submitted.
35. Wallace B, Lin P, Kamdar N, Noureldin M, Curtis JR, Saag KG, Hayward R, Waljee AK: Patterns of Glucocorticoid Prescribing and Provider-Level Variation in a Commercially Insured Rheumatoid Arthritis Population. Submitted.
36. Warriner A, Curtis JR, Saag KG, Matthews R, Smith W, Delzell E: Identification and Validation of Hiv-Positive Persons Using Administrative Claims Data. Submitted.
37. Wei W, Sullivan E, Black S, Chen C-I, Piercy J, Curtis JR: Differences between Rheumatologist-Reported and Das28-Based Assessment of Ra Disease Remission. In Revision.

38. Xie F, Yun H, Levitan EB, Muntner P, Curtis JR: Tocilizumab and the Risk for Cardiovascular Disease: A Direct Comparison among Biologic Disease-Modifying Antirheumatic Drugs for Ra Patient. *Arthritis Care & Research*. Submitted.
39. Yun H, Willig J, Yang S, Auriemma M, Chen L, Curtis D, Filby C, Nowell WB, Curtis JR: Assessing Ra Disease Activity with Promis Measures Using Smartphone Technology. *Arthritis Care and Research*. Submitted.

Review Articles

1. Saag KG, Curtis JR: Use of Glucocorticoids in Arthritis: 20 Clinical Pearls: Maximizing the Benefits, Minimizing the Complications. *The Journal of Musculoskeletal Medicine* 2003;20(9):425-34.
2. Curtis JR, Saag KG: Evaluating and Improving the Quality of Care in Rheumatic Disease. *Expert Rev Pharmacoecon Outcomes Res* 2004;4(4):429-39.
3. Chaiamnuay S, Allison JJ, Curtis JR: Risks Versus Benefits of Cyclooxygenase-2-Selective Nonsteroidal Antiinflammatory Drugs. *Am J Health Syst Pharm* 2006;63(19):1837-51.
4. Gaffo A, Saag KG, Curtis JR: Treatment of Rheumatoid Arthritis. *Am J Health Syst Pharm* 2006;63(24):2451-65.
5. Curtis JR, Saag KG: Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. *Curr Osteoporos Rep* 2007;5(1):14-21.
6. Warriner A, Curtis JR, Saag KG: Challenges in Defining and Improving Osteoporosis Quality of Care. *Clin Exp Rheumatol* 2007;25(6 Suppl 47):142-6.
7. Crawford M, Curtis JR: Tumor Necrosis Factor Inhibitors and Infection Complications. *Curr Rheumatol Rep* 2008;10(5):383-9. PMC3640452.
8. Danila MI, Patkar NM, Curtis JR, Saag KG, Teng GG: Biologics and Heart Failure in Rheumatoid Arthritis: Are We Any Wiser? *Curr Opin Rheumatol* 2008;20(3):327-33. PMC4097098.
9. McDonough AK, Curtis JR, Saag KG: The Epidemiology of Glucocorticoid-Associated Adverse Events. *Curr Opin Rheumatol* 2008;20(2):131-7.
10. Patkar NM, Teng GG, Curtis JR, Saag KG: Association of Infections and Tuberculosis with Antitumor Necrosis Factor Alpha Therapy. *Curr Opin Rheumatol* 2008;20(3):320-6.
11. Teng GG, Warriner A, Curtis JR, Saag KG: Improving Quality of Care in Osteoporosis: Opportunities and Challenges. *Curr Rheumatol Rep* 2008;10(2):123-30.
12. Teng GG, Curtis JR, Saag KG: Mortality and Osteoporotic Fractures: Is the Link Causal, and Is It Modifiable? *Clin Exp Rheumatol* 2008;26(5 Suppl 51):S125-37. PMC4124750.
13. Curtis JR, Adachi JD, Saag KG: Bridging the Osteoporosis Quality Chasm. *J Bone Miner Res* 2009;24(1):3-7.
14. Moreland LW, Curtis JR: Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory Mechanisms. *Semin Arthritis Rheum* 2009;39(2):132-43.
15. Teng GG, Curtis JR, Saag KG: Quality Health Care Gaps in Osteoporosis: How Can Patients, Providers, and the Health System Do a Better Job? *Curr Osteoporos Rep* 2009;7(1):27-34.
16. Warriner AH, Curtis JR: Adherence to Osteoporosis Treatments: Room for Improvement. *Curr Opin Rheumatol* 2009;21(4):356-62. PMC2913429.
17. Warriner AH, Outman RC, Saag KG, Berry SD, Colon-Emeric C, Flood KL, Lyles KW, Tanner SB, Watts NB, Curtis JR: Management of Osteoporosis among Home Health and Long-Term

- Care Patients with a Prior Fracture. *South Med J* 2009;102(4):397-404. PMC2720154.
18. Curtis JR: Improving Osteoporosis Care through Multimodal Interventions: Insights from the University of Alabama at Birmingham Center for Education and Research on Therapeutics. *Osteoporos Int* 2011;22 Suppl 3:445-50. PMC3767024.
 19. Curtis JR, Singh JA: Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care. *Clin Ther* 2011;33(6):679-707. PMC3707489.
 20. Zhang J, Saag KG, Curtis JR: Long-Term Safety Concerns of Antiresorptive Therapy. *Rheum Dis Clin North Am* 2011;37(3):387-400, vi. PMC4420195.
 21. Curtis JR, Safford MM: Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions. *Drugs Aging* 2012;29(7):549-64. PMC3767038.
 22. Navarro-Millan I, Singh JA, Curtis JR: Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor. *Clin Ther* 2012;34(4):788-802 e3. PMC3805022.
 23. Curtis JR, Silverman SL: Commentary: The Five Ws of a Fracture Liaison Service: Why, Who, What, Where, and How? In *Osteoporosis, We Reap What We Sow*. *Curr Osteoporos Rep* 2013;11(4):365-8. PMC3847905.
 24. Navarro-Millan I, Curtis JR: Newest Clinical Trial Results with Antitumor Necrosis Factor and Nonantitumor Necrosis Factor Biologics for Rheumatoid Arthritis. *Curr Opin Rheumatol* 2013;25(3):384-90. PMC4041208.
 25. Silverman SL, Curtis JR: Commentary: Measuring Quality of Care in Osteoporosis. *Curr Osteoporos Rep* 2013;11(4):338-40.
 26. Yun H, Curtis JR: New Methods for Determining Comparative Effectiveness in Rheumatoid Arthritis. *Curr Opin Rheumatol* 2013;25(3):325-33. PMC3815611.
 27. Perry LM, Winthrop KL, Curtis JR: Vaccinations for Rheumatoid Arthritis. *Curr Rheumatol Rep* 2014;16(8):431. PMC4080407.
 28. Zhang J, Curtis JR: Considerations in Using Registry and Health Plan Data for Studying Pregnancy in Rheumatic Diseases. *Curr Opin Rheumatol* 2014;26(3):315-20.
 29. Jagpal A, Curtis JR: Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians. *Drug Saf* 2018;41(6):545-53.
 30. Stirratt MJ, Curtis JR, Danila MI, Hansen R, Miller MJ, Gakumo CA: Advancing the Science and Practice of Medication Adherence. *J Gen Intern Med* 2018;33(2):216-22. PMC5789101.

Book Chapters

1. Abbott J, Ball G, Boumpas D, Bridges S, Chatham W, Curtis JR, Daniel C, Hughes L, Kao A, Langford C: Therapeutic Dictionary of Rheumatology and Immunology. In: *Rheumatology and Immunology Therapy: A to Z Essentials*. Edited by Moreland L. Springer-Verlag Berlin Heidelberg New York: Springer; 2004.
2. Curtis JR, Saag KG: Prevention and Treatment. In: *Bone Disease in Rheumatology*. Edited by Maricic M, Gluck O. Philadelphia: Lippincott Williams & Wilkins; 2005: 111-19.
3. Curtis JR, Saag KG: Glucocorticoid-Induced Osteoporosis. In: *The Year in Osteoporosis*. Edited by Akesson K, Adachi J, Woolf A, vol. 2. Osford: Clinical Publishing; 2006: 69-90.
4. Curtis JR, Moreland LW: New Biologics: Cytokines. In: *Rheumatoid Arthritis: Frontiers in Pathogenesis and Treatment 2nd Edition*. Edited by Firestein, Panayi, Wollheim: Oxford University Press; 2006.
5. Adler RA, Curtis JR, Weinstein RS, Saag KG: Glucocorticoid-Induced Osteoporosis. In: *Osteoporosis*. Edited by Marcus R, Feldman D, Nelson D, Rosen C, 3rd edn: Elsevier Academic Press; 2008: 1135-66.
6. Curtis JR: Bisphosphonate Therapy for Osteoporosis. In: *Atlas of Osteoporosis*. Edited by Orwoll E, 3rd edn: Springer; 2009.
7. Curtis JR, Lewis JD: Studies of Biologics. In: *Pharmacoepidemiology*. Edited by Strom BL, Kimmel SE, Hennessy S, Sixth edn. Newark, NJ Rutgers University; 2018.

Miscellaneous, including Certified Medical Education (CME) Programs

1. Curtis JR. "Smoking Adjusted Occupational Associations with Lung Cancer by Histology". Master's Degree in Public Health (MPH) Thesis. 1999. Oregon Health Sciences University.
2. Curtis JR, Saag KG. Evaluating Quality and Outcomes in Arthritis Care. Medscape Rheumatology. Nov 2002. [Medscape].
3. Curtis JR. Glucocorticoid Induced Osteoporosis. University of Alabama Division of Continuing Medication Education. 2003. [UAB CME].
4. Curtis JR, Buckley L, Adachi JD, Saag KG. Emerging Topics in Musculoskeletal Medicine. University of Alabama Division of Continuing Medication Education. 2004. [UAB CME].
5. Saag KG, Curtis JR. American College of Rheumatology Hotline on Zoledronic Acid. 2007. [American College of Rheumatology Hotline].
6. Warriner A, Curtis JR. Quality of Osteoporosis Care among Older Adults. University of Alabama Division of Continuing Medication Education. 2007. [UAB CME].
7. McDonough A, Curtis JR. Reducing the Risk for Falls and Fractures: The Role of Vitamin D in the Elderly. University of Alabama Division of Continuing Medication Education. 2008. [UAB CME].
8. Mease P, Curtis JR. Current Strategies for the Diagnosis, Management, and Assessment of the Spondyloarthropathies. September 2008. [Coalition of Rheumatology Educators].
9. Curtis JR. Expert Insight on the 2008 ACR RA Recommendations: What do Nurses Need to Know? Winter 2008. Rheumatology Nurse Newsletter, Issue 4.
10. Curtis JR (contributor). Rheumatoid Arthritis in Primary Care: Overcoming Diagnosis, Referral, and Treatment Barriers. Winter 2008. [CME Enterprise].
11. Curtis JR. Identifying and Managing Comorbidities in Patients with Inflammatory Arthritis. Winter 2009. [CME Outfitters and ReachMD Radio].
12. Curtis JR, Saag KG, Winthrop K. Update on the Safety and Recommendations for use of the Herpes Zoster (Shingles) Vaccine for Autoimmune Disease Patients. September 2012. [American College of Rheumatology Hotline].
13. Curtis JR, Rigby W, Cohen S. Looking Beyond RA Treatment Guidelines: Recognizing the Role of Immunogenicity in Therapeutic Success. [Incite CME Video Program].
14. Curtis JR, Levesque M, Kay J, Silverman G. What Would You Do? Challenging Case Scenarios in RA. ACR State of The Art Meeting, Chicago. [Medscape CME].
15. Danila M and Curtis JR. Biologic and newer therapies for rheumatoid arthritis: A Primer for Primary Care Physicians. 2013. [UAB CME]
16. Curtis JR. Optimizing the Clinical Use of Biologics in Rheumatoid Arthritis: A Case-Based Approach to the Assessment of Disease Activity and Response to Therapy. [Purdue University CME]

17. Curtis JR. Personalized Care for Patients with Established Rheumatoid Arthritis. Rheumatology State Society Online enduring Theory to Practice. [Med Learning Group CME]
18. Curtis JR, Clowse MEB, Cush JJ. Getting the Most Out of RA Registries and Patient Reported Outcomes. April 2015. [Medscape/WebMD CME].
19. Kay J, Silverman G, Curtis JR. Expert Guidance on Monotherapy vs. Combination Therapy in RA Management. July 2015. [Global Academy for Medical Education CME, with Rheumatology News].
20. Curtis JR, Key J, Laster A. Disease Activity Assessment Across the RA Continuum: Challenges and Solutions. January 2016. [Medscape CME].
21. Saag KG, Singh J, Curtis JR. The New ACR 2015 Guidelines. February 2016. [Medscape CME].
22. Curtis JR, Kay J. Advancing the Management of RA: Applying Evidence-Based Strategies to Improve Patient Outcomes. April 2016. [Global Academy for Medical Education Enduring Monograph].
23. Curtis JR. Individualizing Treatment Selection for RA: Patient Simulation. May 2016. [Medscape CME Online Simulation].
24. Curtis JR, Kaine J. Healthy Days in RA: Leveraging Disease Pathogenesis to Optimize Treatment Response. August 2016. [Med Learning Group CME Enduring Monograph].
25. Dowd W, Chen L, Curtis JR, Aldridge. National Bone Health Alliance (NBHA) Fracture Liason Service Calculator. August 2016. <http://www.nbha.org/fpc>.
26. Jagpal A, Curtis JR. Mastery in RA. July 2017. [Projects in Knowledge CME].
27. Curtis JR, Bergman MJ, Taylor PC. Clinical Reflections™ Achieving Success in RA Assessment & Management: A Learner Pathway to Improve Patient Outcomes. October 2017. [RMEI Medical Education].
28. Curtis JR, Owensby J. Patient Decision Making Surrounding Treat to Target Strategies for Rheumatoid Arthritis. September 2017. [Medscape Education].

Scientific Abstracts

1. Shatin D, Rawson N, Graun MM, Manda B, Curtis JR, Moreland LW, Saag KG: Impact of Risk Communication on Tuberculosis Testing for Infliximab Users. *Pharmacoepidemiol Drug Saf* 2003; 12(S1):S129.
2. Curtis JR, Shatin D, Rawson NSB, Braun MM, Manda B, Moreland L, Allison J, Saag KG: Impact of Risk Communication on Tuberculin Skin Testing For Infliximab and Etanercept Users. *Arthritis Rheum* 2003; 48(S9):S610.
3. Curtis JR, Smith B, Bailey-Griffin J, Lopez, R, Raper J, Saag M, Venkataraman R, Weaver M, Saag KG: : Ethnic Differences in Bone Disease Among HIV+ Patients with Lipodystrophy. *International Society of Clinical Densitometry Annual Scientific Meeting 2004, Miami, FL.*
4. Curtis JR, Allison J, Becker A, Casebeer L, George V, Kovac S, Spettell C, Westfall A, Weissman N, Wilkie S, Saag KG. Screening and Treatment of Glucocorticoid Induced Osteoporosis by 799 Physicians. *International Society of Clinical Densitometry Annual Scientific Meeting 2004, Miami, FL.*
5. Saag KG, Gehlbach SH, Curtis JR, Worley K, Youket TE, Lange JL. Temporal Trends in Prevention of Glucocorticoid-Induced Osteoporosis. *Journal of Bone and Mineral Research* 2004; 19(S1):S455.
6. Sharma L, Lewis B, Torner J, Saag KG, Curtis JR, Dunlop D, Webb N, Hietpas J, Nevitt M, for the MOST Study Group. The Impact of Gender on Varus-Valgus Laxity in Knees with and without Osteoarthritis. *Arthritis and Rheumatism* 2004; 50(S9): S267.
7. Mikuls TR, Curtis JR, Allison J, Hicks R, Saag KG. Medication Errors with the use of Gout Related Therapies: Results from the United States Pharmacopeia MEDMARXsm Surveillance System. *Arthritis and Rheumatism* 2004; 50(S9): S339.
8. Curtis, JR, Allison J, Becker A, Bijlsma JWJ, Casebeer, L, George V, Kovac S, Spettell C, Westfall A, Weissman N, Wilkie S, Saag KG. Adverse Events associated with Chronic Glucocorticoid Use among 2446 Adults. *Arthritis and Rheumatism* 2004; 50 (S9): S301.
9. Curtis, JR, Allison J, Becker A, Bijlsma JWJ, Casebeer, L, George V, Kovac S, Spettell C, Westfall A, Weissman N, Wilkie S, Saag KG. Screening and Treatment of Glucocorticoid Induced Osteoporosis among 6517 Adults. *Arthritis and Rheumatism* 2004; 50(S9): S314.
10. Curtis JR, Smith B, Landers K, Lopez R, Raper J, Saag M, Venkataraman R, Weaver M, Saag KG. Metabolic Bone Disease among an Ethnically Diverse Cohort of HIV+ Patients with Lipodystrophy. *Journal of Bone and Mineral Research* 2004; 19(S1):S299.
11. Curtis JR, Allison J, Gaffo A, Juarez L, Kovac SH, Olivieri J, Person S, Weissman N, Saag KG. A Group Randomized Controlled Trial to Improve NSAID Related Safety Practices. *Arthritis and Rheumatism* 2004; 50(S9): S313.
12. Curtis, JR, Allison J, Becker A, Bijlsma JWJ, Casebeer, L, George V, Kovac S, Spettell C, Westfall A, Weissman N, Wilkie S, Saag KG. Screening and Treatment of Glucocorticoid Induced Osteoporosis among 6517 Adults. *Journal of Bone and Mineral Research* 2004; 19(S1):S30.
13. Saag KG, Gehlbach SH, Curtis JR, Worley K, Youket TE, Lange JL. Temporal Trends in Prevention of Glucocorticoid-Induced Osteoporosis. *Arthritis and Rheumatism* 2004; 50 (S9): S266.

14. Mikuls TR, Hicks RW, Curtis JR, Allison JJ, Saag KG. Medication errors with the use of allopurinol and colchicines: results from a national, anonymous Internet-based error reporting program. Annual European Congress of Rheumatology EULAR, Vienna, Austria, June 2005.
15. Curtis JR, Becker A, Allison JJ, Casebeer L, Elkins M, George V, Kiefe C, Panjamapiron A, Santhanakrishnan R, Spettell C, Weissman N, Westfall A, Saag KG. Recruiting Physicians to an Internet-based Quality Improvement Project: Effectiveness of a Targeted, Multi-Phase, Incentive-Based Strategy. International Society of Pharmacoepidemiology. Nashville, TN, August 2005.
16. Curtis JR, Westfall AO, Allison JJ, Freeman A, Kovac SH, Spettell CM, Saag KG. Agreement and Validation of Self-report and Pharmacy data for Use of Anti-Osteoporosis Medications. International Society of Pharmacoepidemiology (oral). Nashville, TN, August 2005.
17. Kovac SH, Saag KG, Curtis JR, Allison J. Association of Dual Use of Over the Counter and Prescription Non Steroidal Anti-Inflammatory Drugs (NSAIDs) with Health Related Quality of Life. International Society of Pharmacoepidemiology (oral). Nashville, TN, August 2005.
18. Curtis JR, Bryant T, Kim Y, Scott D, Rousculp M, Saag KG. Osteoporosis Treatment in the Home Health Care Setting: A Window of Opportunity? *Arthritis Rheum* 2005; 52(9):S300.
19. Curtis JR, Westfall AO, Allison JJ, Freeman A, Kiefe CI, Saag KG. Persistence and Adherence to Alendronate And Risedronate Among Chronic Glucocorticoid Users (oral). *Arthritis Rheum* 2005; 52(9):S734.
20. Sharma L, Felson DT, Dunlop D, Nevitt M, Buckwalter J, Hietpas J, Curtis JR, Segal N, Song J, Lewis E. Knee Buckling and its Relationship with Physical Function in Knee OA. *Arthritis Rheum* 2005; 52(9):S396.
21. Mikuls TR, Hughes LB, Westfall A, Saag KG, Curtis JR, Alarcon GS, Conn DL, Jonas BL, Callahan L, Smith EA, Gilkeson G, Howard G, Moreland LW, Bridges SL Jr. and the CLEAR Investigators. Association of Single Nucleotide Polymorphisms (SNPs) in the Vitamin D Receptor (VDR) Gene with Bone Mineral Density (BMD) in African Americans with Early Rheumatoid Arthritis. *Arthritis Rheum* 2005; 52(9):S118.
22. Patkar N, Teng GG, Curtis JR, Allison J, Prevallet B, Avramovski N, Saag M, Martin C, Shatin D, Solomon DH, Saag KG. Reliability and Validity of Evidence-Based Case Definitions of Serious Bacterial Infections among Rheumatoid Arthritis Patients. *Arthritis Rheum* 2005; 52(12):4094.
23. Curtis JR, Saag KG, Martin C, Patkar N, Shatin D, Kramer J, Braun MM. Validation of Claims-Identified Serious Adverse Events in Rheumatoid Arthritis and Crohn's Disease Patients. *Arthritis Rheum* 2005; 52(12):4085.
24. Bian J, Mudano A, Allison J, Briggs D, Cope J, Curtis JR, Elkins M, Gross T, Kim Y, McGunagle D, Nair R, Xie A, Saag KG. Vertebroplasty/Kyphoplasty Increases the Risk of Secondary Vertebral Compression Fractures. *Journal of Bone and Mineral Research* 2006; 21:S105.
25. Curtis JR, Amonkar MM, Mucha L, Barr CE, Saag KG. Osteoporotic Women Adherent to Bisphosphonate Therapy Have Reduced Osteoporosis-Related and Total Healthcare Costs. American Society for Bone and Mineral Research Annual Scientific Meeting 2006, Philadelphia, PA.
26. Curtis JR, Westfall AO, Allison JJ, Becker A, MacArthur M, Ockershausen T, Stewart E, Weissman N, Saag KG. Challenges in Improving Quality of Osteoporosis Care for Long Term Glucocorticoid Users. American Society for Bone and Mineral Research Annual Scientific Meeting 2006, Philadelphia, PA.

27. Curtis JR, Martin C, Saag KG, Kramer J, Patkar N, Shatin D, Xie A, Allison JJ, Braun MM. Risk of Heart Failure among Younger Adults Exposed to Infliximab and Etanercept. *Arthritis & Rheumatism* 2006; 54(9): S372.
28. Neogi T, Nevitt M, Zhu Y, Xie H, Curtis JR, Clark E, Felson D. Frequency and Predictors of Inconsistently Frequent Knee Pain. American College of Rheumatology Annual Scientific Meeting 2006, Washington D.C.
29. Neogi T, Nevitt M, Zhu Y, Xie H, Curtis JR, Clark E, Felson D. Is Chondrocalcinosis Associated with Knee Pain? American College of Rheumatology Annual Scientific Meeting 2006, Washington D.C.
30. Curtis JR, Niu J, Felson D, Hietpas J, Nair R, Nevitt M, Seagal N, Saag KG, Sharma L, Torner J, Lewis C. Occupational Factors Associated with Symptomatic Radiographic Knee Osteoarthritis. American College of Rheumatology Annual Scientific Meeting 2006, Washington D.C.
31. Curtis JR, Reed G, Allison JJ, Saag KG, Moreland LW. How Adequately do Propensity Scores Adjust for Confounding by Indication in the Absence of Disease-Specific Markers of Activity and Severity? *Arthritis & Rheumatism* 2006; 54(9):S346.
32. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag KG. Tumor Necrosis Factor- α Antagonists Increase the Risk of Hospitalization for Bacterial Infections among Rheumatoid Arthritis Patients. *Arthritis & Rheumatism* 2006; 54(9): S517.
33. Curtis JR, Patkar N, Xie A, Martin C, Saag KG. Implications of the Definition of an Infection When Assessing Risk Associated with Medications Used to Treat Rheumatoid Arthritis. *Arthritis & Rheumatism* 2006; 54(9): S516-7.
34. Curtis JR, Amonkar MM, Mucha L, Barr CE, Saag KG. Persistence and Compliance with Daily and Weekly Bisphosphonate Therapy Over 3 Years. American College of Rheumatology Annual Scientific Meeting 2006, Washington D.C.
35. Teng G, Curtis JR, Xie A, Jackson K, Palonen K, Safford M, Morgan S, Saag K. Patterns and Predictors of Effective Methotrexate (MTX) toxicity monitoring in the VA. *Arthritis Rheum* 2006; 54(12):4067.
36. Curtis JR, Carbone L, Cheng H, Hayes B, Laster A, Matthews R, Saag KG, Sepanski R, Tanner B, Womack C, Delzell E. Longitudinal Patterns in Bone Mass Measurement Among U.S. Medicare Beneficiaries. *Journal of Bone and Mineral Research* 2007; 22(1):S192.
37. Curtis JR, Mundano A, Solomon DH, Kim Y, Saag KG. Identifying Clinical Vertebral Fractures Using Administrative Claims Data: A Validation Study. *Journal of Bone and Mineral Research* 2007; 22(1):S199.
38. Cheng H, Gary LC, Curtis JR, Kilgore ML, Saag KG, Yun H, Matthews R, Swaminathan S, Morrisey MA, Delzell E. Prevalence and Patterns of Presumed Osteoporosis (OP) Among Older Americans Based on Medicare Data. *Journal of Bone and Mineral Research* 2007; 22(1):S202.
39. Curtis JR, Westfall A, Cheng H, Delzell E, Lyles K, Saag KG. Bisphosphonates Adherence and Fracture Risk: Time-Dependent Relationships from 103,038 Bisphosphonate Users in the U.S. *Journal of Bone and Mineral Research* 2007; 22(1):S130.
40. Curtis JR, Westfall A, Cheng H, Delzell E, Lyles K, Saag KG. Longitudinal Patterns of Adherence with Bisphosphonates. *Journal of Bone and Mineral Research* 2007; 22(1):S214.
41. Curtis JR, Westfall A, Cheng H, Delzell E, Saag KG. How Quickly Do Oral Bisphosphonates Work, and Are There Differences Between Them? *Journal of Bone and Mineral Research* 2007; 22(1):S326.

42. Javaid M, Lynch J, Tolstykh I, Guermazi A, Roemer F, Curtis JR, Lane N, Felson D, Nevitt M. Pre-Radiographic MRI Findings are Associated with Onset of Knee Pain: the MOST Study. *Arthritis & Rheumatism* 2007; 56(9):S124.
43. Curtis JR, Niu J, Felson D, Nevitt M, Saag KG, Lewis C. Clinical Risk Factors, Symptoms and Signs Can Identify Persons with Radiographic Knee Osteoarthritis: the MOST Study. *Arthritis & Rheumatism* 2007; 56(9):S130.
44. Curtis JR, Felson D, Hietpas J, Nevitt M, Niu J, Lewis C. Repetitive Activities Impact the Risk for Incident and Progressive Radiographic Osteoarthritis. *Arthritis & Rheumatism* 2007; 56(9):S130.
45. Segal NA, Regier J, Curtis JR, Niu J, Torner JC. Personal Characteristics Associated with Widespread Tenderness in the Most Study. *Arthritis & Rheumatism* 2007; 56(9):S97.
46. Curtis JR, Reed G, Greenberg J, Teng GG, Kremer J. Hepatotoxicity Associated with Non-Biologic DMARDs: Implications for Evaluation of New Rheumatic Disease Therapies. *Arthritis & Rheumatism* 2007; 56(9):S169.
47. Greenberg J, Strand V, Keystone E, Curtis JR, Maury E, Reed G, Kremer, Nasir A, Henderson J, Kavanaugh A, Hochberg M. TNF Inhibitors (TNF-I) and Risk of Malignancy in 8,072 RA Patients Followed Over 15,495 Patient Years. *Arthritis & Rheumatism* 2007; 56(9):S158.
48. Curtis JR, Patkar N, Xie A, Martin C, Saag KG. Drug-Specific, Time-Dependent Risks of Serious Bacterial Infections Associated with TNF- α Antagonists. *Arthritis & Rheumatism* 2007; 56(9):S423.
49. Curtis JR, Teng GG, Felson D, Nevitt M, Niu J, Saag KG, Segal N, Lewis C. Symptomatic Knee Osteoarthritis is a Risk Factor for Widespread Pain. *Arthritis & Rheumatism* 2007; 56(9):S668.
50. Nevitt MC, Zhang Y, Javaid MK, Neogi T, Curtis JR, McCulloch CE, Wang N, Felson D. Systemic BMD and Risk of Incident and Progressive Tibiofemoral Radiographic OA in White Men and Women: the MOST Study. *Arthritis & Rheumatism* 2007; 56(9):S784.
51. Furst DE, Sokolove J, Greenberg J, Curtis JR, Kavanaugh A, Kremer J, Reed G, Calabrese L, Hooper M, Baumgarten S, Strand V. Risk of elevated liver enzymes (LFTs) with TNF inhibitors (TNF-I) in rheumatoid arthritis: analysis in 6,861 patients with 22, 552 visits. Annual European Congress of Rheumatology EULAR, Paris, France, June 2008.
52. Kilgore ML, Morrissey MA, Becker D, Gary LC, Curtis JR, Saag KG, Yun H, Matthews R, Smith W, Delzell E. Incremental Costs Associated with Selected Skeletal Fractures. *Journal of Bone and Mineral Research* 2008; 23:S8.
53. Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG. Risk of Hip Fracture after Bisphosphonate Discontinuation: Implication for a Drug Holiday. *Journal of Bone and Mineral Research* 2008; 23:S122.
54. Curtis JR, Xi J, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Improving the prediction of Medication Adherence: The Example of Bisphosphonates for Osteoporosis. *Journal of Bone and Mineral Research* 2008; 23:S466.
55. Curtis JR, Laster A, Becker DJ, Carbone L, Kilgore M, Matthews R, Morrissey MA, Saag KG, Tanner SB. Reimbursement for Bone Mineral Density Testing Among US Medicare Beneficiaries. *Journal of Bone and Mineral Research* 2008; 23:S194.

56. Curtis JR, Laster A, Becker DJ, Carbone L, Kilgore M, Matthews R, Morrisey MA, Saag KG, Tanner SB, Delzell E. What Happens to the Availability of DXA if Physicians Stop Performing Them in Their Offices? *Journal of Bone and Mineral Research* 2008; 23:S304.
57. Curtis JR, Becker DJ, Kilgore M, Gary LC, Matthews R, Morrisey MA, Patkar N, Saag KG, Warriner AH, Delzell E. "Pathologic" Fractures: To Include or Exclude? *Journal of Bone and Mineral Research* 2008; 23:S322.
58. Curtis JR, Xi J, Arora T, Silver AG, Colon-Emeric C, Westfall AO, Delzell E, Saag KG. Do Physicians Who Practice Together Provide Similar Osteoporosis Care? *Journal of Bone and Mineral Research* 2008; 23:S344;
59. McDonough AK, Teng GG, Abbott J, Nair R, Amling C, Colli J, Fiveash JB, Lopez R, Urban D, Curtis JR, Saag KG. Effects of Androgen Deprivation Therapy on Bone Health in Prostate Cancer. *Journal of Bone and Mineral Research* 2008; 23:S187.
60. Manno RL, Calabrese LH, Curtis JR, Cush JJ, Bingham, III CO. Evaluating Immunization Knowledge and Practices by Rheumatologists. *American College of Rheumatology Annual Scientific Meeting 2008, San Francisco, CA.*
61. Warriner A, Patkar NM, Delzell E, Kilgore M, Gary L, Curtis JR, Saag KG. Defining Osteoporosis Fractures Using a Systematic Literature Review and Expert Panel Process. *American College of Rheumatology Annual Scientific Meeting 2008, San Francisco, CA.*
62. Javaid M, Tolstykh I, Neogi T, Guermazi A, Curtis JR, Torner J, Lane N, Felson D, Nevitt M. Non-linear Association between Baseline Serum 25(OH) Vitamin D Concentration and Incident Radiographic Knee OA: The MOST Study. *American College of Rheumatology Annual Scientific Meeting 2008, San Francisco, CA.*
63. Curtis JR, Lui L, Barrett-Connor E, Bauer D, Cauley J, Cummings S, Hoffman A, Lewis C, Orwoll E, Schousboe JT, Stone K. No Relationship between Osteoporosis and Cardiovascular Disease in Men: the MrOS Study. *American College of Rheumatology Annual Scientific Meeting 2008, San Francisco, CA.*
64. Shakoory B, Curtis JR, Arora T, Alarcón G, Bridges, Jr. SL, Callahan L, Donaldson M, Howard G, Moreland LW, Smith EA, Mikuls TR. For Whom does Bone Mineral Density Measurement Enhance Fracture Risk Evaluation? Application of the WHO Fracture Risk Assessment Tool (FRAX) to African Americans with Early Rheumatoid Arthritis. *American College of Rheumatology Annual Scientific Meeting 2008, San Francisco, CA.*
65. Solomon DH, Curtis JR, Kremer JM, Reed G, Hochberg MA, Setoguchi S, Nasir A, Farkhouh M, Greenberg J. TNF Blocker Use and Cardiovascular Outcomes. *American College of Rheumatology Annual Scientific Meeting 2008, San Francisco, CA.*
66. Solomon DH, Kremer J, Curtis JR, Hochberg M, Reed G, Tsao P, Farkouh M, Greenberg J. Explaining the Cardiovascular Risk Associated with Rheumatoid Arthritis: Traditional Versus Disease Related Factors. *American College of Rheumatology Annual Scientific Meeting 2008, San Francisco, CA.*
67. Wise B, Felson D, Clancy M, Niu J, Neogi T, Lane N, Hietpas J, Curtis JR, Bradley L, Torner JC, Zhang YQ. Consistency of Knee Pain and Risk of Knee Replacement: The MOST Study. *American College of Rheumatology Annual Scientific Meeting 2008, San Francisco, CA.*
68. Zhang Y, Felson D, Niu J, Curtis JR, Torner J, Aliabadi P, Sack B, Nevitt M. High BMI and BMD Increase Risk of Moderate to Severe Radiographic Knee Osteoarthritis: The MOST Study. *American College of Rheumatology Annual Scientific Meeting 2008, San Francisco, CA.*

69. Sokolove J, Strand V, Greenberg J, Curtis JR, Kavanaugh A, Kremer J, Reed G, Calabrese L, Hooper M, Baumgarten S, Furst D. Risk of Elevated Liver Enzymes (LFTS) with TNF Inhibitors (TNF-I) in Rheumatoid Arthritis: Analysis in 6,861 Patients with 22,552 Visits. American College of Rheumatology Annual Scientific Meeting 2008, San Francisco, CA.
70. Chaganti RK, Tolstykh I, Javaid MK, Neogi T, Torner J, Curtis JR, Felson DT, Lane NE, Nevitt MC. Association of Vaseline Vitamin C with Incident and Progressive Radiographic Knee OA. The MOST Study. American College of Rheumatology Annual Scientific Meeting 2008, San Francisco, CA.
71. Curtis JR, Arora T, Becker D, Gary L, Kilgore M, Matthews RS, Morrissey M, Saag K, Safford M, Taylor A, Delzell E. Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for recurrent fracture vs death. International Society for Clinical Densitometry Annual Meeting 2009, Orlando, FL.
72. Curtis JR, Arora T, Alarcon G, Bridges SL, Callahan L, Donaldson M, Howard G, Moreland LW, Smith EA, Mikuls T. Skeletal Health among African Americans with rheumatoid arthritis: associations with disease activity and application of the WHO Fracture Risk Assessment Tool (FRAX) and National Osteoporosis Foundation Guidelines. International Society for Clinical Densitometry Annual Meeting 2009, Orlando, FL.
73. Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician preference motivates use of anti-TNF therapy independent of clinical disease activity. Annual European Congress of Rheumatology EULAR 2009, Copenhagen, Denmark.
74. Curtis JR, Arora T, Alarcon GS, Bridges SL, Callahan LF, Donaldson M, Howard G, Moreland LW, Smith EA, Mikuls TR. Skeletal health among African Americans with rheumatoid arthritis: associations with disease activity and application of the WHO fracture risk assessment tool (FRAX) and national osteoporosis foundation guidelines. Annual European Congress of Rheumatology EULAR 2009, Copenhagen, Denmark.
75. Curtis JR, Patkar NM, Jain A, Greenberg J, Solomon DH. The validity of physician-reported hospitalized infections in a U.S. rheumatoid arthritis cohort. Annual European Congress of Rheumatology EULAR 2009, Copenhagen, Denmark.
76. Curtis JR, Arora T, Becker D, Gary L, Kilgore, Matthews R, Morrissey M, Saag KS, Safford M, Taylor A, Warriner A, Delzell E. Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for recurrent fracture versus death. Annual European Congress of Rheumatology EULAR 2009, Copenhagen, Denmark.
77. Curtis JR, Luijstens K. Rapid Prediction of Low Disease Activity at 1 year among RA Patients Treated with Certolizumab Pegol. Annual European Congress of Rheumatology EULAR 2009, Copenhagen, Denmark.
78. Schiff M, Keystone EC, Kevin TK, Curtis JR, Emery P, Luijstens K, Choy E, Furst DE. DAS28(ESR) Response at Week 12 is Predictive of Long-term Disease Activity in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol. Annual European Congress of Rheumatology EULAR 2009, Copenhagen, Denmark.
79. Keystone EC, Curtis JR, Fleischmann, Mease P, Khanna D, Smolen J, Furst D, Coteur G, Combe B. A More Rapid Clinical Response Following Certolizumab Pegol Treatment is Associated With Better 52-Week Outcomes in Patients With Rheumatoid Arthritis. Annual European Congress of Rheumatology EULAR 2009, Copenhagen, Denmark.
80. Curtis JR, Arora T, Becker DJ, Gary LC, Kilgore ML, Matthews RS, Morrissey M, Saag KG, Safford MM, Taylor A, Warriner A, Delzell E. Is Withholding Osteoporosis Medication after Fracture Sometimes Rational? A Comparison of the Risk for Recurrent Fracture vs. Death. 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management ICPE 2009 Providence, RI.

81. Curtis JR, Chen L, Harrold L, Narongroeknawin P, Reed G, Solomon DH. Physician Preference Motivates Use of Anti-TNF Therapy Independent of Clinical Disease Activity. 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management ICPE 2009 Providence, RI.
82. Jain A, Patkar N, Greenberg J, Solomon DH, Curtis JR. The Validity of Physician-Reported Hospitalized Infections in a US Rheumatoid Arthritis Cohort. 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management ICPE 2009 Providence, RI.
83. Curtis JR, Ewing S, Bauer DC, Cauley JA, Cawthon PM, Haney EM, Ishani A. The Longitudinal Relationship Between Intact Parathyroid Hormone Levels and BMD Loss: The Osteoporotic Fractures in Men (MrOS) Study. American Society for Bone and Mineral Research (ASBMR) 2009 Denver, CO.
84. Curtis JR, Adams A, Cauley JA, Cawthon PM, Cummings ST, Ensrud KE, Hoffman A, Judd S. Serum Hydroxyvitamin D, Parathyroid Hormone and the Risk of Falls: the Osteoporotic Fractures in Men (MrOS) Study. American Society for Bone and Mineral Research (ASBMR) 2009 Denver, CO.
85. Curtis JR, Arora T, Becker DJ, Kilgore ML, Matthews RS, Morrissey M, Saag KS, Smith WK, Taylor A. Subtrochanteric Insufficiency Fractures among Medicare Beneficiaries. American Society for Bone and Mineral Research (ASBMR) 2009 Denver, CO.
86. Curtis JR, Arora T, Becker DJ, Gary L, Kilgore ML, Matthews RS, Morrissey M, Narongroeknawin P, Saag KG, Safford M, Taylor A, Warriner A, Delzell E. Is Withholding Osteoporosis Medication after Fracture Sometimes Rational? A Comparison of the Risk for Recurrent Fracture vs. Death. American Society for Bone and Mineral Research (ASBMR) 2009 Denver, CO.
87. Moreland LW, O'Dell JR, Paulus H, Curtis JR, Bridges Jr. SL, Zhang X, Howard G, Cofield SS. Treatment of Early Aggressive RA; A Randomized, Double-Blind, 2-Year Trial Comparing Immediate Triple DMARD Versus MTX Plus Etanercept to Step-up From Initial MTX Monotherapy. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
88. Outman R, Warriner AH, Saag KG, Curtis JR. Improving Osteoporosis Screening through Patient Activation and Self-Scheduling Session Type: Poster Session Name: Quality Measures and Innovations in Practice Management and Delivery of Care. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
89. Curtis JR, John A, Baser O. Frequency of Lipid Testing in Patients with Rheumatoid Arthritis: A Retrospective Database Analysis. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
90. Curtis JR, Luijckens K. Rapid Prediction of Low Disease Activity at 1 Year Among RA Patients Treated with Certolizumab Pegol. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
91. Curtis JR, John A, Baser O. Determinants of TNF Switching in Patients with Rheumatoid Arthritis (RA). American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
92. Curtis JR, John A, Baser O. Quantification of Dyslipidemia Among Patients with Rheumatoid Arthritis and Changes Associated with Initiation of Anti-TNF Therapy: A Retrospective Database Analysis. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
93. Curtis JR, Chen L, Cush J, Dao KH, Delzell E, Furst DE, Greenberg J, Hochberg MC, Jain A, Kremer JM, Patkar N, Solomon DH. The Risk for Hospitalized and Outpatient Infections Related

to Anti-TNF Therapy and Newer Biologics. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.

94. Curtis JR, Judd S, Bauer D, Black D, Delzell E, Ensrud KE, Safford MM, Schwartz A. The Relationship Between Bisphosphonate Adherence and Fracture: Is It the Behavior or the Medication? Results From the Placebo Arm of the Fracture Intervention Trial. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
95. Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician Preference Motivates Use of Anti-TNF Therapy Independent of Clinical Disease Activity. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
96. Curtis JR, Arora T, Taylor AJ, Bingham III CO, Cush J, Narongroeknawin P, Delzell E. Quality of Preventive Care for Older Americans with Rheumatoid, Psoriatic and Osteoarthritis. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
97. Curtis JR, Ewing S, Bauer DC, Cawthon P, Judd S, Haney E, Ishani A. The Longitudinal Relationship Between Intact Parathyroid Hormone Levels and BMD Loss: The Osteoporotic Fractures in Men (MrOS) Study. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
98. Curtis JR, Adams A, Cauley JA, Cawthon P, Cummings SR, Ensrud KE, Hoffman A, Judd S, Lewis CE, Narongroeknawin P, Skikany JM. Serum Hydroxyvitamin D, Parathyroid Hormone, and the Risk of Falls: The Osteoporotic Fractures in Men (MrOS) Study. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
99. Curtis JR, Chen L, Niu J, Delzell E, Felson D, Javaid MK, Katholi C, Nevitt MA, Lewis CE for the MOST Group. Physiologically Optimal Vitamin D Levels in African Americans Based Upon Intact Parathyroid Hormone Suppression: What Vitamin D Should Be Considered "Normal"? American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
100. Curtis JR, Larson J, Delzell E, Judd S, Safford MM, LaCroix A, Chlebowski R. Does the Benefit of Medication Adherence Relate More to a Drug Effect or the Behavior Itself? Quantifying the Effect of Adherence Behavior Using Data From the Placebo Arms of the WHI. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
101. Harrold L, Greenberg JD, Curtis JR, Bentley MJ, Reed G, Harrington JT. Rheumatologists' Prescribing Patterns for Rheumatoid Arthritis Patients with Active Disease. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
102. Van Vollenhoven R, Smolen J, Schiff M, Fleishmann R, Combe B, Goel N, Desai C, Curtis JR, Keystone E. Safety Update on Certolizumab Pegol (CZP) in Patients with Active Rheumatoid Arthritis (RA). American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
103. Van der Heijde D, Schiff M, Keystone E, Landewe R, Kvien TK, Curtis JR, Khanna D, Lijntens K, Furst DE, Cush J. Probability to achieve low disease activity at 52 weeks in rheumatoid arthritis (RA) patients treated with certolizumab pegol (CZP) depends on time to and level of initial response. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
104. Keystone EC, Curtis JR, Fleishmann R, Mease P, Khanna D, Smolen J, Furst DE, Coteur G, Combe B. A Faster Clinical Response to Certolizumab Pegol (CZP) Treatment is Associated with Better 52-Week Outcomes in Patients with Rheumatoid Arthritis (RA). American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.

105. Van Vollenhoven RF, Keystone EC, Furie R, Blesch A, Wang C, Curtis JR. Gastrointestinal Safety in Patients with Rheumatoid Arthritis Treated with Tocilizumab: Data From Roche Clinical Trials. American College of Rheumatology ACR/ARHP Annual Scientific Meeting 2009, Philadelphia, PA.
106. Song X, Shi N, Badamgarav E, Kallich J, Varker H, Lenhart G, Curtis JR. Cost of second fracture among medicare patients with initial hip, vertebral, and non-hip non-vertebral (NHNV) fractures. *ISPOR 15th Annual International Meeting* 2010, Atlanta, GA.
107. Shi N, Song X, Badamgarav E, Kallich J, Varker H, Lenhart G, Curtis JR. Cost burden of second fracture in patients with commercial insurance. *ISPOR 15th Annual International Meeting* 2010, Atlanta, GA.
108. Van der Heijde D, Schiff M, Keystone E, Landewé R, Kvien TK, Curtis JR, Khanna D, Lijitens K, Furst DE. Time to and Level of Initial DAS28 Change With Certolizumab Pegol Predicts the Likelihood of Having Low Disease Activity at Years 1 and 2 in Patients With Rheumatoid Arthritis. Annual European Congress of Rheumatology EULAR 2010, Rome, Italy.
109. Smolen JS, van Vollenhoven RF, Kavanaugh A, Lijitens K, Goetin, van der Heijde D, Curtis JR. Efficacy Sustained After Dose De-escalation of Certolizumab Pegol in Rheumatoid Arthritis Patients: Post-hoc Analysis of the RAPID 2 Open-label Extension. Annual European Congress of Rheumatology EULAR 2010, Rome, Italy.
110. Curtis JR, John A, Gust C. Dyslipidemia and changes in lipid levels associated with initiation of TNF inhibitor therapy among rheumatoid arthritis patients. Oral Presentation. Annual European Congress of Rheumatology EULAR 2010, Rome, Italy.
111. Curtis JR, Delzell E, Chen L, Judd S, Black D, Ensrud K, Palermo L, Safford M, Schwartz A, Bauer D. The relationship between bisphosphonate adherence and fracture: Is it the behaviour or the medication? Results from the Placebo Arm of the Fracture Intervention Trial. International Conference on Pharmacoepidemiology and Therapeutic Risk Management ISPE 2010, Brighton, UK.
112. Curtis JR, Larson J, Delzell E, Brookhart MA, Cadarette S, Chlebowski R, Judd S, Safford D, Solomon D, LaCroix A. Placebo adherence, clinical outcomes and mortality in the Women's Health Initiative Randomized Hormone Therapy Trials. International Conference on Pharmacoepidemiology and Therapeutic Risk Management ISPE 2010, Brighton, UK.
113. Curtis JR, Chen S, Werther W, John A, Johnson D. Validation of ICD-9-CM Codes to identify gastrointestinal perforation (GIP) cases in administrative claims data in Rheumatoid Arthritis (RA) patients. International Conference on Pharmacoepidemiology and Therapeutic Risk Management ISPE 2010, Brighton, UK.
114. Outman RC, Aubert R, Curtis JR, Epstein R, Frueh F, Khalid M, Sanders C, Stanek E, Steinkellner A, Warriner A, Saag K. Factors Associated with the Prevention of Glucocorticoid-Induced Osteoporosis using a Large U.S. National Pharmacy Database. American Society for Bone and Mineral Research (ASBMR) 2010 Toronto, Ontario, Canada.
115. Narongroeknawin P, Patkar NM, Shakoory B, Jain A, Curtis JR, Delzell E, Lander P, Lopez-Ben R, Pitt M, Safford M, Bolgas D, Saag KG. Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Typical Hip Fractures Using Administrative Claims Data. American Society for Bone and Mineral Research (ASBMR) 2010 Toronto, Ontario, Canada.
116. Warriner A., Outman RC, Curtis JR, Feldstein AC, Glauber H, Ren J, Roblin D, Rosales A, Unitan R, Saag K. DXA Screening and Use of Osteoporosis Medications in Two Large Healthcare Systems. American Society for Bone and Mineral Research (ASBMR) 2010 Toronto, Ontario, Canada.

117. Kilgore ML, Outman RC, Saag KG, Locher J, Curtis JR, Outman RC, Locher JL, Allison JJ, Saag KG. Secondary Fracture Prevention in Home Care: Preliminary Results from a Randomized Trial. American Society for Bone and Mineral Research (ASBMR) 2010 Toronto, Ontario, Canada
118. Curtis JR, Larson J, Delzell E, Brookhart MA, Caderette SM, Chlebowski R, Judd S, Safford M, Solomon DH, Lacroix AZ. Does the Benefit of Medication Adherence Relate More to a Drug Effect or the Behavior Itself? Quantifying the Effect of Adherence Behavior Using Data From the Placebo Arms of the WHI. Oral. American Society for Bone and Mineral Research (ASBMR) 2010 Toronto, Ontario, Canada
119. Curtis JR, Matthews R, Yun H, Arora T, Saag KG, Delzell E. Characteristics of U.S. Medicare Enrollees With the New ICD9 Code For Osteonecrosis of the Jaw. American Society for Bone and Mineral Research (ASBMR) 2010 Toronto, Ontario, Canada.
120. Warriner A, Outman RC, Saag KG, Kitchin E, Morgan SL, Curtis JR. DXA Self Screening Improves Osteoporosis Screening. American Society for Bone and Mineral Research (ASBMR) 2010 Toronto, Ontario, Canada.
121. Mudano AS, Outman RC, Kilgore ML, Fraenkel L, Kitchin E, Locher J, Saag KG, Warriner A, Curtis JR. Underuse of Treatment for Osteoporosis Among High Risk Older Adults Living in the Community Receiving Home Health Services. American Society for Bone and Mineral Research (ASBMR) 2010 Toronto, Ontario, Canada.
122. Wade S, Curtis JR, Yu J, White J, Stolshek B, Merinar C, Balasubramanian A, Kallich J, Adams J, Wiswanathan H. Medication Adherence and Fracture risk among patients Using Osteoporosis Medications in a large US Health Plan. American Society for Bone and Mineral Research (ASBMR) 2010 Toronto, Ontario, Canada.
123. Becker DJ, Yun H, Kilgore ML, Curtis JR, Delzell E, Gary L, Saag KG, Morrissey M. Health Services Utilization after Fractures: Recent Evidence from Medicare. American Society for Bone and Mineral Research (ASBMR) 2010 Toronto, Ontario, Canada.
124. Viswanathan H, White J, Wade SW, Yu J, Curtis JR, Stolshek B, Merinar C, Kallich J, Balasubramanian A, Adams J. Incremental Cost of Osteoporosis-related fractures in a large US managed care population. American Society for Bone and Mineral Research (ASBMR) 2010 Toronto, Ontario, Canada.
125. Yazici Y, Curtis JR. Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Active RA and a Previous Inadequate Response to DMARDs: The ROSE Study. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:1808.
126. Narongroeknawin P, Patkar NM, Shakoory B, Jain A, Curtis JR, Delzell E, Lander PH, Lopez-Ben R, Pitt MJ, Safford MM, Volgas DA, Saag KG. Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Typical Hip Fractures Using Administrative Claims Data. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:1573.
127. Curtis JR, Yang S, Chen L, Park G, Bitman B, Wang B, Navarro-Millan I, Kavanaugh A. Prediction of One-Year Response to Etanercept and Methotrexate in Rheumatoid Arthritis Patients in TEMPO. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:1117.
128. Outman R, Markward NJ, Khalid M, Aubert RE, Curtis JR, Epstein RS, Frueh FW, Stanek EJ, Steinkellner A, Warriner A, Saag KG. Screening and Treatment of Glucocorticoid Induced Osteoporosis in a Large U.S. National Pharmacy Database. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:1561.

129. Warriner A, Outman RC, Curtis JR, Feldstein A, Glauber H, Ren J, Roblin D, Rosales A, Unitan R, Saag KG. DXA Screening and Use of Osteoporosis Medications in Two Large Regional Healthcare Systems. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62 Suppl 10:1543.
130. Curtis JR, Yang S, Baddley J, Cannon G, Chen L, Delzell, E, Patkar N, Saag KG, Safford M, Singh J, Mikuls T. Derivation of a Preliminary Administrative Claims-Based Algorithm to Identify Lack of Effectiveness of Rheumatoid Arthritis Medications. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62 Suppl 10:304.
131. Curtis JR, Charles-Schoeman C, Yang S, Chen L, Cofield S, Howard G, McVie T, Moreland L, O'Dell J, Paulus H, Safford M, Bridges Jr SL. Changes in Lipoproteins Associated with MTX, MTX + Etanercept, and Triple DMARD Therapy among Early RA Patients in the TEAR Trial. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62 Suppl 10:299.
132. Curtis JR, Chen L, Baddley J, Beukelman T, Saag KG, Winthrop K, Delzell E. The Comparative Incidence of Serious Infections among Rheumatoid Arthritis Patients Who Switch Biologic Agents. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62 Suppl 10:721.
133. Curtis JR, Haney D, van der Helm A, Shen Y, Knevel R, Cavet G, Dirven L, Allaart C, Huizinga T, Centola M, Hesterberg L, Chernoff D, Carulli J, Shadick N, Weinblatt M, Hamburger M, Fleischmann R, Keystone E. Validation of a Multi-Biomarker Test For Rheumatoid Arthritis (RA) Disease Activity (Vectra DA) in a Multi-Cohort Study. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62 Suppl 10:1782.
134. Curtis JR, Shan Y, Kremer J, Greenberg J, Reed G. Disease Activity, Calendar Year, and Physician Preference Are Associated With Switching of Biologic Agents For Reasons of Inadequate Efficacy. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62 Suppl 10:379c.
135. Warriner A, Outman RC, Saag KG, Kitchin E, Morgan SL, Curtis JR. Self-Scheduling of DXA Scans to Improve Osteoporosis Screening in Women. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62 Suppl 10:1006.
136. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St. Clair EW, Bridges Jr SL, Zhang X, Howard G, van der Heijde D, Cofield SS for the TEAR Trial Investigators. Two-Year Radiographic Results from the TEAR Trial. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62 Suppl 10:1368.
137. Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Delzell E, Kim H, Saag KG, Lewis JD. Rates of Malignancy Associated with Juvenile Idiopathic Arthritis and Its Treatment: An Observational Study of National U.S. Medicaid Administrative Claims Data. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62 Suppl 10 :2084.
138. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of Hospitalized Bacterial Infection in Juvenile Idiopathic Arthritis and Its Treatment: An Observational Study of National U.S. Medicaid Administrative Claims Data. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62 Suppl 10:2103.
139. Curtis JR, Lana A, Werther W, John A, Johnson DA, Schulman K. Factors Associated With Upper and Lower Gastrointestinal Perforation in a Cohort of Patients With Rheumatoid Arthritis. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62 Suppl 10:1031.
140. Viswanathan H, White J, Wade SW, Yu J, Curtis JR, Stolshek B, Merinar C, Kallich J, Balasubramanian A, Adams J. Assessment of the Incremental Cost of Osteoporosis-Related

Fractures among Women in a Large U.S. Managed Care Population. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:1540.

141. Kawai V, Grijalva C, Arbogast P, Curtis JR, Solomon D, Delzell E, Quillet-Helstrom R, Herrinton L, Mitchel E, Stein CM, Griffin MR. Changes in corticosteroid use after DMARD initiation in patients with rheumatoid arthritis. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:54.
142. Beukelman T, Xie F, Chen L, Baddley J, Delzell E, Grijalva C, Patkar N, Saag KG, Winthrop K, Curtis JR. Characteristics of Cases of PML among Patients with Selected Rheumatic and Autoimmune Diseases. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:722.
143. Cannon G, Wolff R, Ying J, Hayden C, Sauer B, Curtis JR, Johnson D, Kerr G, Richards J, Caplan L, Reimold A, Mikuls T. Candidate Gene Analysis in US Veteran Rheumatoid Arthritis Patients with Clinical Improvement during Treatment with Anti-Tumor Necrosis Factor Agents in the Veterans Affairs Rheumatoid Arthritis (VARA) Registry. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:1099.
144. Baddley J, Winthrop K, Patkar N, Delzell E, Xie F, Chen L, Curtis JR. Geographic Distribution of Endemic Fungal Infections among Older Americans. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:1643.
145. Winthrop K, Baddley J, Chen L, Liu L, Grijalva C, Patkar N, Xie F, Delzell E, Beukelman T, Herrinton L, Saag KG, Curtis JR. Rates of tuberculosis and nontuberculous mycobacterial disease among rheumatoid Arthritis patients who use Anti-tumor necrosis factor alpha therapy; from the SAFETY of Biologic ThERapy (SABER) study. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:404.
146. Kilgore ML, Curtis JR, Outman RC, Locher JL, Allison JJ, Saag KG. Secondary Fracture Prevention in Home Health Care: Initial Results from a Group Randomized Trial. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:1005.
147. Harrold L, Greenberg JD, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Harrington T. The Impact of the ACR Treatment Recommendations on Physician Prescribing in a U.S. Cohort of Rheumatoid Arthritis Patients. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:1010.
148. Bakker MF, Shen Y, Bijlsma JWJ, Jacobs JWG, Lafeber FPJG, Cavet G, Centola M, Haney D, Hesterberg LK, Chernoff D, Carulli J, Shadick NA, Weinblatt ME, Hamburger MI, Fleischmann RM, Curtis JR, Keystone EC. Development of a Multi-Biomarker Test for Rheumatoid Arthritis (RA) Disease Activity (Vectra DA). ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:1753.
149. Viswanathan H, Wade SW, Curtis JR, Yu J, White J, Stolshek B, Merinar C, Balasubramanian A, Kallich J, Adams J. Osteoporosis Medication Adherence and Fracture Risk among Women in a Large U.S. Health Plan. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:1552.
150. Beukelman T, Xie F, Curtis JR. Usage of TNF Inhibitors for the Treatment of Juvenile Idiopathic Arthritis: Data from a National U.S. Administrative Claims Database. ACR/ARHP Annual Scientific Meeting 2010 Atlanta, GA. Arthritis Rheum 2010;62Suppl 10:239.
151. Adherence with Intravenous Zoledronic Acid and Ibandronate for Osteoporosis among U.S. Medicare Beneficiaries
152. Warriner A, Outman RC, Curtis JR, Feldstein A, Redder D, Rix M, Robinson B, Roblin D, Rosales A, Safford M, Saag KG. Allowing Patient Self-Referral of DXA Significantly Improves

- Osteoporosis Screening. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
153. Curtis JR, Yun H, Matthews R, Saag KG, Delzell E. Adherence with Intravenous Zoledronic Acid and Ibandronate for Osteoporosis among U.S. Medicare Beneficiaries. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
 154. Burge R, Kim Le T, Zhao Y, Curtis JR. Medical Care Resource Utilization and Costs Associated with Teriparatide Therapy in U.S. Patients. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
 155. Outman RC, Curtis JR, Locher J, Kilgore M, Saag KG, Van Den Bogert C, Mudano, Kitchin E, Chen L. Factors Related to Permanent Discontinuation of Osteoporosis Treatment. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
 156. Zhang J, Curtis JR, Delzell E, Saag KG. Use of Pharmacologic Agents for the Prevention of Osteoporosis among Older Women with Low Bone Mass is Discordant with NOF Guidance. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
 157. Zhang J, Delzell E, Zhao H, Laster A, Saag KG, Kilgore M, Morrissey M, Wright N, Yun H, Curtis JR. Central DXA Utilization in Medicare Beneficiaries in the Wake of Reimbursement Changes. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
 158. Wright N, Delzell E, Muntner P, Curtis JR, Carson A, Safford M. Utilization of Osteoporosis Medications in Women With and Without Diabetes Mellitus. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
 159. Yun H, Curtis JR, Matthews R, Kilgore M, Morrissey M, Wright, Saag KG, Becker D, Delzell E. Osteoporosis Treatment Patterns Among Medicare Beneficiaries. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
 160. Cai Q, Curtis JR, Wade S, Viswanathan H, White J, Balasubramanian A, Kallich J, Adams J, Stolshek B. Medication Adherence in Patients on Osteoporosis Therapy: Physician Perceptions Versus Patient Behavior. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
 161. Yun H, Curtis JR, Smith W, Matthews R, Saag KG, Wright N, Kilgore M, Delzell, E. Generic Alendronate use in Medicare Part D Data. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
 162. Curtis JR, Lang J, Yun H, Delzell E. Does Medication Adherence Itself Confer Fracture protection? An Investigation of the Healthy Adherer Effect in Observational Data. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
 163. Kilgore M, Becker D, Curtis JR, Saag KG, Delzell E, Arora T, Morrissey. Decomposing Health Care Expenditures Relative to Fractures. American Society for Bone and Mineral Research (ASBMR) 2011 San Diego, CA.
 164. Mudano, A, Gary L, Melton M, Warriner A, Harrington TM, Kilgore M, Jester P, Wright N, Curtis JR, Lewis C, Delzell E, Saag KG. Methods to simplify Recruiting for Pragmatic Clinical Trials (PCT's) in Osteoporosis in the Community: iPad vs. Interactive Voice Response (IVRS) Systems. American Society for Bone and Mineral Research (ASBMR), 2011 San Diego, CA.
 165. Nicole C. Wright, Brian T. Walitt, Curtis, JR, Mary Pettinger, Christine G. Parks, Anneclaire J. De Roos, Jean Wactawksi-Wende, Rachel Mackey, Rebecca D. Jackson, Michal L. Melamed, Barbara V. Howard. Is Sunlight Exposure and Vitamin D Intake Associated with Rheumatoid Arthritis? American College of Rheumatology (ACR) 2011 Chicago, IL.

166. Iris Navarro-Millan, Lang Chen, Jeffrey D. Greenberg, Curtis, JR. Application of the New American College of Rheumatology/European League Against Rheumatism Rheumatoid Arthritis Remission Criteria in a United States Cohort. American College of Rheumatology (ACR) 2011 Chicago, IL.
167. Carlos Grijalva, Lang Chen, Elizabeth S. Delzell, John Baddley, Timothy Beukelman, Kevin L. Winthrop, Marie Griffin, Lisa Herrinton, Liyan Liu, Parivash Nourjah, Nivedita M. Patkar, Daniel H. Solomon James Lewis, Fenglong Xie Kenneth G. Saag and Curtis, JR. 801 - Initiation of Biologic DMARDs and the Risk of Hospitalization for Infection in Patients with Autoimmune Diseases. American College of Rheumatology (ACR) 2011 Chicago, IL.
168. Nazia Rashid, T. Craig Cheetham, Curtis, JR, Gerald D. Levy, Kenneth G. Saag, Ted R. Mikuls. Gout Treatment Gaps and Factors Associated with Incident Patients Having Uric Acid Goal Attainment: A Retrospective Cohort Study in An Integrated Healthcare System. American College of Rheumatology (ACR) 2011 Chicago, IL.
169. Amy H. Warriner, Ryan C. Outman, Curtis, JR, Adrienne C. Feldstein, Roslin Nelso, David T. Redden, Junling Ren, Mary M. Rix, Brandi E. Robinson, Douglas W. Roblin, A. Gabriela Rosales, Monika M. Safford, Kenneth G. Saag. Allowing Patient Self-Referral of Dual Energy X-Ray Absorptiometry Significantly Improves Osteoporosis Screening in Two Regional Healthcare Systems. American College of Rheumatology (ACR) 2011 Chicago, IL.
170. Huifeng Yun, Elizabeth S. Delzell, Robert Matthews, Meredith Kilgore, Kenneth G. Saag, Cathleen Colon-Emeric, Christopher M. O'Connor, Kenneth W. Lyles, Michael Morrissey and Curtis, JR. Fractures and Mortality in Relation to Different Osteoporosis Treatments. American College of Rheumatology (ACR) 2011 Chicago, IL.
171. Jie Zhang, Curtis JR, Elizabeth S. Delzell and Kenneth G. Saag. Use of Pharmacologic Agents for the Prevention of Osteoporosis Among Older Women with Low Bone Mass Is Discordant with National Osteoporosis Foundation Guidance. American College of Rheumatology (ACR) 2011 Chicago, IL.
172. Dimitrios A. Pappas, George Reed, Michele M. Hooper, Ying Shan, Bojena Bitman, Jeffrey D. Greenberg, Deborah Wenkert, Jie Zhang, Joel M. Kremer and Curtis, JR. Risk for Herpes Zoster in Patients with Rheumatoid and Psoriatic Arthritis. American College of Rheumatology (ACR) 2011 Chicago, IL.
173. Curtis, JR, Sarika Ogale, Jenny Devenport, Denise Lepley. Effects of Tocilizumab Dose Escalation on Disease Activity in Adult Rheumatoid Arthritis Patients with Inadequate Response At 16 Weeks. American College of Rheumatology (ACR) 2011 Chicago, IL.
174. Curtis, JR, Jeff Lange, Huifeng Yun and Elizabeth S. Delzell, Does Medication Adherence Itself Confer Fracture Protection? An Investigation of the Healthy Adherer Effect In Observational Data. American College of Rheumatology (ACR) 2011 Chicago, IL.
175. Curtis, JR, Pradeep Sharma, Tarun Arora, Aseem Bharat, Michael Morrissey, Kenneth G. Saag, Itara Barnes, Elizabeth S. Delzell. Quality of Care for Rheumatoid Arthritis and Osteoporosis: Results From the U.S. Medicare Physician Quality Reporting Program. American College of Rheumatology (ACR) 2011 Chicago, IL.
176. Leann Maska, James R. O'Dell, Curtis, JR, S. Louis Bridges Jr., Larry W. Moreland, Stacey Cofield, Ted R. Mikuls. Active Smoking Is Not Associated with Treatment Response In Early Rheumatoid Arthritis In a Large Randomized Blinded Trial. American College of Rheumatology (ACR) 2011 Chicago, IL.
177. Curtis, JR, Theresa McVie, Ted R. Mikuls, James R. O'Dell, S. Louis Bridges Jr., Larry W. Moreland, Stacey Cofield. Clinical Response within 12 Weeks As a Predictor of Future Low

Disease Activity in Early RA Patients: Results From the TEAR Trial. American College of Rheumatology (ACR) 2011 Chicago, IL.

178. Curtis, JR, Fenglong Xie, Paul M. Muntner, Lang Chen, Kenneth G. Saag ,Elizabeth S. Delzell. Does the Association Between Anti-TNF Biologics and Serious Infections in Rheumatoid Arthritis Patients Vary by Comorbidity Burden? American College of Rheumatology (ACR) 2011 Chicago, IL.
179. Daniel H. Solomon, Leslie R. Harrold, Jeremy Rassen, HuichuanLii, Lang Chen, David Graham, Marie Griffin, Mary Kowal, BindeeKuriya, James Lewis, Liyan Liu Kenneth G. Saag ,Curtis JR. Cardiovascular Risk Reduction Associated with TNF Blockade: Results From a Large Multi-Site Observational Study? American College of Rheumatology (ACR) 2011 Chicago, IL.
180. Jie Zhang, Fenglong Xie, Elizabeth S. Delzell, Lang Chen, Kenneth G. Saag, Kevin L. Winthrop,Curtis, JR. Safety of Zoster Vaccine in Individuals with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Disease. American College of Rheumatology (ACR) 2011 Chicago, IL.
181. Curtis, JR, Huifeng Yun, Robert Matthews, Kenneth G. Saag, Elizabeth S. Delzell Adherence with Intravenous Zoledronic Acid and Ibandronate for Osteoporosis Among U.S. Medicare Beneficiaries. American College of Rheumatology (ACR) 2011 Chicago, IL.
182. James R. O'Dell, Curtis, JR,Stacey Cofield, S. Louis Bridges, Jr. Validation of Methotrexate First Strategy in Early Rheumatoid Arthritis: A Randomized, Double-Blind, 2-Year Trial. American College of Rheumatology (ACR) 2011 Chicago, IL.
183. Curtis, JR, Fenglong Xie, Paul M. Muntner, Lang Chen, Shuo Yang, Kenneth G. Saag and Elizabeth S. Delzell. Derivation and Validation of An Infection Risk Score to Predict the Risk of Serious Infections for Rheumatoid Arthritis Patients. American College of Rheumatology (ACR) 2011 Chicago, IL.
184. Leslie R. Harrold, George Reed, Curtis. JR, Daniel H. Solomon, Marc Hochberg, Alina U. Onofrei, Joel M. Kremer, Jeffrey D. Greenberg. Comparative Effectiveness of AbataceptVersus Subsequent Anti-TNF Agents Among Rheumatoid Arthritis Patients with Previous Anti-TNF Exposure. American College of Rheumatology (ACR) 2011 Chicago, IL.
185. Curtis JR, Yun H, Matthews RS, Saag KG, Delzell ES, Adherence with Intravenous Zoledronic Acid and Ibandronate for Osteoporosis among U.S. Medicare Beneficiaries, ISPE Chicago, IL. 2011
186. Curtis JR, Delzell ES, Chen L, Judd S, Blac D, Ensrud K, Palermo L, Safford M, Schwartz A, Baurer D. The relationship Between Bisphosphonate Adherence and Fracture: Is It the Behavior or the Medication? Results from the Placebo Arm of the Fracture Intervention Trial. ISPE Chicago, IL 2011
187. Curtis JR, Baddley JW, Yang S, Patkar N, Chen L, Delzell ES, Mikuls TR, Saag KG, Singh J, Safford M, Cannon GW. Validation of Preliminary Administrative Claims-Based Algorithm for the Effectiveness of Medications for Rheumatoid Arthritis. ISPE, Chicago IL, 2011
188. Curits JR, Xie F, Chen L, Beukelman T, Saag K, Winthrop K, Delzell, E. The Comparative Incidence of Serious Infections among Rheumatoid Arthritis Patients Who Switch Biologic Agents. EULAR May 2011, London England.
189. Curtis JR, Shan Y, Kremer J, Greenberg J, Reed, G. Disease Activity Calendar Year And Physician Preference Are Associated With Switching of biologic Agents For Reasons of Inadequate Efficacy. EULAR 2011, London England.
190. Curtis JR, Schoeman-Charles C, Yang S, Chen L, Cofield S, Howard G, McVie T. Moreland L, O'Dell J, Paulus H, Safford M, Bridges SL Jr., Changes in Lipoproteins Associated With MTX,

MTX + Etanercept, and Triple DMARD Therapy Among Early RA Patients in the TEAR Trial, EULAR 2011, London England.

191. Curtis JR, Yang S, Baddley J, Cannon G, Chen L, Delzell E, Patkar N, Saag K, Safford M, Singh J, Mikuls T. Derivation of a Preliminary Administrative Claims-Based Algorithm To Identify Lack of Effectiveness of Rheumatoid Arthritis Medications, EULAR 2011, London England.
192. Zhang J, Delzell E, Xie F, Baddley, J.Spettell C, McMahan R, Fernandes J, Chen L, Winthrop K, Curtis JR, The Use Safety and Effectiveness of Herpes Zoster Vaccination In Individuals with Inflammatory and Autoimmune Diseases. EULAR 2011, London England. 2011
193. Curtis JR, Larson L, Delzell E, Brookhart Ma, Cadarette S, Chelbowski R, Judd S, Safford M, Solomon D, LaCroix A. Placebo Adherence Clinical Outcomes and Mortality in the Women's Health Initiative Randomized Hormone Therapy Trials. ISPE Chicago, IL 2011.
194. Zhang J, Delzell ES, Xie F, Baddley JW, Spettell C, McMahan RM, Fernandes J, Chen L, Winthrop K, Curtis JR. The Use Safety and Effectiveness of Herpes Zoster Vaccination in Individuals with Inflammatory and Autoimmune Diseases. ISPE Chicago, IL 2011.
195. Pappas DA, John A, Greenberg JD, Devenport J, Kremer JM, Ogale S, Reed GW, Saunders KC, Curtis JR: Design Characteristics of the Corrona Certain Study: A Us Comparative Effectiveness and Biomarker Study of Rheumatoid Arthritis Biologic Agents. AB0524. The Annual European Congress of Rheumatology EULAR 2012, Berlin, Germany.
196. Pappas DA, Hooper M, Reed G, Shan Y, Wenkert D, Zhang J, Greenberg J, Curtis J: Risk for Herpes Zoster After Treatment with Biologic and Synthetic Disease Modifying Agents for Rheumatoid Arthritis. FRI0108. The Annual European Congress of Rheumatology EULAR 2012, Berlin, Germany.
197. Lee EB, Curtis JR, Riese R, Connell C, Chew R, Boy M, Maller E, Su C, Wang L, Bradley J: Tofacitinib (Cp-690,550), An Oral Janus Kinase Inhibitor: Analysis of Gastrointestinal Adverse Events Across the Rheumatoid Arthritis Clinical Programme. THU0140. The Annual European Congress of Rheumatology EULAR 2012, Berlin, Ge
198. Mariette X, Curtis JR, Lee EB, Riese R, Kaplan I, Chew R, Geier J, Wang L, Bradley JD: Tofacitinib (Cp-690,550), An Oral Janus Kinase Inhibitor: Analysis of Malignancies Across the Rheumatoid Arthritis Clinical Programme. THU0131. The Annual European Congress of Rheumatology EULAR 2012, Berlin, Germany.
199. Zhang F, Guerin A, Gauthier G, Curtis J: Treatment Patterns in Psoriatic Arthritis (PSA) Patients Newly Initiated on Oral Disease-Modifying Anti-Rheumatic Drugs (DMARDs). OP0159. The Annual European Congress of Rheumatology EULAR 2012, Berlin, Germany.
200. Curtis JR, Lanos A, John A, Johnson DA, Schulman KL: Trends in the Frequency of Gastrointestinal Perforation in a Cohort of Patients with Rheumatoid Arthritis. *Pharmacoepidemiol Drug Saf* 2012; 21: (Suppl. 3) 906. ISPE
201. Curtis JR, Chen L, Xie F, Zhang J, Saag KG, Cofield S, Winthrop KL, Wright NC, Delzell ES. Use of Health Plan Data to Assess Feasibility of Large Pragmatic Clinical Trials in Rheumatoid Arthritis. *ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum* 2012;64 Suppl 10:54
202. Zhang J, Xie F, Delzell ES, Chen L, Lewis J, Haynes K, Saag KG and Curtis JR. Prevalence of Biologic Utilization Over Calendar Time Among Medicare Beneficiaries with Rheumatoid Arthritis. *ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum* 2012;64 Suppl 10:374
203. Belsom R, Jain A, Curtis JR, Yang S, Mikuls TR, Chen L and Gaffo AL. Discordant Inflammatory Markers in Veterans with Rheumatoid Arthritis: Baseline Characteristics and

Relationship with Disease Activity. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:402

204. Yun H, Xie F, Delzell ED, Chen L, Yang S, Saag KG and Curtis JR. The Comparative Effectiveness of Anti-TNF Medications Among Older and Disabled Rheumatoid Arthritis Patients in the U.S. Medicare Population. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:489
205. Navarro-Millan I, Yang S, DuVall SL, Chen L, Baddley J, Cannon GW, Delzell ES, Zhang J, Safford MM, Patkar NM, Mikuls TR, Singh JA and Curtis JR. Role of Inflammation, Serologic Status and Low Density Lipoprotein in Coronary Heart Disease Among Patients with Rheumatoid Arthritis: Data From the National Veterans Health Administration. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:1270
206. Zhang F, Hiscock R, and Curtis JR. Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:1833
207. Curtis JR, Gauthier G, Hiscock, R and Zhang F. Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated On Non-Biologic Disease-Modifying Anti-Rheumatic Drugs. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:1840
208. Wright NC, Oliveira A, Warriner AH, Curtis JR, Binkley N, Cummings SR, Hochberg MC, LaCroix A, Lewieck EM, Schousboe JT, Solomon DH, Wallace RB and Saag KG. What are the Most Clinically Relevant and Feasible Pragmatic Osteoporosis Clinical Trial Designs? ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:1995
209. Curtis JR, Shan Y, Zhang J, Greenberg JD, and Reed GW. How Much Can Patient Reported Outcomes Improve Among Rheumatoid Arthritis Patients Who Have a Clinical Response to Biologic Therapy but Have Not Attained Low Disease Activity? ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:2101
210. Jain A, Belsom R, Curtis JR, Yang S, Mikuls TR, Chen L and Gaffo AL. Patient Characteristics Associated with Discrepancies in Evaluator-Reported and Patient-Reported Outcomes in U.S. Veterans with Rheumatoid Arthritis. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:2106
211. Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, Mikuls TR, Delzell ES, Saag KG, Safford MM, DuVall S, Alexander K, Napalkov P, Kamauu A and Baddley J. Hospitalized Bacterial Infections Among U.S. Veterans with Rheumatoid Arthritis Initiating TNF Antagonist and Newer Biologic Agents? ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:2543
212. Tunceli O, Curtis JR, Woodward TC, Zhou S, Chen YW and Fernandes AW. Biologic Switching Among Patients with Rheumatoid Arthritis in the United States, 2004–2011. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:2638
213. Zhang J, Chen L, Delzell ES, Muntner PM, Hillegass WB, Safford MM, Navarro-Millan I, and Curtis JR. The Association Between Inflammatory Markers and Hyperlipidemia and the Risk of Myocardial Infarction in Patients with Rheumatoid Arthritis. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:2542

214. Zhang F, Li S and Curtis, JR. US Treatment Patterns of Psoriatic Arthritis Patients Newly Initiated On Etanercept or Adalimumab. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:2234
215. Baddley J, Yang S, Brizendine K, DuVall S, Winthrop KL, Burton MJ, Patkar NM, Delzell ES, Safford MM, Singh JA, Navarro IE, Cannon GW, Mikuls TR, Chen L, Saag KG, Alexander K, Napalkov P, Kamauu A, and Curtis JR. Rates of Opportunistic Infections Among Rheumatoid Arthritis Patients Switching Biologic Therapy. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:2093
216. Warriner AH, Outman RC, Markward N, Aubert R, Curtis JR, Epstein R, Freuh F, McEachern J, Redden DT, Safford MM, Stanek E, Steinkellner A and Saag KG. A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:1978
217. Kawai VK, Grijalva C, Arbogast P, Curtis JR, Solomon DH, Delzell ES, Chen L, Herrinton L, Liu L, Mitchell EF Jr., Stein CM, Griffin M. Initiation of Tumor Necrosis Factor Alpha (TNF_α) Antagonists and Risk of Fractures in Patients with Selected Rheumatic and Autoimmune Diseases. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:1960
218. Aslibekyan S, Danila MI, Sha J, Redden DT, Reynolds RJ, Brown E, Hughes LB, Bray MS, Morgan SL, Moreland LW, O'Dell JR, Curtis JR, Kimberly RP, Criswell LA, Plenge RM, Bridges SL Jr. and Arnett DK. Evidence of Novel Genetic Predictors of Methotrexate Efficacy in Rheumatoid Arthritis. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:997
219. Aslibekyan S, Brown E, Reynolds RJ, Redden DT, Morgan SL, Baggott J, Sha J, Moreland LW, O'Dell JR, Curtis JR, Bridges SL Jr., and Arnett DK. Genetic Predictors of Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results From the Treatment of Early Aggressive Rheumatoid Arthritis Trial. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:996
220. Curtis JR, Chen L, Beukelman T, Bharat A, Xie F, Saag KG and Delzell ES. Methods to Link a U.S. Arthritis Cohort with Medicare Administrative Claims Data. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:924
221. Kilgore M, Saag KG, Allison J, Kitchin E, Locher JL, Mudano A, Outman RC and Curtis JR. A Multimodal Intervention to Improve Osteoporosis Care in Home Health Settings: Results From a Cluster Randomized Trial. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:920
222. Beukelman T, Xie, F, Baddley J, Chen L, Delzell ES, Grijalva C, Mannion ML, Patkar NM, Saag KG, Winthrop KL and Curtis JR. Incidence of Selected Opportunistic Infections Among Children with Juvenile Idiopathic Arthritis. ACR/ARHP Annual Scientific Meeting 2012. Arthritis Rheum 2012;64 Suppl 10:763
223. Yun H, Delzell E, Curtis J, Guo L, Sharma P, Kilgore M, Muntner P, Warriner A, Saag K: Comparative Effectiveness and Safety of Generic Versus Branded Alendronate Among Medicare Beneficiaries. J Bone Miner Res 2012; 27 (Suppl 1) MO0367

224. Wright N, Levis S, Bea J, Carbone L, Cauley J, Chen Z, Crandall C, Curtis J, Jackson R, Johnson K, Lacroix A, Robbins J, Stefanick M, Watts N, Wactawski-Wende J: Does Accounting for Bone Mineral Density Alter the Association between Body Mass Index and Fracture? *J Bone Miner Res* 2012; 27 (Suppl 1) MO0329
225. Silverman S, Curtis J, Saag K, Flahive J, Diez-Perez A, Adachi J, Greenspan S, Boonen S, Cooper C, Netelenbos C, Watts N, Compston J: Importance of Physician Communication and BMD testing in Management of Glucocorticoid-Induced Osteoporosis. *J Bone Miner Res* 2012; 27 (Suppl 1) SA0390
226. Pappas DA, Chen L, Harrold LR, Reed GW, Kremer JM, Greenberg JD and Curtis JR: Physician Variability in rheumatoid Patients Not Receiving Biologics or Non-biologic DMARDs: Implications for Quality Reporting. *ACR/ARHP Annual Scientific Meeting 2013. Arthritis Rheum* 2013;65 Suppl 10: S78
227. Rosenblatt L, Curtis JR, Yang G and Hebden T: Outcomes of Patients with Rheumatoid Arthritis and Comorbid Hyperlipidemia. *ACR/ARHP Annual Scientific Meeting 2013. Arthritis Rheum* 2013;65 Suppl 10: S154
228. Pappas DA, John A, Kremer JM, Reed GW, Sommers T, Greenberg JD, Shewade A, and Curtis JR: Management of Hyperlipidemia in Patients with RA: Results From the CORRONA Certain Study: *ACR/ARHP Annual Scientific Meeting 2013. Arthritis Rheum* 2013;65 Suppl 10:S157
229. Curtis JR, Yun H, Zhang J, Xie F, Chen L, Levitan E, Lewis J, Beukelman T, Saag KG and Navarro-Millan I: Comparing Myocardial Infarction Risks Associated With Biologics of Varying Mechanisms of Action Among Older Rheumatoid Arthritis Patients: *ACR/ARHP Annual Scientific Meeting 2013. Arthritis Rheum* 2013;65 Suppl 10:S157
230. Pappas DA, John A, Curtis JR, Reed GW, Sommers T, Greenberg JD, Shewade A, and Kremer JM: Shift in Cardiovascular Risk and Lipids Levels in Rheumatoid Arthritis Patients Using ATP-3 Guidelines: *Corrona Certain Study: ACR/ARHP Annual Scientific Meeting 2013. Arthritis Rheum* 2013;65 Suppl 10:S160
231. Cannon GW, DuVall SL, Hayden CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold AM, Collier DH, Joseph G, Harrison DJ and Sauer BC: US Veterans with Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs: *ACR/ARHP Annual Scientific Meeting 2013. Arthritis Rheum* 2013;65 Suppl 10:S184
232. Curtis JR, Koetse W, Tambiah J, Ionescu L and Yazici Y: Prediction of Week 52 Treatment Response Based On A Week 12 Assessment In Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison of A Patient-Reported Instrument Versus Physician-Based Disease Activity Assessment: *ACR/ARHP Annual Scientific Meeting 2013. Arthritis Rheum* 2013;65 Suppl 10:S186
233. Curtis JR, Xie F, Zhang J, Chen L, Yun H, Schiff MH, Mackey D and Ginsberg S: Patterns of Use of Oral and Subcutaneous Methotrexate Use In Rheumatoid Arthritis Patients Enrolled in the US Medicare Program: *ACR/ARHP Annual Scientific Meeting 2013. Arthritis Rheum* 2013;65 Suppl 10:S190

234. Lee EB, Curtis JR, Riese R, Connell CA, Chew R, Boy MG, Maller E, Su C and Wang L: Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis of Gastrointestinal Adverse Events Across the Rheumatoid Arthritis Clinical Program: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S191
235. Genovese MC, Bingham 3rd CO, Cohen S, Calabrese L, Curtis JR, Block A, Fay J, Kelly S, Luo A, Wong D and Alten R: Antibody Response To Pneumococcal and Influenza Vaccination In Patients With Rheumatoid Arthritis Receiving Subcutaneous Abatacept: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S198
236. Curtis JR, Burton MJ, Yang S, Chen L, Mikuls TR, Winthrop KL and Baddley J: Safety of Biologic Therapy in Veterans with Rheumatoid Arthritis and Chronic Hepatitis B Infection: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S213
237. Mannion ML, Xie F, Curtis JR and Beukelman T: Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of TNF Inhibitors: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S336
238. Mariette X, Curtis JR, Lee EB, Benda B, Kaplan I, Soma K, Chew R, Geier J, Wang L and Riese R: Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across the Rheumatoid Arthritis Clinical Program: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S340
239. Ptacek J, Hawtin R, Louie B, Evensen E, Cordeiro J, Mittleman B, Atallah M, Cesano A, Bingham III CO, Cofield S, Curtis JR, Danila MI, Furie RA, Genovese MC, Levesque MC, Moreland LW, Nigrovic PA, O'Dell JR, Robinson WH, Shadick NA, St Clair EW, Striebich CC, Thiele GM, Gregersen PK and Bridges Jr. SL: Prediction of TNF Inhibitor Response in Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S375
240. Schabert VF, Yeaw J, Korn J, Quach C, Harrison DJ, Yun H, Joseph G, Collier DH, Curtis JR: Long-Term Effectiveness and Cost Per Effectively Treated Patients With Biologics Used in Rheumatoid Arthritis: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S427
241. Lillegraven S, Greenberg JD, Reed GW, Saunders KC, Curtis JR, Harrold LR, Hochberg MC, Pappas DA, Kremer JA and Solomon DH: Use of TNF Inhibitors Is Associated With a Reduced Risk of Diabetes In RA Patients: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S443
242. Curtis JR, Chen L, Yun H, Harrold LR, Greenberg JD and Kremer JM: Generalizability Of a U.S. rheumatoid Arthritis Registry: A Comparison Of Participants Vs. Non-Participants' Characteristics: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S447
243. Yun H, Xie F, Delzell ES, Chen L, Levitan E, Lewis J, Saag KG, Beukelman, Winthrop KL, Baddley J and Curtis JR: Physician Proclivity to use Oral Glucocorticoids Among Rheumatoid Arthritis Patients: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S449

244. Curtis JR, Xie F, Zhang, Chen L, Yun H, Schiff MH, Beukelman T and Ginsberg: Use of Oral and Subcutaneous MTX in a Commercially Insured Rheumatoid Arthritis Population: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S450
245. Warriner AH, Outman RC, Wyman A, Hoover FH, Adachi JD, Chapurlat R, Compston JE, Cooper C, Curtis JR, Diez-Perez A, Lindsay R, March L, Nieves JW and Saag KG: Osteoporosis Medication Adherence: Reasons For Stopping and Not Starting: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S525
246. Lafleur J, DuVall SL, Curtis JR, Adler RA, Wilson T, Agoda I, Stolshek B and Nelson RE: Association Between Bisphosphonate Switching Behavior and Cost Outcomes In Postmenopausal United States Veterans: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S527
247. Navarro-Milan I, Chen L, Harrold LR, Herrinton L, Liu L and Curtis JR: Factors Influencing Selection of Biologic Therapy and Comparative Effectiveness in Patient Reported Outcomes Among Patients With Rheumatoid Arthritis: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S571
248. Metes ID, Cew DW, Patel AM, Balasubramani GK, Bridges Jr. SL, Curtis JR, Wisniewski SR, Moreland LW and Levesque MC: Anti-Tumor Necrosis Factor a Therapy (Etanercept) Plus Methotrexate Lowers Serum Amyloid A Levels to a Great Extent Than Triple Oral Disease Modifying Anti-Rheumatic Drug Therapy in Early Rheumatoid Arthritis Subjects: ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S626
249. Metes ID, Chew DW, Patel AM, Balasubramani GK, Curtis JR, Bridges JR SL, Wisniewski SR, Moreland and Levesque MC: Serum Amyloid A Levels Model Rheumatoid Arthritis Disease Activity Better than C-Reactive Protein Levels Especially During Drug Treatment with Anti-Tumor Necrosis Factor a Therapy (Etanercept): ACR/ARHP Annual Scientific Meeting 2013. *Arthritis Rheum* 2013;65 Suppl 10:S762
250. Ptacek J, Hawtin RE, Evensen E, Cordeiro J, Atallah M, Marimpietri C, Cesano A, TETRAD Investigators, Gregersen PK, Bridges Jr., SL. Comparison of functional immune signaling profiles in peripheral blood mononuclear cells (PBMC) from rheumatoid arthritis (RA) patients versus healthy donors (HD) using Single Cell Network Profiling (SCNP). Presented at 15th International Congress of Immunology, Milan, Italy, August 2013.
251. J Ptacek, R Hawtin, B Louie, E Evensen, J Cordeiro, B Mittleman, M Atallah, A Cesano, CO Bingham III, S Cofield, JR Curtis, MI Danila, RA Furie, MC Genovese, MC Levesque, LW Moreland, PA Nigrovic, JR O'Dell, WH Robinson, NA Shadick, EW St. Clair, CC Striebich, GM Thiele, PK Gregersen, SL Bridges, Jr. Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling. *Arthritis Rheum*, 65; 10 (Suppl), S375, 2013.
252. J Ptacek, R Hawtin, B Louie, E Evensen, J Cordeiro, B Mittleman, M Atallah, A Cesano, CO Bingham III, S Cofield, JR Curtis, MI Danila, RA Furie, MC Genovese, MC Levesque, LW Moreland, PA Nigrovic, JR O'Dell, WH Robinson, NA Shadick, EW St. Clair, CC Striebich, GM Thiele, PK Gregersen, SL Bridges, Jr. Novel Biomarkers From Peripheral Blood Mononuclear Cells Indicate Disease Activity In Rheumatoid Arthritis Patients. *Arthritis Rheum*, 65; 10 (Suppl), S974, 2013.

253. J Zhang, JR Curtis, H Zhao, JG Saag, ML Kilgore, NC Wright, H Yun, L Deng, E Delzell. Bone Density Screening and Reduced Risk of Hip Fracture: Effectiveness or Confounding? ICPE 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei International Conference Center Taiwan, 2014.
254. J Zhang, JR Curtis, J Zhao, L Deng, KG Saag, ML Kilgore, P Muntner, NC Wright, E Delzell. Use of High Dimensional Propensity Scores to control for Confounding in Assessing the Association between Bone Density Screening and Hip Fracture Risk. ICPE 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei International Conference Center Taiwan, 2014.
255. H Yun, S Yang, L Chen, K Winthrop, F Xie, JW Baddley, KG Saag, J Singh and JR Curtis. Herpes Zoster infection Risk in Auto-Immune and Inflammatory Diseases: Implications for Vaccination. ICPE 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei International Conference Center Taiwan, 2014.
256. H Kumamaru, SE Judd, JR Curtis, R Ramachandran, NC Hardy, JD Rhodes, MM Safford, BM Kissela, G Howard, JJ Jalbert, TG Brott and S Setoguchi. Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: REGARDS Study Linked with Medicare Claims. ICPE 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei International Conference Center Taiwan, 2014.
257. H Yun, R Chen, NC Wright, R Matthews, T Arora, AN Milford, F Xue, e Delzell and JR Curtis. Factors Associated with Denosumab Initiation among Postmenopausal Osteoporosis Patients in Medicare. ICPE 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei International Conference Center Taiwan, 2014.
258. NC Wright, W Smith, Warriner AH, Foster J, McConnell R, Yun H, Melton MH, Curtis JR and Saag, KG. Long-Term Oral Bisphosphonate use for Osteoporosis Among Older Women – US and Canadian Perspective: ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66; 11 (Suppl), S20, 2014.
259. KL Winthrop, L Chen, Badley J, Taylor AJ, Chan B, Yun H, Siegel S and Curtis JR. Risk of Hospitalized Infection in a Psoriasis/Psoriatic Arthritis Cohort. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66; 11 (Suppl), S57, 2014.
260. JJ Cush and Curtis JR. Treat-To-Target (T2T) and Measuring Outcomes in RA Care: a 2014 Longitudinal Survey of US Rheumatologists. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66;11 (Suppl), S114, 2014.
261. JA Singh, R Ramachandaran, JS Zhang, F Xie, S Yang, H Yun and JR Curtis. Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes? ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66;11 (Suppl), S169, 2014.
262. G Burmester, GS Kaeley, JR Curtis, Y Yazici, B Guerette, X Wang, A Friedman and V Strand. The Use of Week 12 CDAI, RAPID2 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66; 11 (Suppl), S378, 2014.

263. B Haraoui, J Wade, M de Longueville, P Ralston and JR Curtis. Identification of Baseline Risk Factors for Adverse Events in Certolizumab Pegol Treated Rheumatoid Arthritis Patients. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66; 11 (Suppl), S468, 2014.
264. JR Curtis, D Mackey, N Gerber, A Bharat, L Chen, F Xie, B Nowell, KG Saag and S Ginsberg. Patient Experience with Initiation of SQ and Oral MTX. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66;11 (Suppl), S498, 2014.
265. D Pappas, A John, JR Curtis, GW Reed, C Karki, R Magner, JM Kremer, A Shewade and JD Greenberg. Dosing of Intravenous Tocilizumab in a Real-World Setting – Analyses from a US RA Registry. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66;11 (Suppl), S515, 2014.
266. H Yun, S Yang, L Chen, F Xie, KL Winthrop, J Baddley, KG Saag, JA Singh and JR Curtis. Herpes Zoster Infection Risk in Auto-Immune and Inflammatory Diseases: Implications for Vaccination. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66;11 (Suppl), S820, 2014.
267. JS Zhang, S Yang, L Chen, F Xi, H Yun, PM Muntner, E Levitan, M Safford, KG Saag, JA Singh and JR Curtis. Is Rheumatoid Arthritis a Coronary Heart Disease Risk Equivalent, Similar to Diabetes? ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66;11 (Suppl), S842, 2014.
268. A Balasubramanian, S Wade, RA Adler, C Fang (Lin), M Maricic, S O'Malley, KG Saag and JR Curtis. Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66; 11 (Suppl), S919, 2014.
269. JS Zhang, F Xie, L Chen, JD Greenberg and JR Curtis. Evaluation of a Methodological Approach to Determine Timing of Rheumatoid Arthritis Disease Onset Using Administrative Claims Data. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66;11 (Suppl), S1148, 2014.
270. C Barnabe, Y Sun, G Boire, C Hitchon, EC Keystone, JC Thorne, B Haraoui, JR Curtis, D van der Heijde, D Tin, JE Pope and VP Bykerk. Radiographic Progression Differs
271. Between Trajectory Clusters Defined by DAS28 Scores in Early Rheumatoid Arthritis. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66;11 (Suppl), S1387, 2014.
272. D Mackey, A Bharat, L Chen, B Nowell, L Fraenkel, PJ Embi, KG Saag, J Willig, S Ginsberg, R McConnell and JR Curtis. Demographic Differences in Health Related Information Technology Use Among patients with Rheumatic Diseases. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66;11 (Suppl), S1422, 2014.
273. I Navarro-Millan, A Westfall, E Darrah, A Rosen, TR Mikuls, R Reynolds, MI Danila, JR Curtis and SL Bridges JR. Anti-Peptidyl Arginine Deiminase 4 Antibodies in African-Americans with Rheumatoid Arthritis and Radiographic Scores. ACR/ARHP Annual Scientific Meeting 2014. *Arthritis Rheum*, 66;11 (Suppl), S1474, 2014.
274. H Yun, KL Winthrop, L Chen, W Smith, B Chan, F Xie, J Taylor, R Mamtani, FI Scott, JD Lewis and JR Curtis. Risk of Non Melanoma Skin Cancer Among Medicare Psoriasis/Psoriasis

- Arthritis Patients. ACR/ARHP Annual Scientific Meeting 2014. Arthritis Rheum, 66;11 (Suppl), S1546, 2014.
275. KL Winthrop, L Chen, J Baddley, AJ Taylor, B Chang, H Yun, S Siegel and JR Curtis. Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort. ACR/ARHP Annual Scientific Meeting 2014. Arthritis Rheum, 66;11 (Suppl), S1589, 2014.
276. FI Scott, R Mantani, C Bresinger, K Haynes, Z ChiesaFuxench, H Yun, JS Zhang, L Chen, F Xie, D Margolis, JD Lewis and JR Curtis. Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis. ACR/ARHP Annual Scientific Meeting 2014. Arthritis Rheum, 66;11 (Suppl), S1839, 2014.
277. JR Curtis, M Churchil, A Kivitz, L Gauer, C Herren, D Carter, J Melin and Y Yazici. Identification of a Patient Phenotype Which Impacts Response to Therapy In Rheumatoid Arthritis Clinical Trials: Cerolizumab Pegol Phase 4 Trial Data. ACR/ARHP Annual Scientific Meeting 2014. Arthritis Rheum, 66;11 (Suppl), S1844, 2014.
278. H Yun, KL Winthrop, L Chen, W Smith, B Chan, F Xie, AJ Taylor and JR Curtis. Risk of Malignancy Among Medicare Psoriasis/Psoriasis Arthritis Patients. ACR/ARHP Annual Scientific Meeting 2014. Arthritis Rheum, 66;11 (Suppl), S1849, 2014.
279. H Yun, F Xie, L Chen, J Lewis and JR Curtis. Risk of Hypersensitivity Among Medicare Patients with Rheumatoid Arthritis Who Were Taking Biologics. ACR/ARHP Annual Scientific Meeting 2014. Arthritis Rheum, 66;11 (Suppl), S1910, 2014.
280. JR Curtis, A Bharat, L Chen, JD Greenberg, JM Kremer and DA Pappas. Physician Awareness of Suboptimal patient Adherence to MX: results from a Large U.S. Rheumatoid Arthritis Registry. ACR/ARHP Annual Scientific Meeting 2014. Arthritis Rheum, 66;11 (Suppl), S2367, 2014.
281. H Yun, L Chen, GW Reed, JM Kremer, JD Greenberg and JR Curtis. Should Physician Reduce patients' Glucocorticoids to Offset the Risk of Serious Infection Event Among RA Patients Who Switched from Non-biologic Dmards and Glucocorticoid to Biologics? ACR/ARHP Annual Scientific Meeting 2014. Arthritis Rheum, 66;11 (Suppl), S2375, 2014.
282. JS Zhang, F Xie, L Chen, H Yun, PM Muntner, E Levitan, M Safford, KG Saag, J Singh and JR Curtis. DMARD Use after an Initial Acute MI Is Associated with Reduced Risk of A Recurrent Event and Mortality. ACR/ARHP Annual Scientific Meeting 2014. Arthritis Rheum, 66;11 (Suppl), S2388, 2014.
283. Willig JH, Curtis JR, Guzman A, Johnson B, Nowell B, Safford M, Filby C, Condon DM, Cella, D. Basic PROMIS Panel: A proposal for a unified visual interface to summarize multiple PROMIS domains. PHO Inaugural Conference, May 15, 2015. Philadelphia, PA.
284. Navarro-Millan I, Jain A, Belsom R, Gaffo AL, Yang S, Mikuls TR, Curtis JR. Influence of Anxiety and Depression on the Swollen to Tender Joint Count Ratio: In Pursuit of a Phenotype of RA Patients with Somatic Complaints in a U.S. Veteran Population [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). S2657
285. Chastek B, Curtis JR, Becker LK, Joseph GJ, Chen CI. Effectiveness of Monotherapy in Rheumatoid Arthritis (RA) Patients Initiating a Tumor Necrosis Factor Inhibitor (TNFi) Vs a

- Non-TNFi in a Large US Commercial and Medicare Advantage Plan [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S1655
286. Curtis JR, Greenberg JD, Harrold L, Palmer JL. Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).S478
287. Zhang J, Curtis JR, Xie F, Mannion ML, Lewis JD, Clowse MEB, Saag KG, Bethard S, Biggio J, McGwin G, Beukelman T. Utilization of Immune-Suppressive Medications during Pregnancy Among Women with Inflammatory Arthritis and Other Autoimmune Diseases [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S2528
288. Harrold L, Palmer JL, Curtis JR, Greenberg JD, Kremer JM. Trends over Time in Achievement of Low Disease Activity Among Biologic Initiators with Rheumatoid Arthritis [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S1653
289. Bonafede M, Curtis JR, McMorrow D, Chen CI, Joseph GJ. Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).S433
290. Higginbotham P, Johnson B, O'Beirne R, Safford M, Ginsberg S, Nowell B, Curtis JR. Patients' Prioritization of Patient-Centered Education and Research Topics in Rheumatic Disease [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S2333
291. Curtis JR, Burton MJ, Yang S, Chen L, Mikuls TR, Singh JA, Winthrop KL, Baddley J. Safety of Biologic and Non-Biologic Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Veterans with Rheumatoid Arthritis and Chronic Hepatitis C Infection [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S1603
292. Beukelman T, Xie F, Baddley J, Chen L, Mannion ML, Saag KG, Zhang J, Curtis JR. The Risk of Hospitalized Infection Following Initiation of Biologic Agents Versus Methotrexate in the Treatment of Juvenile Idiopathic Arthritis [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).S426
293. Carlesso L, Segal N, Curtis JR, Wise BL, Frey-Law L, Nevitt MC, Hu A, Neogi T. The Association of Knee Pain and Knee Osteoarthritis with Incident Widespread Pain: The Multicenter Osteoarthritis (MOST) Study [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).S2276
294. Ormseth MJ, Bridges SL Jr., Curtis JR, Solus JF, Yancey P, Linton MF, Davies S, Roberts LJ II, Vickers KC, Kon V, Fazio S, Stein CM. Effect of Drug Therapy on Net Cholesterol Efflux Capacity of HDL-Enriched Serum in Rheumatoid Arthritis [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).S1553
295. Xue F, Wagman RB, Yue S, Smith S, Arora T, Curtis JR, Ehrenstein V, Sørensen HT, Tell G, Kieler H, Wang FT, Dore DD, Sprafka JM. Incidence Rate of Potential Osteonecrosis of the Jaw Among Women with Postmenopausal Osteoporosis Treated with Prolia or Bisphosphonates [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S348

296. Carlesso L, Segal N, Curtis JR, Wise BL, Frey-Law L, Nevitt MC, Hu A, Neogi T. The Effect of Widespread Pain on Incident Knee Pain and Knee Osteoarthritis: The Multicenter Osteoarthritis (MOST) Study [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S2273
297. Alemao E, Simon T, Gandhi K, Kawabata H, Curtis JR. Evaluation of Changes in Cardiovascular Risk Factors Among Patients with RA Prescribed Biologic Dmards [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S1524
298. Navarro-Millan I, Yang S, Safford M, Chen L, Yun H, Curtis JR. Frequency of Lipid Testing and Management Among Rheumatoid Arthritis Patients Compared to the General Population and Patients with Diabetes [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).S131
299. Curtis JR, Turner A, Thomas C, Cofield S, Parks R, Ku JH, Messaoudi- Powers I, Wanzeck K, Winthrop KL. Safety, Clinical and Immunologic Effectiveness of the Live Zoster Vaccine Administered to Patients Receiving Anti-TNF Biologics [abstract].*Arthritis Rheumatol.* 2015; 67 (suppl 10). S1520
300. Yun H, Yang S, Xie F, Chen L, Winthrop KL, Curtis JR. Potential Use of Healthcare Databases for Post-Marketing Surveillance Registry: an Example Using Ustekinumab [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S127
301. Cannon GW, Teng CC, Mikuls TR, Curtis JR, Tang D, Stolshek BS, Sauer B. Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials. [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).S2107
302. Mannion ML, Pedro S, Beukelman T, Curtis JR, Michaud K. Comparison of JIA and RA Patients in the National Data Bank for Rheumatic Diseases [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).S1478
303. Curtis JR, Willig J, Safford M, Coe J, O'Hara K, Sa'adon R. Use of Social Media Data for Comparative Effectiveness and Safety Research: An Example from Rheumatoid Arthritis [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S47
304. Mikuls TR, Cheetham TC, Rashid N, Levy GD, Kerimian A, Low K, Coburn B, Redden DT, Bridges SL Jr., Saag KG, Curtis JR. A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S2108
305. Calabrese LH, Xie F, Yun H, Winthrop KL, Baddley J, Calabrese C, Curtis JR. Herpes Zoster and the Short Term Risk for Ischemic Stroke in Patients with Autoimmune Diseases [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S896
306. Barnard J, Meednu N, Callahan K, Coca A, Marston BA, Thiele RG, Tabechian D, Bolster M, Curtis JR, Mackay MC, Graf JD, Keating R, Smith E, Boyle K, Keyes-Elstein L, Welch B, Goldmuntz E, Anolik JH. Activated Memory B Cells in Rheumatoid Arthritis and Relationship to Anti-TNF Treatment [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).
307. Giles JT, Bridges SL Jr., O'Dell JR, Cofield S, Howard G, Curtis JR, Moreland LW. Increasing Circulating Adiponectin after DMARD Initiation Is Associated with Radiographic Progression in

- Early Aggressive RA, Regardless of Treatment Strategy [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S3102
308. Zhang J, Curtis JR, Xie F, Mannion ML, Lewis JD, Clowse MEB, Saag KG, Bethard S, Biggio J, McGwin G, Beukelman T. Utilization of Immune-Suppressive Medications during Pregnancy Among Women with Inflammatory Arthritis and Other Autoimmune Diseases [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). S2528
309. Impact of Sustained Remission on Risk for Infection in Patients with Rheumatoid Arthritis Enrolled in A Us Registry. J.R. Curtis, M. Liu, S. Rebello, M. Trivedi, T. Lesperance, Y. Li, N. Accortt. *Ann Rheum Dis* 2016;75:Suppl 2 156 doi:10.1136/annrheumdis-2016-eular.1803
310. Treatment Effectiveness for Rheumatoid Arthritis after Switching from A Tumor Necrosis Factor Inhibitor to Another Agent. M. Bonafede, J.R. Curtis, D. McMorrow, P. Mahajan, C. Chen. *Ann Rheum Dis* 2016;75:Suppl 2 1026 doi:10.1136/annrheumdis-2016-eular.1183
311. Risk of Hospitalized Infections in Patients with Rheumatoid Arthritis Initiating Abatacept and Other Biologics: Analysis of A United States Claims Database. N. Baker, M. Boers, M. Hochberg, H. Kawabata, N. Ray, T. Simon. *Ann Rheum Dis* 2016;75:Suppl 2 516 doi:10.1136/annrheumdis-2016-eular.1322
312. An Examination of Dose Escalation among Infliximab Users in The US Corrona RA Registry J.R. Curtis, Y. Shan, K.C. Saunders, D. Parenti, S. Kafka, J.M. Kremer *Ann Rheum Dis* 2016;75:Suppl 2 1009 doi:10.1136/annrheumdis-2016-eular.2002.
313. Real-World Comparative Risks of Herpes Virus Infections in Tofacitinib and Biologic-Treated Rheumatoid Arthritis Patients. J.R. Curtis, F. Xie, H. Yun, S. Bernatsky, K.L. Winthrop *Ann Rheum Dis* 2016;75:Suppl 2 506-507 doi:10.1136/annrheumdis-2016-eular 1734.
314. Use of A Global Risk Score To Identify Patients with Rheumatoid Arthritis at Risk of Serious Infectious Events during Certolizumab Pegol Treatment. J.R. Curtis, K. Winthrop, M. de Longueville, C. O'Brien, M.N. Ndlovu, B. Haraoui. *Ann Rheum Dis* 2016;75:230 doi:10.1136/annrheumdis-2016-eular.1636
315. Long Term Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. H. Yun, F. Xie, J.W. Baddley, K. Winthrop, L. Chen, J.R. Curtis. *Ann Rheum Dis* 2016;75:Suppl 2 641-642 doi:10.1136/annrheumdis-2016-eular.1743
316. High Risk of Second Fracture within 1, 2, 5 years after Prior Fracture among Women 65 years or Older. A Balasubramanian, J Zhang, L Chen, D Wenkert, SG Daigle, A Grauer, JR Curtis
317. The Activating Patients at Risk for OsteoPOroSis (APROPOS) Study: a Randomized Trial within the GLOW Cohort. M. Danila, R. Outman, E. Rahn, A. Mudano, D. Redden, P. Li, F. Anderson, JR Curtis, S Greenspan, A. LaCroix, M. Miller, J. Nieves, S. Silverman, A. Warriner, N. Watts, NC Wright, KG Saag
318. Factors Associated with the Online Uptake of a Multi-modal Educational Intervention for the Activating Patients at Risk for OsteoPOroSis (APROPOS) Study: a Randomized Trial within the GLOW Cohort. M Danila, E Rahn, R Outman, A Mudano, T Thomas, J Allison, FAnderson, J Anderson, P Cram, JR Curtis, L Fraenkel, S Greenspan, A LaCroix, S Majumdar, M Miller, J

Nieves, D Redden, M Safford, S Silverman, E Siris, D Solomon, A Warriner, N Watts, Rt Yood, KG Saag

319. Hip Fractures and Declining DXA Testing: At a Breaking Point? E. Michael Lewiecki, Robert Adler, Jeffrey Curtis, Robert Gagel, Kenneth Saag, Andrea Singer, Ethel Siris, Nicole C. Wright, Huifeng Yun, Peter M. Steve
320. Improving Feasibility for The Effectiveness of Discontinuing bisphosphonates (EDGE) Trial: A Pilot Study. Nicole Wright, P. Jeffrey Foster, Amy Mudano, E. Michael Lewiecki, William Shergy, Jeffrey Curtis, Gary Cutter, Maria Danila, Meredith Kilgore, Cora Lewis, Sarah Morgan, David Redden, Amy Warriner, Kenneth Saag
321. Curtis JR, Elewaut D, Chen S, Hojnik M, Naveh N, Anderson JK. Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 700. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
322. Curtis J, Harrold L, Kremer J, Palmer JL. Higher Multi Biomarker Disease Activity Scores Foreshadow Greater Longitudinal Improvement in RA Disease Activity [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 556. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
323. Yun H, Beaumont J, Yang S, Willig J, Nowell WB, Ginsberg SD, Clayton KV, Hazel S, Wiedmeyer C, Curtis J. Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 86. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
324. Yun H, Nowell WB, Willig J, Beaumont J, Johnson B, Ginsberg SD, Wiedmeyer C, Crow-Hercher R, Johnson BJ, Yang S, Curtis J. What Factors Relate to Patients Contributing Longitudinal Data Using Smartphone Technology? Findings from RA Patients Participating in Arthritispower Registry [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 8. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
325. Gutierrez AK, Bartlett SJ, Jones M, Nowell WB, Ginsberg SD, Bykerk VP, Curtis JR, Bingham C III. People with Rheumatoid Arthritis Recruited from an Online Patient Community May Differ from Clinical Populations in Symptoms and Impacts [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 103. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
326. Gutierrez AK, Bartlett SJ, Butanis A, Bykerk VP, Curtis JR, Leong AL, Lyddiatt A, Bingham C III. Promis Short Forms Are Relevant to People Living with RA: Results of Cognitive Debriefing Interviews [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 539. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
327. Horton DB, Xie F, Chen L, Mannion M, Strom BL, Curtis J, Beukelman T. Oral Glucocorticoids and Rates of Incident Diabetes Mellitus and Hypertension in Children with Juvenile Idiopathic Arthritis and Attention-Deficit/Hyperactivity Disorder [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 412. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
328. Chernoff D, Bolce RJ, Hwang CC, Wang X, Kivitz A, Curtis JR. Examination of Diurnal and Daily Variation of the Multi-Biomarker Disease Activity (MBDA) Score in RA to Establish the

- Minimally Important Difference [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 535. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
329. Erhardt D, Sauer BC, Teng CC, Mikuls TR, Curtis JR, Cannon GW. The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 652. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
330. Beukelman T, Xie F, Baddley J, Chen L, Mannion M, Saag KG, Zhang J, Curtis JR. The Risk of Hospitalized Infection Associated with Initiation of Abatacept Versus TNF Inhibitors in Juvenile Idiopathic Arthritis [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 402. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
331. Danila MI, Outman RC, Rahn EJ, Mudano AS, Redden DT, Li P, Anderson FA, Anderson JP, Greenspan SL, LaCroix AZ, Nieves JW, Silverman SL, Siris ES, Watts NB, Miller MJ, Curtis JR, Warriner AH, Wright NC, Saag KG. The Activating Patients at Risk for Osteoporosis Study: A Randomized Trial within the Global Longitudinal Study of Osteoporosis in Women Cohort [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 322. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
332. Fleischmann R, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Ionescu L, Gervitz L, Peterson L, Smolen J. Efficacy and Safety of Switching Between Certolizumab Pegol and Adalimumab after Primary Anti-TNF Treatment Failure: 2-Year Results from a Randomized, Investigator-Blind, Superiority Head-to-Head Study [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10). 602. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
333. Ogdie A, Palmer JL, Greenberg JD, Harrold LR, Solomon DH, Kavanaugh A, Kremer J, Mease PJ, Curtis JR. Predictors of Achieving Remission Among Patients with Psoriatic Arthritis Prescribed TNF Inhibitors [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10). 1722, 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
334. George MD, Baker JF, Hsu JY, Wu Q, Xie F, Chen L, Yun H, Curtis J. Preoperative Timing of Infliximab and Risk of Post-Operative Infection in a Medicare Cohort [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 2052. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
335. Zerbini CAF, Muram D, Arora VK, Alam J, Curtis JR. Effect of BMI on Baricitinib Efficacy: Pooled Analysis from Two Phase 3 Rheumatoid Arthritis Clinical Trials [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10)1640. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
336. Xie F, Chen L, Yun H, Beukelman T, Curtis J. Ustekinumab, Apremilast, TNFi and the Risk for Hospitalized Infection in Patients with Psoriasis and Psoriatic Arthritis [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10)1718. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
337. Xie F, Chen L, Yun H, Curtis JR. Ustekinumab and the Comparative Risk for Acute Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 1707. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.

338. Curtis J, Xie F, Chen L, Yun H. Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 1492. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
339. Yun H, Yang S, Pedro S, Curtis J, Michaud K. Patterns and Factors Associated with Immunization Among Adult Patients with Rheumatic Diseases in the US [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 1503. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
340. Navarro-Millán I, Yang S, Chen L, Yun H, Bartels CM, Jagpal A, Cherrington A, Fraenkel L, Safford MM, Curtis J. Screening Patterns for Hyperlipidemia Among Patients with Rheumatoid Arthritis Based on Patterns of Care from By Primary Care Physicians, Rheumatologists or Both [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 1493. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
341. Bonafede M, Wei W, Chen CI, McMorro D, Fiore S, Fay J, Kimura T, Curtis JR. Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10)1999. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
342. Vinet E, Moura CS, Curtis JR, Pineau CA, Abrahamowicz M, Bernatsky S. Serious Infections in RA Offspring Exposed to Tumor Necrosis Factor Inhibitors [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 2049. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
343. England BR, Mikuls TR, Xie F, Yang S, Chen L, Curtis J. Herpes Zoster and the Risk of Incident Giant Cell Arteritis [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 2074. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
344. Beukelman T, Xie F, Chen L, Horton D, Lewis JD, Mamtani R, Mannion M, Saag KG, Zhang J, Curtis JR. Tumor Necrosis Factor Inhibitors and the Risk of Malignancy in the Treatment of Juvenile Idiopathic Arthritis [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 2982. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
345. Machado M, Moura CS, Behloui H, Curtis JR, Bernatsky S. Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 2529. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
346. Fleischmann R, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Ionescu L, Gervitz L, Peterson L, Smolen J. Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 2987. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
347. Curtis J, Xie F, Saag K, Chen L, Beukelman T, Mannion M, Yun H. Changing Patterns over Time in Opiate Use in U.S. Rheumatoid Arthritis Patients [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 3086. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.

348. Kan HJ, Dyagilev K, Schulam P, Saria S, Molta C, Curtis J. Factors Related to Physicians' Prescriptions for Rheumatoid Arthritis Drugs Never Filled or Subsequently Discontinued By Patients [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10), 3194. 2016. ACR/ARHP Annual Scientific Meeting 2016, Washington, DC.
349. Mease PJ, Kremer J, Cohen S, Curtis JR, Charles-Schoeman C, Loftus EV, Greenberg JD, Palmetto N, Kanik KS, Graham D, Wang C, Biswas P, Chan G, DeMasi R, Valdez H, Hendrikx T, Jones TV. Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs [abstract 16L]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
350. Bhatt BD, Palmer JL, Curtis JR, Velkuru S, Kremer J. Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis [abstract 1558]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
351. Machado MADA, Moura CS, Ferreira Guerra S, Curtis JR, Abrahamowicz M, Behloul H, Bernatsky S. Serious Infections Associated with Tofacitinib in Rheumatoid Arthritis Patients Previously Treated with Methotrexate [abstract 2785]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
352. Yun H, Yang S, Nowell WB, Filby C, Chen L, Curtis JR. Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry [abstract 446]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
353. Curtis JR, Wallenstein G, Takiya L, Gruben D, Chen C, Shan Y, Blachley T, Dandreo KJ, Kremer J. Patterns of Methotrexate Use and Discontinuation in a U.S. Rheumatoid Arthritis Registry [abstract 1815]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
354. George MD, Baker J, Winthrop K, Alemao E, Chen L, Connolly S, Simon T, Wu Q, Xie F, Yang S, Curtis JR. Timing of Abatacept Infusions before Elective Arthroplasty and the Risk of Post-Operative Infection [abstract 2786]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
355. Weinblatt M, Genovese MC, Kremer J, Sun L, Patel H, Koch A, Muram D, Curtis JR, Larmore CJ, Zhu B. Assessment of Early Improvement in Pain and Other ACR Components As Predictors for Achieving Low Disease Activity or Remission in Three Phase 3 Trials of RA Patients Treated with Baricitinib [abstract 499]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
356. Blalock SJ, Solow E, Nowell WB, Woloshin S, Schwartz L, Carpenter DM, Curtis JR, Moreland LW, Hunt C, Hickey G, Reyna V. A Trial Testing Strategies to Enhance Patient Understanding of Drug Information: Experience Recruiting Subjects through an Online Patient Community [abstract 1860]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
357. Mikuls TR, Cheetham T, Levy GD, Rashid N, Low K, Coburn BW, Saag K, Chen L, Curtis JR. Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAMP-Up) Study [abstract 2848].

- Arthritis Rheumatol. 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
358. Curtis JR, Yun H, FitzGerald O, Winthrop K, Azevedo VF, Burmester GR, Rigby WFC, Kanik KS, Rojo R, Menon S, Wang C, Biswas P, Hendrikx T, Palmetto N. Comparing Tofacitinib Safety Profile in Patients with Psoriatic Arthritis in Clinical Studies with Real-World Data [abstract 617]. Arthritis Rheumatol. 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
 359. Xie F, Chen L, Yun H, Greenberg JD, Curtis JR. An Approach to Linkage of Registry Data to Medicare Claims Using Multiple Non-Unique Identifiers [abstract 1956]. Arthritis Rheumatol. 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
 360. Curtis JR, Yun H, Etzel CJ, Yang S, Chen L. Use of Machine Learning and Traditional Statistical Methods to Classify RA-Related Disability Using Administrative Claims Data [abstract 128]. Arthritis Rheumatol. 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
 361. Willig J, Curtis JR, Westfall A, Lein D, Smith CR, Cortis J, Rice C, Hurt C. Optimizing Data Capture for Performance – Metrics Using Smartphone App Technology [abstract 2854]. Arthritis Rheumatol. 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
 362. Curtis JR, Chen R, Li Z, Arora T, Saag K, Wright NC, Daigle S, Kilgore M, Delzell E. The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates [abstract 828]. Arthritis Rheumatol. 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
 363. Yun H, Xie F, Yang S, Chen L, Curtis JR. Rates of Malignancy Associated with Anti-TNF Agents and Subsequent Biologic Use after Malignancy Using U.S. SEER Registry Data [abstract 1962]. Arthritis Rheumatol. 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
 364. Curtis JR, Ford K, Chen L, Yun H, Xie F. Impact of the Multi-Biomarker Disease Activity Score Results on Whether Rheumatologists Changed Biologic Therapy for RA Patients [abstract 129]. Arthritis Rheumatol. 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
 365. Curtis JR, Conaway D, Schechtman J, Broadwell A, Kivitz AJ, Bray V, Kafka S, Parenti D, Black S, Xu S, Langholff W, Bingham III CO. Responsiveness of the Patient Reported Outcomes Measurement Information System to Golimumab Intravenous and Infliximab Treatment in a Real World Clinical Trial in Rheumatoid Arthritis Patients [abstract 2951]. Arthritis Rheumatol. 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
 366. Incerti D, Curtis JR, Lorenzi M, Jansen J. Open-Source Consensus-Based Models to Improve the Cost-Effectiveness of Rheumatology Care [abstract 925]. Arthritis Rheumatol. 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
 367. Nowell WB, Jordan K, Gavigan K, Tharp L, Curtis JR, Pennebaker J. Linguistic Differences in Gout-Related Online Content: A Comparison of Professional Health Literature for Consumers

- Vs Patients' Online Discussions of Gout [abstract 2250]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
368. Xie F, Annapureddy N, Chen L, Lobo JL, Oates JC, Shah A, Yun H, Yang S, Curtis JR. Rheumatoid Arthritis and the Risk for Interstitial Lung Disease: A Comparison of Risk Associated with Biologic and Conventional Dmards [abstract 137]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
369. Haroun T, Eudy AM, Jayasundara M, Nowell WB, Curtis JR, Whitney White C, Crow-Hercher R, Ginsberg SD, Clowse MEB. Tough Choices: Understanding the Medication Decision-Making Process for Women with Inflammatory Arthritis during Pregnancy and Lactation [abstract 1298]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
370. Danila MI, Rahn EJ, Mudano AS, Outman R, Li P, Redden DT, Anderson FA, Greenspan SL, LaCroix AZ, Nieves JW, Silverman SL, Siris ES, Watts NB, Ladores S, Meneses K, Curtis JR, Saag K. Temporal Increases in Side Effect Concerns of Osteoporosis Medications Among Women with Previous Fractures [abstract 2256]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
371. Xie F, Chen L, Yun H, Curtis JR. Prediction of Cardiovascular Events in Rheumatoid Arthritis Patients Using a Multi-Biomarker of Disease Activity [abstract 138]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
372. Jayasundara M, Eudy AM, Haroun T, Nowell WB, Curtis JR, Crow-Hercher R, Whitney White C, Ginsberg SD, Clowse MEB. Answering Reproductive Health Questions That Your Patients Want to Know: Impediments to Family Building and Risks of Contraception [abstract 1308]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
373. Dikranian A, Gonzalez-Gay MA, Wellborne F, Alvaro-Gracia JM, Takiya L, Stockert L, Chapman D, Tatulych S, Dahl P, Curtis JR. The Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis Stratified By Baseline Body Mass Index [abstract 2371]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
374. Teeple A, Ellis LA, Huff L, Reynolds C, Ginsberg SD, McCormick Howard L, Walls D, Curtis JR. Patients' Experiences and Attitudes about Non-Medical Switching of Biologics: Results from an Online Patient Survey [abstract 362]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
375. Danila MI, Rahn EJ, Mudano AS, Outman RC, Li P, Redden DT, Anderson FA, Greenspan SL, LaCroix AZ, Nieves JW, Silverman SL, Siris ES, Watts NB, Ladores S, Meneses K, Curtis JR, Saag K. Factors Associated with Readiness for Adopting Osteoporosis Treatment Change [abstract 2777]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
376. George MD, Baker J, Winthrop K, Alemao E, Chen L, Connolly S, Simon T, Wu Q, Xie F, Yang S, Curtis JR. Comparative Risk of Biologic Therapies in Patients with Rheumatoid Arthritis Undergoing Elective Arthroplasty [abstract 2755]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.

377. Danila MI, Ruderman EM, Harrold LR, Melnick JA, O'Beirne R, Safford MM, Kremer J, Curtis JR. Patient-Reported Barriers to Achieving Rheumatoid Arthritis Disease Control [abstract 336]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
378. Curtis JR, Schwartzman S, Kafka S, Parenti D, Black S, Xu S, Langholff W, Bingham III CO. Real World Clinical Trial Comparing the Patient Reported Outcomes Measurement Information System Short Forms and Profiles to CDAI Disease Classification in Rheumatoid Arthritis Patients [abstract 344]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
379. Curtis JR, Brahe CH, Østergaard M, Lund Hetland M, Hambardzumyan K, Saevarsdottir S, Wang X, Sasso EH, Huizinga TWJ. High Multi-Biomarker Disease Activity Score Is Associated with High Risk of Radiographic Progression in Six Cohorts [abstract 438]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
380. Yun H, Yang S, Nowell WB, Filby C, Chen L, Curtis JR. Assessing RA Disease Activity with Promis Measures Using Smartphone Technology [abstract 2781]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
381. Curtis JR, Flake DD II, Weinblatt M, Shadick NA, Østergaard M, Lund Hetland M, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS. Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage [abstract 1371]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
382. Navarro-Millán I, Cornelius-Schechter A, Jagpal A, Johnson B, Fraenkel L, Safford MM, Curtis JR. Patient Reported Outcomes in Rheumatoid Arthritis: Best Domain, Best Interface [abstract 1391]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
383. Deodhar AA, Winthrop K, Chan B, Siegel SAR, Pisenti L, Stark J, Suruki RY, Bohn RL, Yun H, Chen L, Curtis JR. Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations? [abstract 1527]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). ACR/ARHP Annual Scientific Meeting 2017, San Diego, CA.
384. Stark, J.L., Yassine, M., Nowell, W.B., Gavigan, K., Ginsberg, S., Serna, M.S., Curtis, J.R. Barriers to rheumatoid arthritis treatment optimisation: real-world data from the arthritispower registry. EULAR 2018. *Ann Rheum Dis*, volume 77, supplement Suppl, year 2018, page A299.
385. I.Y. Navarro-Millan, S. Young, S. Shurbaji, C. McDavid, A. Cornelius-Schechter, B. Johnson, A. Cherrington, L. Fraenkel, J. Curtis, M. Safford. Building a patient-centred cardiovascular risk reduction program for patients with inflammatory arthritis. EULAR 2018. *Ann Rheum Dis*, volume 77, supplement Suppl, year 2018, page A1350.
386. M. George, J. Baker, K. Winthrop, E. Alemao, L. Chen, S. Connolly, T. Simon, Q. Wu, F. Xie, S. Yang, J. Curtis. Comparative risk of biologic therapies and risk of glucocorticoids in patients

- with rheumatoid arthritis undergoing elective arthroplasty. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page A163.
387. A. Deodhar, K.L. Winthrop, R.L. Bohn, B.K. Chan, R.Y. Suruki, J.L. Stark, H. Yun, S.A.R. Siegel, L. Chen, M. Yassine, J.R. Curtis. Do tnf inhibitors impact the comorbidities and extra-articular manifestations, and thereby alter the natural history of ankylosing spondylitis? EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page A1000.
388. M.I. Danila, E.J. Rahn, A.S. Mudano, R.C. Outman, P. Li, D.T. Redden, F.A. Anderson, S.L. Greenspan, A.Z. LaCroix, J.W. Nieves, S.L. Silverman, E.S. Siris, N.B. Watts, S. Ladores, K.M. Meneses, J.R. Curtis, K.G. Saag. Factors associated with readiness for adopting osteoporosis treatment change. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page A445.
389. J. Curtis, K. Ford, L. Chen, H. Yun, F. Xie. Impact of the multi-biomarker disease activity score results on whether rheumatologists changed biologic therapy for ra patients. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page A853.
390. P.J. Mease, J. Kremer, S. Cohen, J.R. Curtis, C. Charles-Schoeman, E.V. Loftus, J. Greenberg, N. Palmetto, K. S. Kanik, D. Graham, C. Wang, P. Biswas, G. Chan, R. DeMasi, H. Valdez, T. Hendriks, T. V. Jones. Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page page A983.
391. F. Xie, L. Chen, H. Yun, E. Levitan, P. Muntner, J.R. Curtis. Methotrexate use and the risk for cardiovascular disease among rheumatoid patients initiating biologic disease-modifying antirheumatic drugs. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page page A145.
392. J.R. Curtis, E. Sullivan, J. Kershaw, S. Blackburn, P. Mahajan, S. Boklage. Physician-reported behaviours and treatment trends of tumour necrosis factor inhibitor use: cycling versus switching in five european countries: France, Germany, Italy, Spain and the UK. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page page A1385.
393. F. Xie, L. Chen, H. Yun, J.R. Curtis. Prediction of cardiovascular events in rheumatoid arthritis patients using a multi-biomarker of disease activity. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page page A1197.
394. J. Curtis, S. Schwartzman, S. Kafka, D. Parenti, S. Black, S. Xu, W. Langholff, C.O. Bingham III. Real world clinical trial comparing the patient reported outcomes measurement information system short forms and profiles to cdai disease classification in rheumatoid arthritis patients. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page page A1303.
395. J. R. Curtis, G. St John, M. Panucci, J. A. Maldonado-Cocco. Reversible decreases in absolute neutrophil count (ANC) in rheumatoid arthritis (RA) patients (PTS) on sarilumab: comparison of dose delay and dose decrease vs continued treatment. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page page A946.
396. M.I. Danila, E.J. Rahn, A.S. Mudano, R.C. Outman, P. Li, D.T. Redden, F.A. Anderson, S.L. Greenspan, A.Z. LaCroix, J.W. Nieves, S.L. Silverman, E.S. Siris, N.B. Watts, S. Ladores, K.M. Meneses, J.R. Curtis, K.G. Saag. Temporal increases in side effect concerns of

osteoporosis medications among women with previous fractures. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page page A452.

397. A. Dikranian, M. A. Gonzalez-Gay, F. Wellborne, J. M. Alvaro-Gracia, L. Takiya, L. Stockert, D. Chapman, S. Tatulych, P. Dahl, J. R. Curtis. The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page page A925.
398. J.R. Curtis, R. Chen, Z. Li, T. Arora, K.G. Saag, N.C. Wright, S. Daigle, M. Kilgore, E. Delzell. The impact of the duration of bisphosphonate drug holidays on hip fracture rates. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page page A58.
399. M. George, J. Baker, K. Winthrop, E. Alemao, L. Chen, S. Connolly, T. Simon, Q. Wu, F. Xie, S. Yang, J. Curtis. Timing of abatacept before elective arthroplasty and post-operative outcomes. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page page A162.
400. F. Xie, H. Yun, E. Levitan, P. Muntner, J.R. Curtis. Tocilizumab and the risk for cardiovascular disease events among rheumatoid arthritis patients: a direct comparison in real world setting. EULAR 2018. Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page page A145.